$$ Paradigm Medical Ind. +41 % bei Rekordvolumen $$ - 500 Beiträge pro Seite (Seite 7)
eröffnet am 31.01.06 06:36:17 von
neuester Beitrag 17.04.09 07:26:27 von
neuester Beitrag 17.04.09 07:26:27 von
Beiträge: 3.223
ID: 1.036.559
ID: 1.036.559
Aufrufe heute: 0
Gesamt: 173.993
Gesamt: 173.993
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 22:59 | 809 | |
| 02.05.24, 18:44 | 634 | |
| 01.05.24, 18:36 | 631 | |
| gestern 22:26 | 380 | |
| vor 41 Minuten | 316 | |
| vor 1 Stunde | 283 | |
| heute 05:31 | 276 | |
| gestern 22:06 | 252 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 2. | 18.044,44 | +0,12 | 112 | |||
| 2. | 1. | 169,06 | +0,51 | 98 | |||
| 3. | 3. | 0,1915 | +2,68 | 42 | |||
| 4. | 4. | 2.313,74 | +0,52 | 26 | |||
| 5. | 6. | 0,0793 | +15,09 | 25 | |||
| 6. | 5. | 0,1764 | +13,00 | 25 | |||
| 7. | 10. | 0,8750 | 0,00 | 15 | |||
| 8. | 8. | 38.715,47 | +0,12 | 15 |
Feedback
Antwort auf Beitrag Nr.: 33.075.655 von STARSWEEPER am 16.01.08 22:44:16hier mal ein Link zum im Artikel erwähnten Unternehmen.
Übrigens-Die Amis sehen das ganze absolut positiv.
Hier der Link:
http://www.corcoranccg.com/NewsAndEvents.aspx
Sweeper
Übrigens-Die Amis sehen das ganze absolut positiv.
Hier der Link:
http://www.corcoranccg.com/NewsAndEvents.aspx
Sweeper
Ich bin auch der Meinung das ein weiterer Schritt getan ist um die Geräte zu verkaufen.
Das Geld ist nicht zum Fenster rausgeworfen!!!!!!
Wetten????
Übrigens finde ich es immer so toll das Leute bei der OTC einsteigen und innerhalb von 2 Wochen Millionär werden wollen.
Hier ist ein wenig Geduld gefragt.
Es ist nervig immer den gleichen Schrott zu lesen von entäuschten Anlegern, es hält nur unnötig von den interessanten Meldungen ab.
Ansonsten ist es hier echt gut was für News bei allen Werten von den Jungs und Madels rangetragen wird.
Dank an alle!!!!!!!
Gruss
Das Geld ist nicht zum Fenster rausgeworfen!!!!!!
Wetten????
Übrigens finde ich es immer so toll das Leute bei der OTC einsteigen und innerhalb von 2 Wochen Millionär werden wollen.
Hier ist ein wenig Geduld gefragt.
Es ist nervig immer den gleichen Schrott zu lesen von entäuschten Anlegern, es hält nur unnötig von den interessanten Meldungen ab.
Ansonsten ist es hier echt gut was für News bei allen Werten von den Jungs und Madels rangetragen wird.
Dank an alle!!!!!!!
Gruss
Gerade im Ami-Board gefunden:
Posted by: voitsi
In reply to: None Date:1/17/2008 1:35:49 PM
Post #of 2378
Mr. Cannefax CEO of Paradigm bought 1Mio shares recently. He must be confident about the future.
http://www.sec.gov/Archives/edgar/data/916444/00010969060800…
IST DOCH EIN FEINER ZUG VON IHM!!!
Grüsse Sweeper
Posted by: voitsi
In reply to: None Date:1/17/2008 1:35:49 PM
Post #of 2378
Mr. Cannefax CEO of Paradigm bought 1Mio shares recently. He must be confident about the future.
http://www.sec.gov/Archives/edgar/data/916444/00010969060800…
IST DOCH EIN FEINER ZUG VON IHM!!!
Grüsse Sweeper
Antwort auf Beitrag Nr.: 33.087.326 von STARSWEEPER am 17.01.08 20:41:10
January 23, 2008 - 9:50 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.0014 0.0001
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries Settles Last of Active Lawsuits
Paradigm Medical Industries, Inc. (OTCBB: PMED), a leader in glaucoma diagnostic and management devices, announced today it has settled the last of its currently active lawsuits against the Company. The Company disclosed it had reached an out-of-court settlement with Larry Hicks, a former consultant. Terms were not disclosed.
In 2006, Paradigm Medical resolved two suits filed by former employees via summary judgments in favor of the Company. Paradigm Medical also resolved several class-action suits out of court in 2005. All of these lawsuits, including Hicks and the class action suits, were filed in 2003.
“We can now fully concentrate on our core business of developing, manufacturing and marketing of diagnostic glaucoma equipment that we provide to the ophthalmic industry,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “Management has spent substantial time defending the Company in these suits. We can now have full focus in implementing our strategies and business plan.”
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
Source: Business Wire (January 23, 2008 - 9:50 AM EST)
News by QuoteMedia
www.quotemedia.com
January 23, 2008 - 9:50 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.0014 0.0001
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries Settles Last of Active Lawsuits
Paradigm Medical Industries, Inc. (OTCBB: PMED), a leader in glaucoma diagnostic and management devices, announced today it has settled the last of its currently active lawsuits against the Company. The Company disclosed it had reached an out-of-court settlement with Larry Hicks, a former consultant. Terms were not disclosed.
In 2006, Paradigm Medical resolved two suits filed by former employees via summary judgments in favor of the Company. Paradigm Medical also resolved several class-action suits out of court in 2005. All of these lawsuits, including Hicks and the class action suits, were filed in 2003.
“We can now fully concentrate on our core business of developing, manufacturing and marketing of diagnostic glaucoma equipment that we provide to the ophthalmic industry,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “Management has spent substantial time defending the Company in these suits. We can now have full focus in implementing our strategies and business plan.”
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
Source: Business Wire (January 23, 2008 - 9:50 AM EST)
News by QuoteMedia
www.quotemedia.com
ob hier überhaupt mal was passiert ?
Trading Spotlight
Antwort auf Beitrag Nr.: 33.159.095 von maverick0279 am 24.01.08 17:43:23und ob.
behalte diesen Wert mal lieber die kommenden Wochen im Auge.
Sweeper
behalte diesen Wert mal lieber die kommenden Wochen im Auge.
Sweeper
naja im Auge ist gut ich habe 500000 Shares hiervon
Nja was heist im Auge behalten, ich habe 500.000 Shares von diesem Wert.
Antwort auf Beitrag Nr.: 33.160.441 von maverick0279 am 24.01.08 19:36:28Du wirst noch foh sein diesen Wert in's Depot gelegt zu haben. Schau Di dazu nur den 2-Jahreschart an.
Sweeper
Sweeper
Antwort auf Beitrag Nr.: 33.162.769 von om628 am 24.01.08 22:29:43Warum?????? 
ich glaube es schadet nichts sich mal ca.500 bis 600000 zu kaufen...oder was meint ihr??
Antwort auf Beitrag Nr.: 33.188.734 von hessenkoenig am 28.01.08 11:23:16 January 28, 2008 - 9:42 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.001 -0.0001
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries to Market Proprietary Electrophysiology Device for Early Detection of Glaucoma
Company Signs Exclusive Distribution Agreement With Italy’s LACE ELETTRONICA
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), a leader in glaucoma diagnostic and management devices, disclosed today it has signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the latter’s proprietary GLAID electrophysiology instrument for the early detection of glaucoma. Terms were not disclosed.
LACE’s GLAID is a revolutionary diagnostic device that utilizes Pattern Electroretinogram (PERG) to provide a visual stimulus that generates electrical responses of the retina to measure the physical condition of the retina’s ganglion cells. Retinal ganglion cells collectively transmit visual information from the retina to several regions in the midbrain. There are about 1.2-1.5 million retinal ganglion cells in the human retina. The GLAID device was approved by the U.S. Food and Drug Administration (FDA) in 2007.
The GLAID device has undergone extensive testing and clinical studies in the U.S., Canada and Italy, including Bascom Palmer Eye Institute (Miami and Palm Beach, FL), University of California at San Diego’s Hamilton Glaucoma Center, New York State College of Optometry, University of Laval (Quebec, Canada), and the University of Alabama. The current state of the GLAID technology was developed by Dr. Vittorio Porciatti, who is also involved in further GLAID-related research at Bascom Palmer Eye Institute.
“We believe the GLAID device is the most significant development in glaucoma detection in the last 20 years,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “It represents a multimillion-dollar market opportunity for our Company.”
“We are pleased to be working with Paradigm Medical in introducing and promoting GLAID,” said Alessio Romani, chief executive of LACE. “The Company is well known and respected for its glaucoma diagnostic devices. The agreement is expected to accelerate acceptance of the GLAID technology in North America and Canada in 2008.”
“The GLAID device is believed to be the fastest method of testing for retinal ganglion cell loss,” Mr. Cannefax noted. “The GLAID not only measures dead and living ganglion cells, but also detects ailing ganglion cells. Due to the device’s ability to detect dying ganglion cells, in most cases the viability of these cells can be fully restored with treatment.”
Mr. Cannefax added that “GLAID provides a test that is fast and easy to understand and administer, easy to interpret by the clinician, and is non-invasive. It is reliable, operator independent, and is able to detect dysfunction of the ganglion cells in patients who are glaucoma suspects. GLAID can detect the onset of retinal defects significantly earlier than can be measured by the current standard of detection method of Visual Fields Analysis (Perimeters). We expect to begin filling orders during the first quarter of 2008.”
Glaucoma, caused by deterioration of the optic nerve and related ganglion cells, is the second leading cause of permanent vision loss. It affects one in five people over age 50. Some 75% of glaucoma goes undiagnosed because of the lack of sophisticated instrumentation. There are more than 64 million cases of glaucoma worldwide, including more than three million in the U.S. About 120,000 people in this country are blind as a result of glaucoma. Nearly 16,000 surgeries are performed in the U.S. each year on patients with glaucoma, with the cost averaging about $3,200, depending on the severity of the glaucoma. In terms of Social Security benefits, loss of income tax revenues and health-care expenditures, the cost to the U.S. government related to glaucoma is estimated to be more than $1.5 billion annually.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
Source: Business Wire (January 28, 2008 - 9:42 AM EST)
News by QuoteMedia
www.quotemedia.com
NEWS !
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.001 -0.0001
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries to Market Proprietary Electrophysiology Device for Early Detection of Glaucoma
Company Signs Exclusive Distribution Agreement With Italy’s LACE ELETTRONICA
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), a leader in glaucoma diagnostic and management devices, disclosed today it has signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the latter’s proprietary GLAID electrophysiology instrument for the early detection of glaucoma. Terms were not disclosed.
LACE’s GLAID is a revolutionary diagnostic device that utilizes Pattern Electroretinogram (PERG) to provide a visual stimulus that generates electrical responses of the retina to measure the physical condition of the retina’s ganglion cells. Retinal ganglion cells collectively transmit visual information from the retina to several regions in the midbrain. There are about 1.2-1.5 million retinal ganglion cells in the human retina. The GLAID device was approved by the U.S. Food and Drug Administration (FDA) in 2007.
The GLAID device has undergone extensive testing and clinical studies in the U.S., Canada and Italy, including Bascom Palmer Eye Institute (Miami and Palm Beach, FL), University of California at San Diego’s Hamilton Glaucoma Center, New York State College of Optometry, University of Laval (Quebec, Canada), and the University of Alabama. The current state of the GLAID technology was developed by Dr. Vittorio Porciatti, who is also involved in further GLAID-related research at Bascom Palmer Eye Institute.
“We believe the GLAID device is the most significant development in glaucoma detection in the last 20 years,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “It represents a multimillion-dollar market opportunity for our Company.”
“We are pleased to be working with Paradigm Medical in introducing and promoting GLAID,” said Alessio Romani, chief executive of LACE. “The Company is well known and respected for its glaucoma diagnostic devices. The agreement is expected to accelerate acceptance of the GLAID technology in North America and Canada in 2008.”
“The GLAID device is believed to be the fastest method of testing for retinal ganglion cell loss,” Mr. Cannefax noted. “The GLAID not only measures dead and living ganglion cells, but also detects ailing ganglion cells. Due to the device’s ability to detect dying ganglion cells, in most cases the viability of these cells can be fully restored with treatment.”
Mr. Cannefax added that “GLAID provides a test that is fast and easy to understand and administer, easy to interpret by the clinician, and is non-invasive. It is reliable, operator independent, and is able to detect dysfunction of the ganglion cells in patients who are glaucoma suspects. GLAID can detect the onset of retinal defects significantly earlier than can be measured by the current standard of detection method of Visual Fields Analysis (Perimeters). We expect to begin filling orders during the first quarter of 2008.”
Glaucoma, caused by deterioration of the optic nerve and related ganglion cells, is the second leading cause of permanent vision loss. It affects one in five people over age 50. Some 75% of glaucoma goes undiagnosed because of the lack of sophisticated instrumentation. There are more than 64 million cases of glaucoma worldwide, including more than three million in the U.S. About 120,000 people in this country are blind as a result of glaucoma. Nearly 16,000 surgeries are performed in the U.S. each year on patients with glaucoma, with the cost averaging about $3,200, depending on the severity of the glaucoma. In terms of Social Security benefits, loss of income tax revenues and health-care expenditures, the cost to the U.S. government related to glaucoma is estimated to be more than $1.5 billion annually.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
Source: Business Wire (January 28, 2008 - 9:42 AM EST)
News by QuoteMedia
www.quotemedia.com
NEWS !
Antwort auf Beitrag Nr.: 33.191.304 von kirroyal am 28.01.08 15:54:49Thanks! Hört sich gut an!
Antwort auf Beitrag Nr.: 33.192.781 von hessenkoenig am 28.01.08 17:58:02sag ich doch. Mit solchen Meldungen fing bis jetzt immer das Warmlaufen an. Febr. is coming!
Jetzt gilt es diesen Wert täglich zu beobachten.
Auf ein grünendes Depot!
Sweeper
Jetzt gilt es diesen Wert täglich zu beobachten.
Auf ein grünendes Depot!
Sweeper
Antwort auf Beitrag Nr.: 33.195.059 von STARSWEEPER am 28.01.08 21:19:39läuft heute schon wie geschmiert da drüben!
Sweeper
Sweeper
Antwort auf Beitrag Nr.: 33.195.596 von STARSWEEPER am 28.01.08 21:54:03MACD u. RSI sehen sehr gut aus!
Pmed schließt auf Tageshoch bei 0,0015.
Gut so!
Sweeper
Gut so!
Sweeper
Antwort auf Beitrag Nr.: 33.207.959 von STARSWEEPER am 29.01.08 22:24:42wollte am 28.1.600000 über xetra haben war nix zu kriegen,steht noch nicht mal im BID!!??
Antwort auf Beitrag Nr.: 33.211.895 von hessenkoenig am 30.01.08 12:13:36Ging mir im Okt. genau so. Habe dann bei den Amis gekauft-war absolut problemlos.
Sweeper
Sweeper
Antwort auf Beitrag Nr.: 33.211.895 von hessenkoenig am 30.01.08 12:13:36zu welchem Preis?
wollte 100000 in frankfurt zu 0,001 haben,hat leider nicht mehr geklappt.
pitschi
wollte 100000 in frankfurt zu 0,001 haben,hat leider nicht mehr geklappt.
pitschi
Antwort auf Beitrag Nr.: 33.212.127 von pitschi am 30.01.08 12:33:28jetzt stehn sie wenigstens im BID drin bei Xetra...obs was wird?Wohl nur wenns drüben heute drastisch runter geht...morgen kanns ja wieder up gehn!
Antwort auf Beitrag Nr.: 33.212.127 von pitschi am 30.01.08 12:33:28zu 0,001 - xetra bedient auch teilmengen,standen in Ffm bei 2,5 mio zu 0,002(gestern).
Antwort auf Beitrag Nr.: 33.211.979 von STARSWEEPER am 30.01.08 12:21:39Hi Sweeper ! Hab meine 600000 bekommen - jetzt kanns losgehen!!!
warum sollte der kurs wieder so ausbrechen, wie die jahre zuvor?? sind das nur charttechnische vermutungen oder wartet ihr auf besondere news???
Antwort auf Beitrag Nr.: 33.216.570 von hessenkoenig am 30.01.08 17:39:22Freut mich-da hast Du ganz sicher nichts mit verkehrt gemacht. Zu welchem Kurs hast Du sie bekommen? Der Newsflow seitens Pmed für Januar war schon ok. Der Ausbruch kam meistens zwischen dem 1. u. 15.2. Schaun wir mal wie es demnächst läuft. In den AMERIKANISCHEN Boards überschlagen sie sich schon. Bin gespannt wie wir heute dort schliessen. Im Moment liegen wir dort bei 0.0014 d. h. es ging die vergangenen Stunde leicht nach unten-besagt allerdins nichts. Der Trend stimmt noch.
Alles Gute!
Sweeper
Alles Gute!
Sweeper
Antwort auf Beitrag Nr.: 33.217.216 von Illuminat85 am 30.01.08 18:29:36warum sollte der kurs wieder so ausbrechen, wie die jahre zuvor?? sind das nur charttechnische vermutungen oder wartet ihr auf besondere news???
Die Frage stelle ich mir auch schon seit längerem....
Eine vernünftige Antwort ist hier im Thread bisher auch noch nicht aufgetaucht....
Hab PMED mal auf meine WL gepackt!
Die Frage stelle ich mir auch schon seit längerem....
Eine vernünftige Antwort ist hier im Thread bisher auch noch nicht aufgetaucht....
Hab PMED mal auf meine WL gepackt!
@ starsweeper
@ hessenkoenig
spekuliert ihr nur auf einen ausbruch, weil dieser in den letzten jahren um die selbe zeit erfolgte oder wird hier auf eine besondere news oder ähnliches gewartet??
danke
@ hessenkoenig
spekuliert ihr nur auf einen ausbruch, weil dieser in den letzten jahren um die selbe zeit erfolgte oder wird hier auf eine besondere news oder ähnliches gewartet??
danke
Antwort auf Beitrag Nr.: 33.219.647 von STARSWEEPER am 30.01.08 21:28:30In den AMERIKANISCHEN Boards überschlagen sie sich schon
mag ja sein, je nachdem wie man überschlagen definiert..
sie reden dort von "death spiral financing", welches sie aus einem SEC filling herausgelesen haben wollen...
kling jedenfalls nicht sehr vielversprechend, was haltet ihr davon??
mag ja sein, je nachdem wie man überschlagen definiert..
sie reden dort von "death spiral financing", welches sie aus einem SEC filling herausgelesen haben wollen...
kling jedenfalls nicht sehr vielversprechend, was haltet ihr davon??
Antwort auf Beitrag Nr.: 33.219.647 von STARSWEEPER am 30.01.08 21:28:30zu 0,001 bekommen....wo würdest du Limit setzen??
Antwort auf Beitrag Nr.: 33.222.986 von Illuminat85 am 31.01.08 09:56:58Hallo Illu! Ist bei mir ne Gefühlssache bzw. siehe auch Beitrag von KIRROYAL 28.1.08 15.54 Uhr.Partner aus Italien...hört sich gut an!
Antwort auf Beitrag Nr.: 33.223.887 von hessenkoenig am 31.01.08 11:08:00ok, also in naher zukunft werden sie das GLAID-system der italiener vertreiben. es wird dann wohl hier aufgelistet:
http://www.paradigm-medical.com/web/index.php?page=shop.brow…
wenn ich das richtig verstanden habe ist dieses gerät eine art diagnosemaschiene für die augenkrankheit grüner-star (u. abhandlungen), die zur erblindung führen kann:
http://www.augenklinik-bellevue.de/de/therapie_gruenerstar.p…
hier ist die beschreibung des herstellers:
http://www.lace.it/html/index_diagnostica_e.htm
ob dieses gerät in den usa erfolgreich abgesetzt werden kann bleibt natürlich fraglich. der markt dafür ist jedenfalls da. trotzdem denke ich es ist nicht gerade eine news die den kurs beflügeln müsste.....
ps: wenn ihr dem etwas hinzuzufügen oder zu korrigieren habt, dann tut dies bitte. sind alles nur annahmen von mir...
http://www.paradigm-medical.com/web/index.php?page=shop.brow…
wenn ich das richtig verstanden habe ist dieses gerät eine art diagnosemaschiene für die augenkrankheit grüner-star (u. abhandlungen), die zur erblindung führen kann:
http://www.augenklinik-bellevue.de/de/therapie_gruenerstar.p…
hier ist die beschreibung des herstellers:
http://www.lace.it/html/index_diagnostica_e.htm
ob dieses gerät in den usa erfolgreich abgesetzt werden kann bleibt natürlich fraglich. der markt dafür ist jedenfalls da. trotzdem denke ich es ist nicht gerade eine news die den kurs beflügeln müsste.....
ps: wenn ihr dem etwas hinzuzufügen oder zu korrigieren habt, dann tut dies bitte. sind alles nur annahmen von mir...
Antwort auf Beitrag Nr.: 33.224.963 von Illuminat85 am 31.01.08 12:24:03Danke,ich schau mal rein!
Antwort auf Beitrag Nr.: 33.223.844 von hessenkoenig am 31.01.08 11:04:03Grüss Dich Hessenkönig!
Deine Frage nach einem sinnvollen VK-Limit kann ich Dir leicht beantworten.
Ich habe in USA zu umgerechnet 0.0016€ gekauft. Für 0.001 war damals hier nichts zu bekommen. Deshalb schonmal Gratulation zu Deinem Einstiegskurs.
Also ich werde mein VK-Limit bei 0.02 einloggen. Ich gehe mal Kavon aus, dass der Wert in der Spitze noch darüber marschiert.
Je nach dem wie die Käuferseite während des Hypes aussieht, ist es durchaus möglich, dass ich mein VK-Ziel dann noch nach oben korrigiere.
@Illuminate85
klare Frage-klare Antwort.
Es bleibt dabei wie ich schon bei meinem Wiedereinstieg schrieb-Pmed betrachte ich als reinen Zock also reines Bauchgefühl.
Allerdings sei gesagt, dass die Anzeichen für einen erneuten Anstieg denen von letztem u. vorletztem Jahr ähneln.
Grüsse Sweeper
Deine Frage nach einem sinnvollen VK-Limit kann ich Dir leicht beantworten.
Ich habe in USA zu umgerechnet 0.0016€ gekauft. Für 0.001 war damals hier nichts zu bekommen. Deshalb schonmal Gratulation zu Deinem Einstiegskurs.
Also ich werde mein VK-Limit bei 0.02 einloggen. Ich gehe mal Kavon aus, dass der Wert in der Spitze noch darüber marschiert.
Je nach dem wie die Käuferseite während des Hypes aussieht, ist es durchaus möglich, dass ich mein VK-Ziel dann noch nach oben korrigiere.
@Illuminate85
klare Frage-klare Antwort.
Es bleibt dabei wie ich schon bei meinem Wiedereinstieg schrieb-Pmed betrachte ich als reinen Zock also reines Bauchgefühl.
Allerdings sei gesagt, dass die Anzeichen für einen erneuten Anstieg denen von letztem u. vorletztem Jahr ähneln.
Grüsse Sweeper
Antwort auf Beitrag Nr.: 33.226.998 von STARSWEEPER am 31.01.08 15:09:10genau da hab ich gestern eingeloggt!0,02
Gruß aus Hessen
Gruß aus Hessen
ok, also obald mal volumen reinkommt werde ich mir wohl auchmal eine kleine position gönnen. es kann jedenfalls nicht schaden noch ein wenig zu streuen...
PARADIGM MED. INDS
Hinzufügen zu:
Portfolio
Watchlist
1,00
+99.900,00 %
+1,00
Frankfurt (EUR), 01.02.08 | 09:06
Intraday-Chart
WKN: 905600
ISIN: US69900Q1085
Symbol: PDI
Hinzufügen zu:
Portfolio
Watchlist
1,00
+99.900,00 %
+1,00
Frankfurt (EUR), 01.02.08 | 09:06
Intraday-Chart
WKN: 905600
ISIN: US69900Q1085
Symbol: PDI
Antwort auf Beitrag Nr.: 33.236.904 von Sensorvol am 01.02.08 11:59:22WOW! Das wär ein Hammer!!Dann würd ich gerade kündigen!!!
Antwort auf Beitrag Nr.: 33.237.070 von hessenkoenig am 01.02.08 12:12:26Ich hab schon ein neues BMW bestelt.
hallo
kenn mich nicht so aus,aber wie kommt denn der eine Euro
in Frankfurt zustande.dafür würde ich natürlich gerne verkaufengruß
pitschi
kenn mich nicht so aus,aber wie kommt denn der eine Euro
in Frankfurt zustande.dafür würde ich natürlich gerne verkaufen
grußpitschi
also wenn ich meine jetzt zu 1,00 € verkaufen könnte wäre mein Haus auf einen Schlag abbezahlt.....
Träümen darf man ja....
Träümen darf man ja....
50 cent wären ja auch nicht schlecht....wird aber noch dauern...
Antwort auf Beitrag Nr.: 33.246.589 von hessenkoenig am 02.02.08 09:46:43
NEWS !
February 4, 2008 - 9:51 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.0014 0.00
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries Promotes Mostacero to Chief Financial Officer
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), a leader in glaucoma diagnostic and management devices, announced today the promotion of Luis Mostacero to Chief Financial Officer, effective immediately. He has served as Vice President Finance since March 2006.
“We are fortunate to have someone of Luis’ multi-faceted talents managing our financial organization and structure,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “He has been very instrumental in coordinating our financial planning and metrics for the last two years, resulting in our improving balance sheet and cash flow.”
Mr. Mostacero, 43, rejoined Paradigm Medical in 2006. He originally joined the Company in March 2000. He served as Controller of Distinctive Creations, a Utah-based manufacturing company, from September 2005-March 2006.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Raymond Cannefax, CEO
801-977-8970
www.paradigm-medical.com
Source: Business Wire (February 4, 2008 - 9:51 AM EST)
News by QuoteMedia
www.quotemedia.com
NEWS !
February 4, 2008 - 9:51 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.0014 0.00
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries Promotes Mostacero to Chief Financial Officer
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), a leader in glaucoma diagnostic and management devices, announced today the promotion of Luis Mostacero to Chief Financial Officer, effective immediately. He has served as Vice President Finance since March 2006.
“We are fortunate to have someone of Luis’ multi-faceted talents managing our financial organization and structure,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “He has been very instrumental in coordinating our financial planning and metrics for the last two years, resulting in our improving balance sheet and cash flow.”
Mr. Mostacero, 43, rejoined Paradigm Medical in 2006. He originally joined the Company in March 2000. He served as Controller of Distinctive Creations, a Utah-based manufacturing company, from September 2005-March 2006.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Raymond Cannefax, CEO
801-977-8970
www.paradigm-medical.com
Source: Business Wire (February 4, 2008 - 9:51 AM EST)
News by QuoteMedia
www.quotemedia.com
Ach man, jetzt hab ich mich schon auf den 1 € Kurs gefreut
Naja, vielleicht kommt der Euro schnell wieder.
Warum war der Kurs den in Frankfurt bei 1 € und nicht im Xetra oder Berlin?
Naja, vielleicht kommt der Euro schnell wieder.
Warum war der Kurs den in Frankfurt bei 1 € und nicht im Xetra oder Berlin?
war einfach ne Falschmeldung....
las es gerade in einem ami-board u. dacht es interessiert Euch.
Denk,das lässt hoffen!!!
Grüsse Sweeper
Date:2/5/2008 5:06:19 PM
Post #of 2656
Gentlemen (and Ladies)
Talked to PMED today and received an e-mail from Mr. Cannefax. He said he too is hoping for the trading cycle to end and to see an increase in the pps but there is no control over the trading rooms on Wall St. He is very satisfied to have all the law suits and other actions behind them allowing them to progress to the next level of introducing "new products" (my emphasis). He said they have a great number of things on the horizon and is optimistic that their team will help grow the company back to the stature it had previously.
Also, Mr. Cannefax is leaving for a week long conference in Barcelona, Spain of the European Society of Cataract and Refractive Surgeons. They have a website escrs.org. Go to meetings and then Barcelona 2008. He has other business to attend to and will be back in the office around the 22nd of Feb.
We may or may not have our February surprise spike but I think we have good news in the near future. I thought you might be interested in this information and make the patient waiting a little easier till the good news comes out. Good luck to us all.
Denk,das lässt hoffen!!!
Grüsse Sweeper
Date:2/5/2008 5:06:19 PM
Post #of 2656
Gentlemen (and Ladies)
Talked to PMED today and received an e-mail from Mr. Cannefax. He said he too is hoping for the trading cycle to end and to see an increase in the pps but there is no control over the trading rooms on Wall St. He is very satisfied to have all the law suits and other actions behind them allowing them to progress to the next level of introducing "new products" (my emphasis). He said they have a great number of things on the horizon and is optimistic that their team will help grow the company back to the stature it had previously.
Also, Mr. Cannefax is leaving for a week long conference in Barcelona, Spain of the European Society of Cataract and Refractive Surgeons. They have a website escrs.org. Go to meetings and then Barcelona 2008. He has other business to attend to and will be back in the office around the 22nd of Feb.
We may or may not have our February surprise spike but I think we have good news in the near future. I thought you might be interested in this information and make the patient waiting a little easier till the good news comes out. Good luck to us all.
Antwort auf Beitrag Nr.: 33.290.310 von STARSWEEPER am 06.02.08 22:52:21
der kurs im amiland sieht aber nicht nach hoffnung aus!
was meint ihr???????????????????????????:O:O:O
der kurs im amiland sieht aber nicht nach hoffnung aus!was meint ihr???????????????????????????:O:O:O
Antwort auf Beitrag Nr.: 33.301.080 von pitschi am 07.02.08 20:18:42Hi pitschi,
für heute u. den Moment muss ich Dir leider recht geben. Werde mir gleich mal die Statements der amerikanischen User reinziehen. Mal lesen was die dort dazu sagen. Ich könnte mir vorstellen, dass Viele auf den Tag genau auf den Anstieg wie im Febr. letzten Jahres spekuliert hatten u. jetzt aus dem Wert eigentlich grundlos rausgehen. Nun, ich weiss es nicht. Schaun wir mal was die Amis so von sich geben. Falls ich dort etwas erfahre, werde ich diese Info direkt hier im Board weitergeben.
In diesem Sinne
Grüsse Sweeper
für heute u. den Moment muss ich Dir leider recht geben. Werde mir gleich mal die Statements der amerikanischen User reinziehen. Mal lesen was die dort dazu sagen. Ich könnte mir vorstellen, dass Viele auf den Tag genau auf den Anstieg wie im Febr. letzten Jahres spekuliert hatten u. jetzt aus dem Wert eigentlich grundlos rausgehen. Nun, ich weiss es nicht. Schaun wir mal was die Amis so von sich geben. Falls ich dort etwas erfahre, werde ich diese Info direkt hier im Board weitergeben.
In diesem Sinne
Grüsse Sweeper
Antwort auf Beitrag Nr.: 33.301.304 von STARSWEEPER am 07.02.08 20:37:17hier mal ein Statement, das in die von mir vorhin angedeutete Richtung geht:
SweeperPosted by: Investolator
In reply to: None Date:2/7/2008 9:19:28 AM
Post #of 2669
Good Morning each and everyone. Here is hoping that you all have a great day today. It was 1 year ago today that PMED shot up to .034 and then the next day to .04. IMO, if it does run like in the past, I believe we will see volume of 200m or more. When will it run, if it does? I don't know. How high will it run, if it does? I don't know. Right now, I am just wanting to see it at .01, and when we are at that level, then I will consider what might lay ahead at that point. All we can do is take one day at a time. GLTA
Seán
--------------------------------------------------------------------------------
May our up days be many and the down days few.
Fada cónaigh agus brabach.
SweeperPosted by: Investolator
In reply to: None Date:2/7/2008 9:19:28 AM
Post #of 2669
Good Morning each and everyone. Here is hoping that you all have a great day today. It was 1 year ago today that PMED shot up to .034 and then the next day to .04. IMO, if it does run like in the past, I believe we will see volume of 200m or more. When will it run, if it does? I don't know. How high will it run, if it does? I don't know. Right now, I am just wanting to see it at .01, and when we are at that level, then I will consider what might lay ahead at that point. All we can do is take one day at a time. GLTA
Seán
--------------------------------------------------------------------------------
May our up days be many and the down days few.
Fada cónaigh agus brabach.
PMED schließt drüben im Plus. Es sieht gut aus.
Allen ein vergnügliches Wochenende sowie ein grünendes Depot!
Sweeper
Allen ein vergnügliches Wochenende sowie ein grünendes Depot!
Sweeper
Mit etwas Verwunderung lese ich die Beiträge einiger Investierten, die ernsthaft davon überzeugt waren, dass es genau zum gleichen Datum wie 2007, nämlich am 07. Februar, mit unserer Perle senkrecht nach oben geht. Wie naiv denken hier einige überhaupt??
Bin trotzdem fest davon überzeugt, dass es hier bald richtig abgeht. Habe mich nicht umsonst mit 4,6 Mill. Stück eingedeckt.
Auf fette Beute, Gruß Stern
Bin trotzdem fest davon überzeugt, dass es hier bald richtig abgeht. Habe mich nicht umsonst mit 4,6 Mill. Stück eingedeckt.
Auf fette Beute, Gruß Stern
und wieder schließt unser Wert drüben auf Tageshoch.
Allen eine erfolgreiche Börsenwoche!
Gruss Sweeper
Allen eine erfolgreiche Börsenwoche!
Gruss Sweeper
Antwort auf Beitrag Nr.: 33.336.335 von STARSWEEPER am 11.02.08 22:49:59Dir auch Sweeper!Danke.
Einfach mal abwarten, was die nächsten Monate so bringen. Ich denke mal das es sich sehr lohnen wird.
Pmed schließt heute drüben im neutralen Bereich bei 0,0012.
Hier mal wieder ein aufbauendes Posting aus einem Ami-Board:
Grüsse Sweeper
Posted by: fillinggood
In reply to: None Date:2/13/2008 4:04:33 PM
Post #of 2705
The CEO is working; he should be wrapping up his trip to Barcelona with the surgeons and then other business and be back in the office by the 22nd of Feb. I mught be wrong but I don't think we will get any PRs until then but I suspect the next one will be big with either sales or new products. Until then I think the PPS will stay flat but ready to take off with the next news. It is so hard to wait without news but the CEO doesn't put out fluff PRs and 3-4 more weeks isn't that much to ask if we get what we all really expect from this company. They have real products recognized by other companies of the same ilk as attested by the Italian co. that chose PMED to distribute their machine because PMED had a good reputation with their own products. NIR will end eventually, maybe longer than we would like, but it is just one other thing to wait for as we know this company is here to stay. Here's to tempered patience and long suffering and G
Hier mal wieder ein aufbauendes Posting aus einem Ami-Board:
Grüsse Sweeper
Posted by: fillinggood
In reply to: None Date:2/13/2008 4:04:33 PM
Post #of 2705
The CEO is working; he should be wrapping up his trip to Barcelona with the surgeons and then other business and be back in the office by the 22nd of Feb. I mught be wrong but I don't think we will get any PRs until then but I suspect the next one will be big with either sales or new products. Until then I think the PPS will stay flat but ready to take off with the next news. It is so hard to wait without news but the CEO doesn't put out fluff PRs and 3-4 more weeks isn't that much to ask if we get what we all really expect from this company. They have real products recognized by other companies of the same ilk as attested by the Italian co. that chose PMED to distribute their machine because PMED had a good reputation with their own products. NIR will end eventually, maybe longer than we would like, but it is just one other thing to wait for as we know this company is here to stay. Here's to tempered patience and long suffering and G
Antwort auf Beitrag Nr.: 33.361.301 von STARSWEEPER am 13.02.08 22:53:38...so langsam könnte es hier jetzt endlich mal zum Urknall kommen. Ich warte jeden Tag, dass es losgeht. Wird schon!
Der momentane Kurs ist ein absoluter Witz, ich nutze nach wie vor jede Gelegenheit, um mich einzudecken,
Gruß Stern
Der momentane Kurs ist ein absoluter Witz, ich nutze nach wie vor jede Gelegenheit, um mich einzudecken,
Gruß Stern
Feiertag überm Teich??(OTCB)
Antwort auf Beitrag Nr.: 33.404.797 von hessenkoenig am 18.02.08 19:48:18Market closed for presidentsday.
Schaun wir mal wie es morgen läuft.
Gruss Sweeper
Schaun wir mal wie es morgen läuft.
Gruss Sweeper
Tach auch, sagt mal Leute wer von Euch glaubt denn noch dran das hier bei PMED nochmal was nach oben geht???
Bei mir verpufft der Glaube daran so langsam.....
Bei mir verpufft der Glaube daran so langsam.....
... @max82... dann kannst du mir gerne Deine Anteile verkaufen
Antwort auf Beitrag Nr.: 33.414.158 von Max82 am 19.02.08 18:02:25Keine Panik
Unsere Zeit kommt noch!!!
Unsere Zeit kommt noch!!!
Antwort auf Beitrag Nr.: 33.414.836 von udoliane am 19.02.08 19:13:43So sieht es aus!
Schlusskurs drüben heute wieder im grünen Bereich bei 0,0013.
Das wird schon. Lasst mal den CEO ab dem 22.02.08 wieder im Büro sein. Ich denke dann werden die News nicht lange auf sich warten lassen.
In diesem Sinne.
Keep
Sweeper
Schlusskurs drüben heute wieder im grünen Bereich bei 0,0013.
Das wird schon. Lasst mal den CEO ab dem 22.02.08 wieder im Büro sein. Ich denke dann werden die News nicht lange auf sich warten lassen.
In diesem Sinne.
Keep
Sweeper
Antwort auf Beitrag Nr.: 33.414.333 von stern16 am 19.02.08 18:16:00was würdest denn bezahlen stern? Ich hab meine schon ein Jahr!!!
sieht so aus als gibt es hier keine Hoffnung mehr
oder wie seht ihr das???????????????????
oder wie seht ihr das???????????????????
immer locker bleiben!!
..in den nächsten zwei Wochen knallts!
Hallo Hessenkönig,
hast du irgendwelche Anhaltspunkte für Deine Behauptung oder ist es nur so ein Gefühl?
Gruss Stern
hast du irgendwelche Anhaltspunkte für Deine Behauptung oder ist es nur so ein Gefühl?
Gruss Stern
Hier zum Vertreiben der newsarmen Zeit mal ein paar Auszüge aus einem Ami-Board:
Posted by: fillinggood
In reply to: None Date:2/21/2008 4:56:00 PM
Post #of 2786
It's kind of like a vacation; the closer you get to it the more time drags. I have been preaching patience but I am just as impatiently expectant about a good PR as everyone else. I don't think we will get a PR on a Friday, but I just don't know how that works and I certainly hope Mr. Cannefax doesn't wait until after the stockholders meeting to issue the next PR. We could really use any PR but especially a good one. We would all like our dinners to digest a little easier. Keep the faith brothers and GLTA!
Posted by: fillinggood
In reply to: None Date:2/20/2008 12:09:16 PM
Post #of 2788
Good morning to all! Just as a remimder, I was told by the secretary that Cannefax would be back in the office by the 22nd this Friday. We probably won't get a PR until then so we might need to be patient until next week, unfortunately. Additionally, for whatever reason, they might not want to let out a PR, even if it is good, until after the meeting to increase the AS to 1,400,000,000 due to whatever effect it might have on the PPS, even if it is good. In that case, we might have to be patient awhile longer. I am no expert in this, it is all just my subjective and humble opinion, nothing based in fact. Hope you have a pain free day Sean! GLTA
Übrigens-wir schlossen heute drüben 20%im Plus.
Allen eine grünende Woche!
Sweeper
Posted by: fillinggood
In reply to: None Date:2/21/2008 4:56:00 PM
Post #of 2786
It's kind of like a vacation; the closer you get to it the more time drags. I have been preaching patience but I am just as impatiently expectant about a good PR as everyone else. I don't think we will get a PR on a Friday, but I just don't know how that works and I certainly hope Mr. Cannefax doesn't wait until after the stockholders meeting to issue the next PR. We could really use any PR but especially a good one. We would all like our dinners to digest a little easier. Keep the faith brothers and GLTA!
Posted by: fillinggood
In reply to: None Date:2/20/2008 12:09:16 PM
Post #of 2788
Good morning to all! Just as a remimder, I was told by the secretary that Cannefax would be back in the office by the 22nd this Friday. We probably won't get a PR until then so we might need to be patient until next week, unfortunately. Additionally, for whatever reason, they might not want to let out a PR, even if it is good, until after the meeting to increase the AS to 1,400,000,000 due to whatever effect it might have on the PPS, even if it is good. In that case, we might have to be patient awhile longer. I am no expert in this, it is all just my subjective and humble opinion, nothing based in fact. Hope you have a pain free day Sean! GLTA
Übrigens-wir schlossen heute drüben 20%im Plus.
Allen eine grünende Woche!
Sweeper
Antwort auf Beitrag Nr.: 33.450.109 von stern16 am 22.02.08 17:37:59moin stern-komme erst heute zum beantworten.Ist ein reines Bauchgefühl wobei ich mich auf meinen Bauch schon sehr sehr oft verlassen konnte ! Ich gene davon aus das auch sweeper so ein
Kribbeln im Bauch hat!!
Kribbeln im Bauch hat!!
Na, dann mal auf Euer Bauchgefühl. Aber auch ich glaube das sich bald etwas positives tut. So wie ich Hr. Cannafax einschätze, kommt der erst mit neuen News raus, wenn diese wirklich hieb- und stichfest sind, nicht wie bei vielen Börsenbriefen, die die Wahrheit oft schamlos verbiegen.
Auf das wir bald einen schönen gewinn mitnehmen, schönes WE,
gruss Stern
Auf das wir bald einen schönen gewinn mitnehmen, schönes WE,
gruss Stern
Moin Gemeinde,
das Ding wird nicht im Börsenbrief auftauchen.
Taucht PMED auf ist vorsicht angesagt, dann wird Kohle verbrannt.
Aber dazu ist es schon zu beständig!
Die ersten Geräte sind ausgeliefert und laufen.
Jetzt kommen die nächsten Aufträge.....
Das dauert halt ein bischen....
Die Grundlage ist geschaffen.
Bin im Amiland bei 0,001 eingestiegen und warte einfach mal ab.
Allen noch ein schönes WO und GRÜNE ZAHLEN in der Zukunft
Gruss
Übrigens: Bauchgefühl ist gut sehr gut
das Ding wird nicht im Börsenbrief auftauchen.
Taucht PMED auf ist vorsicht angesagt, dann wird Kohle verbrannt.
Aber dazu ist es schon zu beständig!
Die ersten Geräte sind ausgeliefert und laufen.
Jetzt kommen die nächsten Aufträge.....
Das dauert halt ein bischen....
Die Grundlage ist geschaffen.
Bin im Amiland bei 0,001 eingestiegen und warte einfach mal ab.
Allen noch ein schönes WO und GRÜNE ZAHLEN in der Zukunft
Gruss
Übrigens: Bauchgefühl ist gut
sehr gut
Na ganz großes Kino 0,0009 in Amiland...also so langsam glaub ich echt nicht mehr dran das sich hier nochmal was bewegt....
ruhig mein lieber Max , ruhig!Sieht nach momentanen Stand schon wieder beruhigender aus!
Aktueller Stand in Frankfurt 1,00 + 99.9990 % Da ist ja wieder der Euro
Antwort auf Beitrag Nr.: 33.504.199 von AW-Spezi am 28.02.08 15:36:17jetzt brauch ich nur jemand der mir meine zu dem 1,- € in Fra abkauft...dann bin ich vollkommen zufrieden....
Und schon ist der € wieder weg. Was machen die nur ion Frankfurt, vor 2 Wochen das gleiche Spielchen.
Antwort auf Beitrag Nr.: 33.515.181 von AW-Spezi am 29.02.08 13:50:03das iss so ne Art Wachrütteln....
Sehr gut erkannt Hessenkönig,
vielen Dank für diesen wertvollen Hinweis! ;-)
vielen Dank für diesen wertvollen Hinweis! ;-)
Weiß jemand Neuigkeiten über Verkaufszahlen von PM?? Seit den Geschäften mit der Optikerkette in England kurz vor Weihnachten hat man diesbezüglich nicht viel neues gehört.
Na, das sieht ja heute gar nicht gut aus im Amiland. Diesen Kurs sollte man eigentlich zum Nachlegen nutzen. Hier mal ein interesantes Posting aus einem dortigen Board:
Grüsse Sweeper
Posted by: voitsi
In reply to: None Date:3/5/2008 3:26:36 AM
Post #of 2862
Email from Mr. Cannefax:
Hello Franz -
Regretfully, the NIR Group is providing us the capital to keep moving forward as our group redesings our product line. Our current tasks are things that are over-due and we are interested in continuing to provide the best devices into the industry. The increase in shares is necessary for us to continued to make our payments through stock conversions.
The meeting in Barcelona went quite well and, if you follow our press releases, you will see that the new device, the Glaid glaucoma diagnostic tool, will be coming out soon. I expect this device to have a tremendous impact on the industry following its years of testing at places such ad Bascom-Palmer Eye Institute, Hamiltorn Glaucoma center and in Pisa, Italy.
Thank you for your continued support and confidence.
Best regards,
Raymond Canefax
xxxxxxxxxxxxxx
Dear Mr. Cannefax.
Is it possible to give us shareholders a few updates regarding the development in the company and the meeting in Barcelona.
As well we are very concerned about the financing with the NIR Group. Many believe they only want to drive the stock price down and force PMED into massive dilution(Death Spiral Financing). The following increase in authorized shares of common stock to 1,400,000,000 is a sign what's going on.
The recent pps is horrible and in my opinion a sign of massive dilution.
I hope we hear from you soon!
With best regards,
Franz
Grüsse Sweeper
Posted by: voitsi
In reply to: None Date:3/5/2008 3:26:36 AM
Post #of 2862
Email from Mr. Cannefax:
Hello Franz -
Regretfully, the NIR Group is providing us the capital to keep moving forward as our group redesings our product line. Our current tasks are things that are over-due and we are interested in continuing to provide the best devices into the industry. The increase in shares is necessary for us to continued to make our payments through stock conversions.
The meeting in Barcelona went quite well and, if you follow our press releases, you will see that the new device, the Glaid glaucoma diagnostic tool, will be coming out soon. I expect this device to have a tremendous impact on the industry following its years of testing at places such ad Bascom-Palmer Eye Institute, Hamiltorn Glaucoma center and in Pisa, Italy.
Thank you for your continued support and confidence.
Best regards,
Raymond Canefax
xxxxxxxxxxxxxx
Dear Mr. Cannefax.
Is it possible to give us shareholders a few updates regarding the development in the company and the meeting in Barcelona.
As well we are very concerned about the financing with the NIR Group. Many believe they only want to drive the stock price down and force PMED into massive dilution(Death Spiral Financing). The following increase in authorized shares of common stock to 1,400,000,000 is a sign what's going on.
The recent pps is horrible and in my opinion a sign of massive dilution.
I hope we hear from you soon!
With best regards,
Franz
Paradigm Medical Industries Introduces Advances on the LD400 Full-Field Autoperimetry System
Wednesday March 5, 4:42 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB - News), a leader in glaucoma diagnostic and management devices, is introducing new advance developments to the Paradigm-Dicon LD400 full-field autoperimetry system. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
ADVERTISEMENT
“The Company has redesigned what we believe to be the industry’s superior autoperimeter,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “Demand for our proprietary Paradigm-Dicon LD400 product continues to be extremely high in the U.S. and globally, and this updated product incorporates all the changes the medical profession has requested. We believe we are also broadening the market for autoperimeters.
“The kinetic fixation feature of the LD400 Autoperimeter is unique and exclusive to perimetry and offers full kinetic fixation for greater reliability, improved test results and patient comfort,” Mr. Cannefax added. “Kinetic fixation reduces patient fatigue and increases patient interest resulting in higher exam accuracy. The Paradigm-Dicon LD400 provides the highest standard of care from a full-field autoperimeter.”
New developments to the LD400 include redesigning the existing software, assuring device compatibility with a variety of printers and making the device fully networkable. All connections will be through USB ports. The patient data base will be similar to the Paradigm P60 Ultrasound BioMicroscope (UBM) and the printed examination reports will be grayscale, making them much easier to read.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
--------------------------------------------------------------------------------
Source: Paradigm Medical Industries, Inc.
Wednesday March 5, 4:42 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB - News), a leader in glaucoma diagnostic and management devices, is introducing new advance developments to the Paradigm-Dicon LD400 full-field autoperimetry system. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
ADVERTISEMENT
“The Company has redesigned what we believe to be the industry’s superior autoperimeter,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “Demand for our proprietary Paradigm-Dicon LD400 product continues to be extremely high in the U.S. and globally, and this updated product incorporates all the changes the medical profession has requested. We believe we are also broadening the market for autoperimeters.
“The kinetic fixation feature of the LD400 Autoperimeter is unique and exclusive to perimetry and offers full kinetic fixation for greater reliability, improved test results and patient comfort,” Mr. Cannefax added. “Kinetic fixation reduces patient fatigue and increases patient interest resulting in higher exam accuracy. The Paradigm-Dicon LD400 provides the highest standard of care from a full-field autoperimeter.”
New developments to the LD400 include redesigning the existing software, assuring device compatibility with a variety of printers and making the device fully networkable. All connections will be through USB ports. The patient data base will be similar to the Paradigm P60 Ultrasound BioMicroscope (UBM) and the printed examination reports will be grayscale, making them much easier to read.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
--------------------------------------------------------------------------------
Source: Paradigm Medical Industries, Inc.
kann mir jemand auf die Schnelle in etwa den Kram übersetzen?
Scheinen keine guten News zu sein bei 30% Minus drüben!!
Scheinen keine guten News zu sein bei 30% Minus drüben!!
Ich kanns dir nicht übersetzten aber ich glaub fast mittlerweile das das egal ist was da für ne News kommt, das Teil bleibt da wos ist oder geht noch runter......zum kot....
Antwort auf Beitrag Nr.: 33.567.165 von hessenkoenig am 06.03.08 13:14:46Die Presseinformation kam nach Börsenende.
Antwort auf Beitrag Nr.: 33.570.654 von Bombenleger am 06.03.08 17:52:47Kann bitte einer die Pressemitteilung und die gepostete email übersetzten!! Wäre klasse!! Mit meinem Englisch kann ich zwar ein bisschen was rauslesen, aber ne Übersetzung wäre klasse!!
danke schonmal!!!
danke schonmal!!!
"Die Firma hat neu gestaltet, was wir zu sein glauben, die Industrie autoperimeter überlegen", sagte Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "Die Nachfrage nach unseren proprietären Paradigm-Dicon LD400 Produkt ist nach wie vor extrem hoch in den USA und weltweit, und das aktualisierte Produkt enthält alle Änderungen der Ärzteschaft gefordert hat. Wir glauben, dass wir auch die Erweiterung des Marktes für autoperimeters.
"Die kinetische Fixierung Merkmal der LD400 Autoperimeter ist einmalig und exklusiv von Perimetrie und bietet volle kinetische Fixierung für eine größere Zuverlässigkeit, bessere Testergebnisse und Komfort für den Patienten," Mr. Cannefax hinzugefügt. "Kinetic Fixierung des Patienten reduziert die Müdigkeit und erhöht die Patienten höhere Zinsen in Klausur Genauigkeit. Die Paradigm-Dicon LD400 bietet den höchsten Standard der Gesundheitsversorgung von einer vollständigen autoperimeter-Bereich. "
Neue Entwicklungen auf den LD400 gehören Neugestaltung der bestehenden Software und garantiert Kompatibilität mit einer Vielzahl von Druckern und machen das Gerät voll netzwerkfähig. Alle Verbindungen werden über den USB-Ports. Die Patienten-Datenbank wird ähnlich wie der P60 Paradigm BioMicroscope Ultraschall (UBM) und der gedruckten Prüfung Berichte werden Graustufen, wodurch sie viel einfacher zu lesen.
Paradigm Medical Industries, Inc., ist ein führender Anbieter von Ultraschall-Geräten, Glaukom-und Erkennungs-und Management-Produkten.
genau
und deshalb ist der kurs ja auch so schön gefallen
oh gott
klasse ausgedrückt
"Die kinetische Fixierung Merkmal der LD400 Autoperimeter ist einmalig und exklusiv von Perimetrie und bietet volle kinetische Fixierung für eine größere Zuverlässigkeit, bessere Testergebnisse und Komfort für den Patienten," Mr. Cannefax hinzugefügt. "Kinetic Fixierung des Patienten reduziert die Müdigkeit und erhöht die Patienten höhere Zinsen in Klausur Genauigkeit. Die Paradigm-Dicon LD400 bietet den höchsten Standard der Gesundheitsversorgung von einer vollständigen autoperimeter-Bereich. "
Neue Entwicklungen auf den LD400 gehören Neugestaltung der bestehenden Software und garantiert Kompatibilität mit einer Vielzahl von Druckern und machen das Gerät voll netzwerkfähig. Alle Verbindungen werden über den USB-Ports. Die Patienten-Datenbank wird ähnlich wie der P60 Paradigm BioMicroscope Ultraschall (UBM) und der gedruckten Prüfung Berichte werden Graustufen, wodurch sie viel einfacher zu lesen.
Paradigm Medical Industries, Inc., ist ein führender Anbieter von Ultraschall-Geräten, Glaukom-und Erkennungs-und Management-Produkten.
genau
und deshalb ist der kurs ja auch so schön gefallen
oh gott
klasse ausgedrückt
Antwort auf Beitrag Nr.: 33.578.335 von Saftladen am 07.03.08 14:00:30Danke mein lieberSaftladen...hört sich in diesem Kauderwelch in etwa an wie im Englischenaber sind doch keine schlechten news??warum der Einbruch SWEEPER du hälts dich so merkwürdig zurück....!?
aber sind doch keine schlechten news??warum der Einbruch SWEEPER du hälts dich so merkwürdig zurück....!?
Hallo Hessenkönig,
so manche Entwicklungen an der Börse sind mit normalem Menschenverstand nicht nachvollziehbar.
Weiß irgendjemand wann die nächsten Geschäftszahlen rauskommen??
Wenn es stimmen sollte, was Herr Cannefax schreibt, dass die Nachfrage nach dem LD 400 so enorm hoch sei, müsste sich dies in den Zahlen wiederspiegeln.
Auf das es hier bald abgeht, Gruss Stern
so manche Entwicklungen an der Börse sind mit normalem Menschenverstand nicht nachvollziehbar.
Weiß irgendjemand wann die nächsten Geschäftszahlen rauskommen??
Wenn es stimmen sollte, was Herr Cannefax schreibt, dass die Nachfrage nach dem LD 400 so enorm hoch sei, müsste sich dies in den Zahlen wiederspiegeln.
Auf das es hier bald abgeht, Gruss Stern
heute gibt es wohl den Todesstoß in den USA,
schade eigentlich
oder doch nur die Ruhe vor dem Sturm
schade eigentlich
oder doch nur die Ruhe vor dem Sturm
Antwort auf Beitrag Nr.: 33.582.332 von pitschi am 07.03.08 19:19:18Wenn ich mir vorstelle, daß PMED selbst bei 1 Milliarde O/S eine Kapitalisierung von gerade mal 600 - 700000 Dollar hat, dann würde ich am liebsten die ganze Klitsche aufkaufen.(Wenn ich's Geld hätte).
Aber im Ernst: Es ist schon unglaublich wie diese Geldgeber(NIR Group) diese Firma zerstören wollen. Sollten wir dieses Jahr keine guten Zahlen sehen, dann Gute Nacht!
Aber im Ernst: Es ist schon unglaublich wie diese Geldgeber(NIR Group) diese Firma zerstören wollen. Sollten wir dieses Jahr keine guten Zahlen sehen, dann Gute Nacht!
Antwort auf Beitrag Nr.: 33.580.547 von hessenkoenig am 07.03.08 16:37:20SWEEPER du hälts dich so merkwürdig zurück....!?
That's right!
Sehe im Moment keinen Grund die z: Zt. negative Entwicklung zu kommentieren. Ich gehe mal davon aus, dass dieser Abschwung bis zum Shareholder-Meeting anhalten wird. Danach jedoch sollte es wieder aufwärts gehen. Ich gebe zu, dass das mit dem schnellen Euro vergangenes Jahr besser klappte. Bei solche Werten jedoch kann das mit dem Anstieg auch relativ schnell gehen. Warten wir's ab wie es hier Ende März aussieht.
Good luck to all
Sweeper
That's right!
Sehe im Moment keinen Grund die z: Zt. negative Entwicklung zu kommentieren. Ich gehe mal davon aus, dass dieser Abschwung bis zum Shareholder-Meeting anhalten wird. Danach jedoch sollte es wieder aufwärts gehen. Ich gebe zu, dass das mit dem schnellen Euro vergangenes Jahr besser klappte. Bei solche Werten jedoch kann das mit dem Anstieg auch relativ schnell gehen. Warten wir's ab wie es hier Ende März aussieht.
Good luck to all
Sweeper
Antwort auf Beitrag Nr.: 33.584.488 von STARSWEEPER am 07.03.08 22:11:53Moin zusammen, Frage: Wann ist das Shareholder Meeting???
Antwort auf Beitrag Nr.: 33.591.186 von Max82 am 09.03.08 09:42:18soviel mir bekannt findet dieses am 21.3.08 ab 10am statt.
Hier noch ein Schreiben vom CEO an einen User in einem Ami-Board:
Posted by: tasti
In reply to: Investolator who wrote msg# 2898 Date:3/8/2008 7:12:45 PM
Post #of 2899
np here is another E-mail I received today from the CEO
Dear mr. Seid
I will begin by stating the the financing deal we have been working with was well in place when I took over as CEO and the penalties for terminating the agreement were too severe for me to maintain the interest of other investment parties.
I can only share information that is public and will let you know that we continue to overcome the obsolete product issues internally as well as locate new product for distribution/sale by us. Please look at the press releases to gain insight in respect to what Paradigm has been doing for the past two years to move the company forward. We are looking at a number of options in respect to what steps we can take to keep us moving forward.
Be assured the best interest of all our investors are under constant consideration as we strategize.
Best regards,
Raymond Cannefax
President & CEO
Sweeper
Hier noch ein Schreiben vom CEO an einen User in einem Ami-Board:
Posted by: tasti
In reply to: Investolator who wrote msg# 2898 Date:3/8/2008 7:12:45 PM
Post #of 2899
np here is another E-mail I received today from the CEO
Dear mr. Seid
I will begin by stating the the financing deal we have been working with was well in place when I took over as CEO and the penalties for terminating the agreement were too severe for me to maintain the interest of other investment parties.
I can only share information that is public and will let you know that we continue to overcome the obsolete product issues internally as well as locate new product for distribution/sale by us. Please look at the press releases to gain insight in respect to what Paradigm has been doing for the past two years to move the company forward. We are looking at a number of options in respect to what steps we can take to keep us moving forward.
Be assured the best interest of all our investors are under constant consideration as we strategize.
Best regards,
Raymond Cannefax
President & CEO
Sweeper
Antwort auf Beitrag Nr.: 33.593.256 von STARSWEEPER am 09.03.08 20:41:22
March 11, 2008 - 9:37 AM EDT
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.0008 0.0001
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries to Introduce Early Glaucoma Detection Device at ASCRS Conference
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), said today it will introduce the Glaid-PERG electrophysiology instrument for the early detection of glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, IL, next month.
“All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. The Company signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the Glaid-PERG instrument earlier this year.
After many years of clinical studies at major U.S. and European glaucoma centers, as well as at universities and research centers, the Glaid-PERG has proven to provide high test repeatability and a high level of accuracy. Ongoing research is indicating testing application for ocular ailments other than glaucoma.
“We are excited about the impact the new instrument will have—not only in our industry, but in medical benefits to those who will be diagnosed early as glaucoma suspects,” Mr. Cannefax added. “Early diagnosis will help reduce vision loss and help preserve sight. This is a logical progression in the early detection of glaucoma, the world’s major contributor to vision loss.”
Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
“The introduction of these two devices is further indication of our Company’s leading technology in eye care,” Mr. Cannefax noted. “It is all part of our ‘Continuous Improvement’ commitment.”
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
Source: Business Wire (March 11, 2008 - 9:37 AM EDT)
News by QuoteMedia
www.quotemedia.com
March 11, 2008 - 9:37 AM EDT
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PMED 0.0008 0.0001
Today 5d 1m 3m 1y 5y 10y
Paradigm Medical Industries to Introduce Early Glaucoma Detection Device at ASCRS Conference
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), said today it will introduce the Glaid-PERG electrophysiology instrument for the early detection of glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, IL, next month.
“All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. The Company signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the Glaid-PERG instrument earlier this year.
After many years of clinical studies at major U.S. and European glaucoma centers, as well as at universities and research centers, the Glaid-PERG has proven to provide high test repeatability and a high level of accuracy. Ongoing research is indicating testing application for ocular ailments other than glaucoma.
“We are excited about the impact the new instrument will have—not only in our industry, but in medical benefits to those who will be diagnosed early as glaucoma suspects,” Mr. Cannefax added. “Early diagnosis will help reduce vision loss and help preserve sight. This is a logical progression in the early detection of glaucoma, the world’s major contributor to vision loss.”
Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
“The introduction of these two devices is further indication of our Company’s leading technology in eye care,” Mr. Cannefax noted. “It is all part of our ‘Continuous Improvement’ commitment.”
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com
Source: Business Wire (March 11, 2008 - 9:37 AM EDT)
News by QuoteMedia
www.quotemedia.com
Endlich mal prima news!!Überm Teich + 57%,73mio.Shares umsatz
nun sollte man KAUFEN!!Spätestens!!!
Antwort auf Beitrag Nr.: 33.610.036 von hessenkoenig am 11.03.08 16:22:42Du sagst es!!!
U. von wegen tot-wie mancher hier im Thread uns glauben machen will!!! Der heutige Tag beweist mal wieder genau das Gegenteil.
Ich bleibe dabei-wir werden noch viel Freude u. positive Aufregung mit diesem Wert haben.
Sweeper
U. von wegen tot-wie mancher hier im Thread uns glauben machen will!!! Der heutige Tag beweist mal wieder genau das Gegenteil.
Ich bleibe dabei-wir werden noch viel Freude u. positive Aufregung mit diesem Wert haben.
Sweeper
Antwort auf Beitrag Nr.: 33.614.403 von STARSWEEPER am 11.03.08 22:04:50Was steht in der News? Bitte kurze Info! Wäre Prima!
Danke!!
Max
Danke!!
Max
Antwort auf Beitrag Nr.: 33.614.421 von Max82 am 11.03.08 22:07:22Hi Max,
halte diese News für eine großartige Meldung.
Man hat seitens PMED ein Abkommen mit einer italienischen Fa. unterzeichnet das den Verkauf bzw. die Verteilung der Glaid-Perg-Instrumente früher als geplant vorsieht.
Man ist seitens PMED überrascht,welchen Eindruck die neuen Geräte überall hinterlassen.
PMED wird die neue Version des LD 400 auf einer der größten Messen des Landes vorstellen.
Übrigens heute,ob dieser Meldung, ausschließlich positive Kommentare in den Ami-Boards.
Grüsse Sweeper
halte diese News für eine großartige Meldung.
Man hat seitens PMED ein Abkommen mit einer italienischen Fa. unterzeichnet das den Verkauf bzw. die Verteilung der Glaid-Perg-Instrumente früher als geplant vorsieht.
Man ist seitens PMED überrascht,welchen Eindruck die neuen Geräte überall hinterlassen.
PMED wird die neue Version des LD 400 auf einer der größten Messen des Landes vorstellen.
Übrigens heute,ob dieser Meldung, ausschließlich positive Kommentare in den Ami-Boards.
Grüsse Sweeper
Hört sich ja mal nicht schlecht an!
Danke!
Max
Danke!
Max
Antwort auf Beitrag Nr.: 33.614.690 von STARSWEEPER am 11.03.08 22:42:26...und heut gehts wieder runter!!!!alles beim leider alten....
Antwort auf Beitrag Nr.: 33.621.689 von hessenkoenig am 12.03.08 16:47:04jeep du sagst es....
Antwort auf Beitrag Nr.: 33.621.689 von hessenkoenig am 12.03.08 16:47:04Na und?
Lass das mal so, sobald es weitere Auslieferungen gibt
knallt es gen Norden.Dann laufen alle hinterher.
Verträge sind da, interesse ist da (mehr als erwartet)und die ersten Geräte laufen positiv, mehr als positiv.
Bin hier auf Long eingestellt
Das Ding kann man einfach nur liegenlassen, es vermehrt sich von allein.
Zur zeit ist es etwas ein Spielball, das wird sich noch ändern!
Auf Grüüüüüüne Zahlen und gruss an alle Investierten!!
Lass das mal so, sobald es weitere Auslieferungen gibt
knallt es gen Norden.Dann laufen alle hinterher.
Verträge sind da, interesse ist da (mehr als erwartet)und die ersten Geräte laufen positiv, mehr als positiv.
Bin hier auf Long eingestellt
Das Ding kann man einfach nur liegenlassen, es vermehrt sich von allein.
Zur zeit ist es etwas ein Spielball, das wird sich noch ändern!
Auf Grüüüüüüne Zahlen und gruss an alle Investierten!!
Antwort auf Beitrag Nr.: 33.621.689 von hessenkoenig am 12.03.08 16:47:04Yes Sir!
Wie ich bereits schonmal ausführte-hier ist jetzt Geduld gefragt u. diese wird sich auch auszahlen-da bin ich fest von überzeugt.
Dieser Wert muss unter täglicher Beobachtung bleiben. Er wird sich-so meine Meinung,noch lange wie ein noch nicht zugerittenes Wildpferd verhalten. Ich jedenfall habe min VK-Limit immer bei 0.025€ eingestellt.
In diesem Sinne
Sweeper
Wie ich bereits schonmal ausführte-hier ist jetzt Geduld gefragt u. diese wird sich auch auszahlen-da bin ich fest von überzeugt.
Dieser Wert muss unter täglicher Beobachtung bleiben. Er wird sich-so meine Meinung,noch lange wie ein noch nicht zugerittenes Wildpferd verhalten. Ich jedenfall habe min VK-Limit immer bei 0.025€ eingestellt.
In diesem Sinne
Sweeper
Antwort auf Beitrag Nr.: 33.625.299 von STARSWEEPER am 12.03.08 22:15:14dito----0,024! bist noch nen Schuss optimist.als ich!
mal eine frage an die longies:
ist die mk von 322$ bei einem kurs von 0,0008 noch aktuell oder wurde diluted??
ist die mk von 322$ bei einem kurs von 0,0008 noch aktuell oder wurde diluted??
Antwort auf Beitrag Nr.: 33.630.177 von Illuminat85 am 13.03.08 13:53:23Ich denke, da sollten wir mal abwarten, was am 21.3.08 während des shareholdermeeting passiert.
Gruss Sweeper
Gruss Sweeper
Antwort auf Beitrag Nr.: 33.631.330 von STARSWEEPER am 13.03.08 15:24:21hat denn keiner kontakt zum ceo??
Antwort auf Beitrag Nr.: 33.635.439 von Illuminat85 am 13.03.08 20:24:25Doch-selbst ich habe mich vor einiger Zeit mal mit ihm ausgetauscht. Denke aber, dass er so kurz vor dem am 21.3. anstehenden Shareholdermeeting keine Statements abgeben wird. Ich kann's ja am Wochenende trotzdem mal versuchen. Sollte ich was hören, stelle ich's in's Board.
Grüsse Sweeper
Grüsse Sweeper
Übrigens: Der MADC drehte heute !
Sweeper
Sweeper
Antwort auf Beitrag Nr.: 33.636.586 von STARSWEEPER am 13.03.08 22:39:46Meint natürlich den MACD
Sweeper
Sweeper
Antwort auf Beitrag Nr.: 33.636.602 von STARSWEEPER am 13.03.08 22:41:31Das ist richtig!
Leider kann er sich nicht richtig entscheiden!
Neue Woche, neue GRÜNE Zahlen und der 21te ist nicht mehr weit.
Bin Long, hier ist richtig Gewinn drin.
Gruss
Leider kann er sich nicht richtig entscheiden!
Neue Woche, neue GRÜNE Zahlen und der 21te ist nicht mehr weit.
Bin Long, hier ist richtig Gewinn drin.
Gruss
Antwort auf Beitrag Nr.: 33.651.900 von Trucker-Jens am 15.03.08 22:17:27Leider kann er sich nicht richtig entscheiden!
das sehe ich auch so-aber das wird schon. Der Wert hat noch viel Potential.
Aber-immer schön im Auge behalten-möglichst dauernd ein VK-Limit einestellen.Das schützt vor unliebsamen Überraschungen.
Sweeper
das sehe ich auch so-aber das wird schon. Der Wert hat noch viel Potential.
Aber-immer schön im Auge behalten-möglichst dauernd ein VK-Limit einestellen.Das schützt vor unliebsamen Überraschungen.
Sweeper
Falls sich die Verkaufszahlen des LD 400 als wirklich so phänomenal herausstellen, geht der Kurs auf jeden Fall senkrecht nach oben. Ich glaube es aber erst so richtig, wenn der nächste Quartalsbericht veröffentlicht wird.
Bin aber sehr, sehr optimistisch!
Gruß Stern
P.S. .... und außerdem ist das LD 400 ja bei weitem nicht das einzige Produkt vom PM.
Bin aber sehr, sehr optimistisch!
Gruß Stern
P.S. .... und außerdem ist das LD 400 ja bei weitem nicht das einzige Produkt vom PM.
Antwort auf Beitrag Nr.: 33.651.944 von STARSWEEPER am 15.03.08 22:37:52Bin auf Long!!!!
Die Bude kracht noch in diesem Jahr richtig.
Wenn ich das richtig gelesen habe haben sie schon einen Folgeauftrag, da die ersten Geräte sehr gut angenommen werden.
Auch für ein anderes Gerät haben sie Aufträge bekommen.
(Ich hoffe mein Translator hat richtig übersetzt)
Ich habe hier irgend etwas vom 21.03 gelesen.
Shareholder Meeting am Feiertag?
Im Amiland ist Good Friday = Feiertag und kein Handel.
Das muss ein anderes Datum sein.....
Gruss
Die Bude kracht noch in diesem Jahr richtig.
Wenn ich das richtig gelesen habe haben sie schon einen Folgeauftrag, da die ersten Geräte sehr gut angenommen werden.
Auch für ein anderes Gerät haben sie Aufträge bekommen.
(Ich hoffe mein Translator hat richtig übersetzt)
Ich habe hier irgend etwas vom 21.03 gelesen.
Shareholder Meeting am Feiertag?
Im Amiland ist Good Friday = Feiertag und kein Handel.
Das muss ein anderes Datum sein.....
Gruss
Antwort auf Beitrag Nr.: 33.654.742 von Trucker-Jens am 16.03.08 19:48:20Im Amiland ist Good Friday = Feiertag und kein Handel.
Da hast Du recht.
Habe gerade Deine Frage in's Ami-Board gestellt.
Melde mich, sobald eine Antwort da ist.
Gruss Sweeper
Da hast Du recht.
Habe gerade Deine Frage in's Ami-Board gestellt.
Melde mich, sobald eine Antwort da ist.
Gruss Sweeper
Antwort auf Beitrag Nr.: 33.654.913 von STARSWEEPER am 16.03.08 20:24:33Starsweeper: Das Meeting wurde auf Montag, den 14. April verschoben.
Dear Shareholder:
On behalf of the Board of Directors, it is my pleasure to invite you to attend the Special Meeting of Shareholders (the "Special Meeting") of Paradigm Medical Industries, Inc. (the "Company") to be held on Monday, April 14, 2008,at 10:00 a.m., Mountain Standard Time, at 2355 South 1070 West, Salt Lake City,
Utah 84119. The formal notice of the Special Meeting and the Proxy Statement have been made a part of this invitation.
http://www.sec.gov/Archives/edgar/data/916444/00010969060800…
Dear Shareholder:
On behalf of the Board of Directors, it is my pleasure to invite you to attend the Special Meeting of Shareholders (the "Special Meeting") of Paradigm Medical Industries, Inc. (the "Company") to be held on Monday, April 14, 2008,at 10:00 a.m., Mountain Standard Time, at 2355 South 1070 West, Salt Lake City,
Utah 84119. The formal notice of the Special Meeting and the Proxy Statement have been made a part of this invitation.
http://www.sec.gov/Archives/edgar/data/916444/00010969060800…
Antwort auf Beitrag Nr.: 33.660.043 von voitsi am 17.03.08 13:39:45Hi voitsi,
das nenne ich Service!
Danke für die Info.
Hattest Du meine Frage im Ami-Board oder hier gelesen?
Grüsse Sweeper
das nenne ich Service!
Danke für die Info.
Hattest Du meine Frage im Ami-Board oder hier gelesen?
Grüsse Sweeper
Was ich nicht nachvollziehen kann, ist wieso die Anzahl der "shares" schon wieder drastisch erhöht werden sollen?????? vielleicht kann das jemand erklären?
Antwort auf Beitrag Nr.: 33.664.902 von STARSWEEPER am 17.03.08 19:38:41Hallo starsweeper, habe es im Ami-Board gelesen. Ich glaube dort kann man etwas schneller an Infos kommen. Bin immer noch optimistisch.
stern16, Die Anzahl der Aktien müssen erhöht werden um die Finanzierung abzudecken, da PMED momentan nicht das Tilgungs-Kapital hat. Deshalb müssen sie es mit Aktien bezahlen, ein riskanter Weg der nur funktioniert, wenn bald gute Verkaufszahlen erreicht werden. Ansonsten steigt die Aktienanzahl auf Milliarden.
stern16, Die Anzahl der Aktien müssen erhöht werden um die Finanzierung abzudecken, da PMED momentan nicht das Tilgungs-Kapital hat. Deshalb müssen sie es mit Aktien bezahlen, ein riskanter Weg der nur funktioniert, wenn bald gute Verkaufszahlen erreicht werden. Ansonsten steigt die Aktienanzahl auf Milliarden.
Hallo Voitsi, danke für die Info.
Na also,
der MACD ging heute wieder einen Tick nach oben. Schaun wir mal wie es bis zum Shareholder-Meeting noch läuft.
Wünsche allen eine grüne Woche.
Sweeper
der MACD ging heute wieder einen Tick nach oben. Schaun wir mal wie es bis zum Shareholder-Meeting noch läuft.
Wünsche allen eine grüne Woche.
Sweeper
Antwort auf Beitrag Nr.: 33.734.572 von STARSWEEPER am 26.03.08 21:27:24Tach zusammen, bin echt mal gespannt ob hier irgendwann mal was passiert...hab das Teil jetzt schon 1 Jahr und absolut nix kam....
Die Aktienanzahl ist mal wieder um 280 Mill. erhöht worden, nervt mich erlich gesagt ziemlich!!
Jetzt in Summe 680.98 Mill. Ätzend
Jetzt in Summe 680.98 Mill. Ätzend
Hier mal ein Posting aus einem Ami-Board:
Launch of there new product Friday, hoping for a little hike in price!
Hier noch eins aus einem anderen Board welches auf den gleichen Vorgang Bezug nimmt:
Posted by: jagz1414
In reply to: None Date:3/29/2008 8:13:39 PM
Post #of 2995
Not going to be a slow week!! PMED is finally launching the Glaid-PERG glaucoma detection device on Friday, after years of development!! Look what the stock did in mid-2007 on the product's approval!! How can you all be so calm and hope for another week like last week?
Sweeper
Launch of there new product Friday, hoping for a little hike in price!
Hier noch eins aus einem anderen Board welches auf den gleichen Vorgang Bezug nimmt:
Posted by: jagz1414
In reply to: None Date:3/29/2008 8:13:39 PM
Post #of 2995
Not going to be a slow week!! PMED is finally launching the Glaid-PERG glaucoma detection device on Friday, after years of development!! Look what the stock did in mid-2007 on the product's approval!! How can you all be so calm and hope for another week like last week?
Sweeper
sollte heute nicht irgendwas posit.bekannt gegeben werden??
Wird Zeit!!
Wird Zeit!!
Antwort auf Beitrag Nr.: 33.807.847 von hessenkoenig am 04.04.08 11:26:47ich wüsste nicht was, aber hier der starsweeper ist doch voll im thema drin, vielleicht weis er ja was....
Antwort auf Beitrag Nr.: 33.810.609 von Max82 am 04.04.08 15:33:07das meeting jedenfalls wurde auf dem 14.04. veschoben...
Antwort auf Beitrag Nr.: 33.810.618 von Max82 am 04.04.08 15:33:52ja , genau das meinte ich---Danke!
Antwort auf Beitrag Nr.: 33.810.609 von Max82 am 04.04.08 15:33:07@all
ja, ich denke schon, dass es Neuigkeiten gibt. Ich kopiere mal ein paar statements aus investors Hub hier rein. Bin dann auch mal auf kommende Woche gespannt.
Gruss Sweeper
Posted by: Neocheeseater
In reply to: None Date:4/3/2008 11:55:02 PM
Post #of 3016
Bought back in today. Hope something happens tomorrow.
Posted by: starsweeper
In reply to: Neocheeseater who wrote msg# 3012 Date:4/4/2008 12:35:27 PM
Post #of 3017
Hi Neocheeseater,
pardon, what please should happens today?
Thx for your answer.
Sweeper
Hi starsweeper, I am not sure what Neocheeseater has in mind, but it is might be what this poster in post 2994 stated:
Posted by: jagz1414
In reply to: None Date:3/29/2008 8:13:39 PM
Post #of 3013
Not going to be a slow week!! PMED is finally launching the Glaid-PERG glaucoma detection device on Friday, after years of development!! Look what the stock did in mid-2007 on the product's approval!! How can you all be so calm and hope for another week like last week?
Posted by: Neocheeseater
In reply to: Investolator who wrote msg# 3014 Date:4/4/2008 1:42:34 PM
Post #of 3017
"Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show."
-March 13 2008
If you research this show it will show you that it starts today and runs through Monday. Hopefully we get some news on Monday.
Posted by: tasti
In reply to: None Date:4/4/2008 2:34:06 PM
Post #of 3017
Why is E-trade moving to 0.2509 from 0.009 this morning, do they know something that we don’t, they have been buying last couple weeks and controlling the price movement last couple of days, so they must know something good is coming. I am looking forward to next week. This is the biggest show in the industry
ja, ich denke schon, dass es Neuigkeiten gibt. Ich kopiere mal ein paar statements aus investors Hub hier rein. Bin dann auch mal auf kommende Woche gespannt.
Gruss Sweeper
Posted by: Neocheeseater
In reply to: None Date:4/3/2008 11:55:02 PM
Post #of 3016
Bought back in today. Hope something happens tomorrow.
Posted by: starsweeper
In reply to: Neocheeseater who wrote msg# 3012 Date:4/4/2008 12:35:27 PM
Post #of 3017
Hi Neocheeseater,
pardon, what please should happens today?
Thx for your answer.
Sweeper
Hi starsweeper, I am not sure what Neocheeseater has in mind, but it is might be what this poster in post 2994 stated:
Posted by: jagz1414
In reply to: None Date:3/29/2008 8:13:39 PM
Post #of 3013
Not going to be a slow week!! PMED is finally launching the Glaid-PERG glaucoma detection device on Friday, after years of development!! Look what the stock did in mid-2007 on the product's approval!! How can you all be so calm and hope for another week like last week?
Posted by: Neocheeseater
In reply to: Investolator who wrote msg# 3014 Date:4/4/2008 1:42:34 PM
Post #of 3017
"Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show."
-March 13 2008
If you research this show it will show you that it starts today and runs through Monday. Hopefully we get some news on Monday.
Posted by: tasti
In reply to: None Date:4/4/2008 2:34:06 PM
Post #of 3017
Why is E-trade moving to 0.2509 from 0.009 this morning, do they know something that we don’t, they have been buying last couple weeks and controlling the price movement last couple of days, so they must know something good is coming. I am looking forward to next week. This is the biggest show in the industry
Nachdem ich mich jetzt eine längere zeit mit Paradigm beschäftigt habe bin ich nun auch eingestiegen. Ich sehe beste Aussichten die nächsten Monate.
Bombenleger
Bombenleger
was mich doch sehr zuversichtlich stimmt, ist die Tatsache, dass P. - M. Vertriebspersonal sucht.
Schaut doch in
http://hotjobs.yahoo.com/careers-657812-Paradigm_Medical_Ind…
rein. Wenn ich bei google P. - M. eingebe, finde ich ganze Video - Clips zu diesem Thema.
In anderen Worten, es geht voran, muss sich bald auf den Kurs auswirken. Publicity & Verkaufszahlen.... wird ein heißer Sommer!!
Schaut doch in
http://hotjobs.yahoo.com/careers-657812-Paradigm_Medical_Ind…
rein. Wenn ich bei google P. - M. eingebe, finde ich ganze Video - Clips zu diesem Thema.
In anderen Worten, es geht voran, muss sich bald auf den Kurs auswirken. Publicity & Verkaufszahlen.... wird ein heißer Sommer!!
Antwort auf Beitrag Nr.: 33.839.741 von stern16 am 08.04.08 20:06:13Dein Wort in "Gottes Ohren" wie man so schön sagt!
Antwort auf Beitrag Nr.: 33.844.519 von hessenkoenig am 09.04.08 12:17:06Gestern war doch das Meeting oder???? Gibts was interessantes zu melden????
Max
Max
Antwort auf Beitrag Nr.: 33.885.084 von Max82 am 15.04.08 08:25:43also selbst auf der hp steht überhaupt nix....was soll der sch....??
Antwort auf Beitrag Nr.: 33.885.367 von Max82 am 15.04.08 09:06:16Habe gestern Abend diese Frage schon in's Ami-Board gestellt.
Denke, heute kommt da noch eine Antwort.
Stelle sie dann sofort hier rein.
Sweeper
Denke, heute kommt da noch eine Antwort.
Stelle sie dann sofort hier rein.
Sweeper
Antwort auf Beitrag Nr.: 33.885.432 von STARSWEEPER am 15.04.08 09:12:50ich sag mal so...der kurs bei den amis hat keinen sprung gemacht von daher kanns nicht so wild sein was das meeting ergeben hat....oder wurde das ganze nachbörslich bzw. noch garnicht veröffentlicht???
max
max
Antwort auf Beitrag Nr.: 33.886.929 von Max82 am 15.04.08 11:57:57Hi Max,
scheinbar wissen die Amis selbst nicht was es da gestern gegeben hat,es kam keine Antwort auf meine Frage. Aus diesem Grund habe ich gerade eine Mail direkt an PMED abgesetzt. Schaun wir mal ob da was kommt.
Gruss Sweeper
scheinbar wissen die Amis selbst nicht was es da gestern gegeben hat,es kam keine Antwort auf meine Frage. Aus diesem Grund habe ich gerade eine Mail direkt an PMED abgesetzt. Schaun wir mal ob da was kommt.
Gruss Sweeper
Antwort auf Beitrag Nr.: 33.892.311 von STARSWEEPER am 15.04.08 20:58:56dann bin ich mal gespannt ob und was da kommt....
Max
Max
Antwort auf Beitrag Nr.: 33.894.577 von Max82 am 16.04.08 08:36:53das mit der Antwort ging ja ratz fatz. Werde sie heute Abend den Amis auch noch reinstellen.
Gruss Sweeper
Gentlemen & Ladies -
In response to your inquiry regarding yesterdays special shareholder meeting, I can report that the majority of shareholders voted for Paradigm to increase the authorized shares from 800,000,000 to 1.4 billion shares. This was done to have adequate shares in our treasury to meet the payments to the investors who loaned the money to Paradigm.
The other discussions were in respect to the new product we introduced at the ASCRS Congress 10 days earlier, the PERG which stands for Pattern Electroretinagram. This is the earliest means of detecting glaucoma and one of the most effective methods of managing the disease by helping to arrest the deterioration of retinal ganglion cells. We also discuss the progress of the redesign of the LD400 Autoperimeter of which a prototype was also introduced at the ASCRS Congress.
Hopefully this is helpful to you and your investment group.
Best regards,
Raymond Cannefax
Paradigm Medical Industries, Inc.
801-977-8970
This e-mail is confidential and intended only for those to whom it is addressed. If received by accident, please delete.
P Please consider the environment before printing this e-mail
_______________________________________
Gruss Sweeper
Gentlemen & Ladies -
In response to your inquiry regarding yesterdays special shareholder meeting, I can report that the majority of shareholders voted for Paradigm to increase the authorized shares from 800,000,000 to 1.4 billion shares. This was done to have adequate shares in our treasury to meet the payments to the investors who loaned the money to Paradigm.
The other discussions were in respect to the new product we introduced at the ASCRS Congress 10 days earlier, the PERG which stands for Pattern Electroretinagram. This is the earliest means of detecting glaucoma and one of the most effective methods of managing the disease by helping to arrest the deterioration of retinal ganglion cells. We also discuss the progress of the redesign of the LD400 Autoperimeter of which a prototype was also introduced at the ASCRS Congress.
Hopefully this is helpful to you and your investment group.
Best regards,
Raymond Cannefax
Paradigm Medical Industries, Inc.
801-977-8970
This e-mail is confidential and intended only for those to whom it is addressed. If received by accident, please delete.
P Please consider the environment before printing this e-mail
_______________________________________
Antwort auf Beitrag Nr.: 33.894.916 von STARSWEEPER am 16.04.08 09:19:28ganz großes kino...noch mehr shares....das kann ja noch heiter werden...ich hab meine kohle gedanklich schon abgeschrieben....
das andere blabla ist echt nur blabla oder seh ich das so falsch?
max
das andere blabla ist echt nur blabla oder seh ich das so falsch?
max
hallo heute keiner da???
what's going on with our invest today????????????
Im Amiboard rätseln sie heute auch rum.
Kein Handel? YAOO-Finanzen ohne Einträge!?
Na ja, wir werden's mal im Auge behalten
Sweeper
Im Amiboard rätseln sie heute auch rum.
Kein Handel? YAOO-Finanzen ohne Einträge!?
Na ja, wir werden's mal im Auge behalten
Sweeper
Antwort auf Beitrag Nr.: 33.920.760 von STARSWEEPER am 18.04.08 17:15:27Hi sweeper !
wird bei der OTC nicht mehr unter pmed sondern pmede (also nochn e hintendran) geführt.Warum auch immer.Gehandelt wird auch heute(zwischen 0,006 und 0,009 - momentan 0,009)
Hab das Gefühl , das es so schnell nicht aufwärts geht...
Nice Weekend!
wird bei der OTC nicht mehr unter pmed sondern pmede (also nochn e hintendran) geführt.Warum auch immer.Gehandelt wird auch heute(zwischen 0,006 und 0,009 - momentan 0,009)
Hab das Gefühl , das es so schnell nicht aufwärts geht...
Nice Weekend!
Heute gigt es ja richtig was auf die Fresse - bereits minus 44 %.
Gab es etwa irgendwelche negative Neuigkeiten, von denen ich noch nichts weiss??
Gab es etwa irgendwelche negative Neuigkeiten, von denen ich noch nichts weiss??
Antwort auf Beitrag Nr.: 33.922.912 von stern16 am 18.04.08 21:04:27Vielleicht gab es mal wieder die berühmte Aktienvermehrung so um die 200 Mio. neue Aktien!
Antwort auf Beitrag Nr.: 33.922.912 von stern16 am 18.04.08 21:04:27Die einzige negative news,die mir bekannt ist lautete: Vergrösserung der Aktienanzahl von 800.000.000 auf 1.4Bil.
Kann mir allerdings nich vorstellen, dass das zum heutigen Kursrutsch geführt hat.
Bin auch schon gespannt zu welchem Kurs wir heute drüben schliessen.
Sweeper
Kann mir allerdings nich vorstellen, dass das zum heutigen Kursrutsch geführt hat.
Bin auch schon gespannt zu welchem Kurs wir heute drüben schliessen.
Sweeper
Antwort auf Beitrag Nr.: 33.923.020 von STARSWEEPER am 18.04.08 21:16:25Nicht schlecht. Jetzt gibt es bereits 1,4 Mrd.Aktien.
Diese exponentiale Vermehrung der Aktien ist die letzte Affenpisse, der Wert der Firma steigt ja schließlich nicht, nur der Wert der einzelnen Aktien sinkt anteilig. Auf der Strecke bleibt der Anleger. Keine Ahnung, ob das überhaupt rechtens ist, was PM da treibt. Bei einem regulären Aktiensplitt hat zumindest der normale Anleger keinerlei Nachteile, da ja seine Aktienbestände entsprechend erhöht werden.
Für mich grenzt dies an Diebstahl.
Für mich grenzt dies an Diebstahl.
meiner meinung nach hat das was mit dem zusatz "e" zu tun, hab mal in nem anderen thread gelesen das der wert ein "e" dazu bekommt wenn sie mit ner medlung an die aussichtsbehörde sec (richtig?) im verzug sind...ich mein so war es..aber nagelt mich nicht darauf fest...
wenn es aber so ist kann man das durchaus negativ werten ebenso die aktienvervielfältigung....ist eben ein scheiss mittel um sich seinen laden zu finanzieren...aber bei 94% verlust (mein persönlicher) kommst auf die letzten 6 % auch nicht mehr an...darum die hoffnung stirbt zuletzt...
schönen Abend noch!!
Max
wenn es aber so ist kann man das durchaus negativ werten ebenso die aktienvervielfältigung....ist eben ein scheiss mittel um sich seinen laden zu finanzieren...aber bei 94% verlust (mein persönlicher) kommst auf die letzten 6 % auch nicht mehr an...darum die hoffnung stirbt zuletzt...
schönen Abend noch!!
Max
... vielleicht bringt PM ja Hammer - News heraus, nachdem die Aktienanzahl so drastisch erhöht haben, um sich selbst den Säckel vollzumachen. Könnte ja eventuell alles Taktik sein.
Wer weiß!!!
Wer weiß!!!
Antwort auf Beitrag Nr.: 33.926.711 von Max82 am 19.04.08 21:01:48Hallo Max82,
das "e" steht für den Verzug der Berichte bei der Behörde!!!
Das wir jetzt ins endlose rutschen ist klar.....
Erst Aktienerhöhung und dann werden die Berichte nicht abgegeben.
Das ist einfach nur bescheuert.
Die haben mehrere (grosse?) Aufträge und die Kohle für die Geräte bis zum Verkauf (Zahlung) können nicht aufgebracht werden. Aufträge sind seit Monaten da und die ausgelieferten Geräte laufen super...so hab ich es zumindest gelesen.
Deshalb sind auch keine Berichte da bei dem Chaos.
Vielleicht wollte ein Geldgeber (Bank) der Firma den Hals umdrehen und sie sind nicht drauf eingegangen.Dann wäre dieses durcheinander zu erklären.
Nur mal ne Überlegung meinerseits.
Gruss an alle Investierten
Trucker-Jens
das "e" steht für den Verzug der Berichte bei der Behörde!!!
Das wir jetzt ins endlose rutschen ist klar.....
Erst Aktienerhöhung und dann werden die Berichte nicht abgegeben.
Das ist einfach nur bescheuert.
Die haben mehrere (grosse?) Aufträge und die Kohle für die Geräte bis zum Verkauf (Zahlung) können nicht aufgebracht werden. Aufträge sind seit Monaten da und die ausgelieferten Geräte laufen super...so hab ich es zumindest gelesen.
Deshalb sind auch keine Berichte da bei dem Chaos.
Vielleicht wollte ein Geldgeber (Bank) der Firma den Hals umdrehen und sie sind nicht drauf eingegangen.Dann wäre dieses durcheinander zu erklären.
Nur mal ne Überlegung meinerseits.
Gruss an alle Investierten
Trucker-Jens
Die Internet-Seite von Paradigm-Medical kann ab sofort nicht aufgerufen werden, sind die jetzt etwa pleite oder doch nur eine technische Störung??
Beunruhigt mich schon. weiß irgend jemand etwas konkretes??
Beunruhigt mich schon. weiß irgend jemand etwas konkretes??
Antwort auf Beitrag Nr.: 33.996.235 von stern16 am 29.04.08 19:07:58Tach, also ich war grad auf ihrer HP und sie funktioniert...war wohl bloß ne Störung....
Max
Max
Hey Leute jemand hier?? wird eigentlich noch gehandelt? wenn ja wo kann ich das sehen??
Max
Max
Antwort auf Beitrag Nr.: 34.014.243 von Max82 am 02.05.08 11:33:36hab mir die frage selbst beantwortet....
Antwort auf Beitrag Nr.: 34.014.280 von Max82 am 02.05.08 11:36:35http://investorshub.advfn.com/boards/read_msg.asp?message_id…
Antwort auf Beitrag Nr.: 34.014.596 von marko35 am 02.05.08 12:06:35danke!
kann mir denn einer genau sagen was es mit den "e" auf sich hat und was für folgen?? gehn wir jetzt bald komplett pleite??
kann mir denn einer genau sagen was es mit den "e" auf sich hat und was für folgen?? gehn wir jetzt bald komplett pleite??
Ich hab mich mal schlau gemacht was das "e" angeht:
Das "E" gibt es, wenn eine Firma "non compliance" ist. Sprich, die Zulassungsregeln des Börsensegmentes, in dem sie gelistet ist, nicht mehr einhält.
Das ist genau geregelt, ab wann das kommt. Da gibt es vorher eine Warnung, dann eine Frist. Dann gibt es das "E" für eine bestimmte Zeit. Hat die Firma dann immer noch die Defizite nicht beseitigt, dann steigt die Aktie ab. Bis in die Pink Sheets (other OTC).
Bei Insolvenz eines Unternehmens (Chapter 11) gibt es ein "Q" angefügt.
Diese Zusätze vergibt die SEC (US-Börsenaufsicht)
In wie weit das jetzt gut oder schlecht für den Laden ist kann sich jetzt jeder selbst zusammendichten...
ganz großes Kino von den A....
Max
Das "E" gibt es, wenn eine Firma "non compliance" ist. Sprich, die Zulassungsregeln des Börsensegmentes, in dem sie gelistet ist, nicht mehr einhält.
Das ist genau geregelt, ab wann das kommt. Da gibt es vorher eine Warnung, dann eine Frist. Dann gibt es das "E" für eine bestimmte Zeit. Hat die Firma dann immer noch die Defizite nicht beseitigt, dann steigt die Aktie ab. Bis in die Pink Sheets (other OTC).
Bei Insolvenz eines Unternehmens (Chapter 11) gibt es ein "Q" angefügt.
Diese Zusätze vergibt die SEC (US-Börsenaufsicht)
In wie weit das jetzt gut oder schlecht für den Laden ist kann sich jetzt jeder selbst zusammendichten...
ganz großes Kino von den A....
Max
Antwort auf Beitrag Nr.: 34.014.916 von Max82 am 02.05.08 12:45:53Guten Morgen zusammen, schreibt denn außer mir keiner mehr was!?!
Bei den Amis war SK 0,0003 wenn ichs richtig gesehen hab...
Bei den Amis war SK 0,0003 wenn ichs richtig gesehen hab...
Antwort auf Beitrag Nr.: 34.026.237 von Max82 am 05.05.08 09:47:49So, wie es aussieht ist es für den Moment ruhig geworden um PMEDE.
Ich für meinen Teil gehe ganz einfach davon aus, dass dies' nicht so bleibt. Viel tiefer als z. Zt. kann der Wert wohl nicht mehr fallen. Ich jedenfalls bleibe investiert-auch im Hinbick
darauf, dass es sich bei unserem Unternehmen um einen der leader auf diesem Gebiet handelt; u. der wird-davon gehe ich nunmal aus auch wieder in die Puschen kommen. Übrigens-da soll doch irgendetwas am 15.5. d. J. stattfinden. Bin allerdings noch nicht dahintergekommen um was es da genau geht. Weiss da jemand mehr?
Gruss
Sweeper
Ich für meinen Teil gehe ganz einfach davon aus, dass dies' nicht so bleibt. Viel tiefer als z. Zt. kann der Wert wohl nicht mehr fallen. Ich jedenfalls bleibe investiert-auch im Hinbick
darauf, dass es sich bei unserem Unternehmen um einen der leader auf diesem Gebiet handelt; u. der wird-davon gehe ich nunmal aus auch wieder in die Puschen kommen. Übrigens-da soll doch irgendetwas am 15.5. d. J. stattfinden. Bin allerdings noch nicht dahintergekommen um was es da genau geht. Weiss da jemand mehr?
Gruss
Sweeper
Ende Gelände !
Labersäcke
Hier die Antwort aus einem Amiboard auf meine Frag,was es denn wohl mit dem nun schon öfters erwähnten 15./16.5. auf sich habe.
they've got till then to file their annual report. if they don't then we are demoted to the pinksheets and as a rule, we'll probably lose some investors that don't dig the stigma of the pinksheets.
however if they file a 15-12g where they elect to go into the pinksheets as they need more time to file their paperwork, then our pps will go up.
i don't think this play is based on a filing but it'd definitely help!
i'm in this cuz the technicals say i should be in it.
Sweeper
they've got till then to file their annual report. if they don't then we are demoted to the pinksheets and as a rule, we'll probably lose some investors that don't dig the stigma of the pinksheets.
however if they file a 15-12g where they elect to go into the pinksheets as they need more time to file their paperwork, then our pps will go up.
i don't think this play is based on a filing but it'd definitely help!
i'm in this cuz the technicals say i should be in it.
Sweeper
Mal wieder ein Lebenszeichen von PMED. Auf meine Frage wann der Jahresabschluss 2007 erscheint erhielt ich folgende Antwort:
The annual report should be finished by 5/14/08. We had some very specific questions from the SEC regarding our investment and it caused us to have to recalculate each quarter beginning in 2005. It has been a very time consuming and costly task and has delayed our 10K filing.
Raympond Cannefax
Paradigm Medical Industries, Inc.
801-977-8970
----
Das wäre also morgen. Ich bin gespannt!
The annual report should be finished by 5/14/08. We had some very specific questions from the SEC regarding our investment and it caused us to have to recalculate each quarter beginning in 2005. It has been a very time consuming and costly task and has delayed our 10K filing.
Raympond Cannefax
Paradigm Medical Industries, Inc.
801-977-8970
----
Das wäre also morgen. Ich bin gespannt!
Antwort auf Beitrag Nr.: 34.083.196 von voitsi am 13.05.08 16:37:43Hi voitsi,
danke für die Info. Wenn ich richtig informiert bin müssen sie ja auch bis zum 16.5.08 die Unterlagen eingereicht haben.
Bin auch gespannt wie es weitergeht. Habe trotz allem jedoch ein gutes Gefühl.
Sweeper
danke für die Info. Wenn ich richtig informiert bin müssen sie ja auch bis zum 16.5.08 die Unterlagen eingereicht haben.
Bin auch gespannt wie es weitergeht. Habe trotz allem jedoch ein gutes Gefühl.
Sweeper
Antwort auf Beitrag Nr.: 34.084.960 von STARSWEEPER am 13.05.08 19:50:48Hallo starsweeper,
recht viele Optimisten gibt's nicht mehr. Es ist gut zu hören, daß Du so denkst!
Viel Glück....können wir brauchen.
recht viele Optimisten gibt's nicht mehr. Es ist gut zu hören, daß Du so denkst!
Viel Glück....können wir brauchen.
Auf den 16.5.2008 bin ich auch gespannt.
Ich denke POSITIV
Ich denke POSITIV
Schicht im Schacht ?
16-May-2008
Non-Reliance on Previous Financials, Audits or Interim Review
ITEM 4.02 NON-RELIANCE OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS OR RELATED AUDIT REPORT
On December 17, 2007, Paradigm Medical Industries, Inc. (the "Company") received a letter from the Securities and Exchange Commission (the "Commission") stating that the staff had reviewed the financial statements and related documents in the Company's Form 10-KSB for the fiscal year ending December 31, 2006. As a result of its review, the staff had several comments on the disclosures in the financial statements of the December 31, 2006 Form 10-KSB. The letter additionally stated that in future filings the Company's Form 10-KSB should be revised in response to the comments.
On March 14, 2008, the Company filed a letter by Edgar with the Commission responding to the December 17, 2007 comment letter from the Commission. After reviewing the Company's response to the December 17, 2007 comment letter, the Commission staff arranged for a telephone conference with the Company's executive officers on March 26, 2008 to discuss the Company's March 14, 2008 letter. The staff expressed its view during the telephone conference that the $5,139,010 in convertible notes the Company issued to investors during the period from April 27, 2005 to December 24, 2007 to obtain funding for the Company's ongoing operations contained embedded derivatives. As a consequence, in disclosing these convertible notes in the financial statements of the Company's Form 10-KSB for the fiscal year ending December 31, 2006, the Company did not correctly follow the disclosure requirements of Statement of Financial Accounting Standards No. 133 ("SFAS 133") ACCOUNTING FOR DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES, which was issued by the Financial Accounting Standards Board. The staff requested that in order to comply with the disclosure requirements of SFAS 133, the Company would need to value the convertible notes in the financial statements of its Form-KSB using the Monte Carlo simulation model (or Lattice model).
On April 17, 2008 the Company's executive officers had another telephone conference with the Commission staff to discuss further issues concerning compliance with SFAS 133 by valuing the convertible notes in the financial statements using the Monte Carlo simulation model. The Company was advised during the conference by the Commission staff that it would not be required to amend its Form 10-KSB for the fiscal year ended December 31, 2006 but the Form 10-KSB for the fiscal year ended December 31, 2007 must include revised financial information and disclosures for fiscal 2006 as a result of valuing the convertible notes using the Monte Carlo simulation model.
On April 24, 2008, the Company entered into an agreement with Monarch Bay Management Company to value the Company's convertible notes pursuant to SFAS-133 using the Monte Carlo simulation model. Monarch Bay completed its valuation work on the convertible notes on May 5, 2008. The Company paid a total of $32,000 for Monarch Bay's valuation report.
As a result of using the Monte Carlo simulation model to value the convertible notes in the financial statements, certain amounts that were recorded in the financial statements for the fiscal year ended December 31, 2006 were incorrect. In the Statement of Operations for the twelve months ended December 31, 2006, the net loss was overstated by $618,000. It should have been reported as a net loss of $1,198,000 rather than a net loss of $1,816,000 as previously reported. This difference in the net loss was primarily the result of recognizing in the previously reported financial statements an expense of $1,207,000 in other expenses rather than an expense of $207,000 and not recognizing in the previously reported financials an expense of $952,000 for interest expense-accetion of debt discount, which was partially offset by a $570,000 gain on derivative valuation. In the Balance Sheet as of December 31, 2006, total long-term liabilities were overstated by $1,122,000. They should have been reported as $1,533,000 rather than $2,655,000 as previously reported. This difference in total long-term liabilities was primarily the result of recognizing in the previously reported financial statements a $1,288,000 decrease in convertible notes payable, net of discount.
Certain amounts in the financial statements for the fiscal year ended December 31, 2005 were also incorrect as a result of valuing the convertible notes using the Monte Carlo simulation model. In the Statement of Operations for the twelve months ended December 31, 2005, the net loss was overstated by $4,004,000. It should have been reported as a net loss of $1,385,000 rather than a net loss of $5,389,000 as previously reported. The difference in the net loss was primarily the result of recognizing in the previously reported financial statements an expense of $2,870,000 in other expenses rather than an expense of $370,000 and not recognizing in the previously reported financials a $3,974,000 gain in derivative valuation, which was partially offset by a $1,669,000 expense in initial fair value of derivative and warrant. In the Balance Sheet as of December 31, 2005, total long-term liabilities were overstated by $1,504,000. They should have been reported as $534,000 rather than $2,038,000 as previously reported. This difference in total long-term liabilities was primarily the result of recognizing in the previously reported financial statements a $1,669,000 decrease in convertible notes payable, net of discount.
The Company expects to file a Form 10-KSB for the fiscal year ended December 31, 2007, which will include revised financial information and disclosures for fiscal 2006 as a result of valuing the convertible notes using the Monte Carlo simulation model. The revised financial information for fiscal 2006 will include a restated Balance Sheet as of December 31, 2006 and a restated Statement of Operations for 2006.
Non-Reliance on Previous Financials, Audits or Interim Review
ITEM 4.02 NON-RELIANCE OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS OR RELATED AUDIT REPORT
On December 17, 2007, Paradigm Medical Industries, Inc. (the "Company") received a letter from the Securities and Exchange Commission (the "Commission") stating that the staff had reviewed the financial statements and related documents in the Company's Form 10-KSB for the fiscal year ending December 31, 2006. As a result of its review, the staff had several comments on the disclosures in the financial statements of the December 31, 2006 Form 10-KSB. The letter additionally stated that in future filings the Company's Form 10-KSB should be revised in response to the comments.
On March 14, 2008, the Company filed a letter by Edgar with the Commission responding to the December 17, 2007 comment letter from the Commission. After reviewing the Company's response to the December 17, 2007 comment letter, the Commission staff arranged for a telephone conference with the Company's executive officers on March 26, 2008 to discuss the Company's March 14, 2008 letter. The staff expressed its view during the telephone conference that the $5,139,010 in convertible notes the Company issued to investors during the period from April 27, 2005 to December 24, 2007 to obtain funding for the Company's ongoing operations contained embedded derivatives. As a consequence, in disclosing these convertible notes in the financial statements of the Company's Form 10-KSB for the fiscal year ending December 31, 2006, the Company did not correctly follow the disclosure requirements of Statement of Financial Accounting Standards No. 133 ("SFAS 133") ACCOUNTING FOR DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES, which was issued by the Financial Accounting Standards Board. The staff requested that in order to comply with the disclosure requirements of SFAS 133, the Company would need to value the convertible notes in the financial statements of its Form-KSB using the Monte Carlo simulation model (or Lattice model).
On April 17, 2008 the Company's executive officers had another telephone conference with the Commission staff to discuss further issues concerning compliance with SFAS 133 by valuing the convertible notes in the financial statements using the Monte Carlo simulation model. The Company was advised during the conference by the Commission staff that it would not be required to amend its Form 10-KSB for the fiscal year ended December 31, 2006 but the Form 10-KSB for the fiscal year ended December 31, 2007 must include revised financial information and disclosures for fiscal 2006 as a result of valuing the convertible notes using the Monte Carlo simulation model.
On April 24, 2008, the Company entered into an agreement with Monarch Bay Management Company to value the Company's convertible notes pursuant to SFAS-133 using the Monte Carlo simulation model. Monarch Bay completed its valuation work on the convertible notes on May 5, 2008. The Company paid a total of $32,000 for Monarch Bay's valuation report.
As a result of using the Monte Carlo simulation model to value the convertible notes in the financial statements, certain amounts that were recorded in the financial statements for the fiscal year ended December 31, 2006 were incorrect. In the Statement of Operations for the twelve months ended December 31, 2006, the net loss was overstated by $618,000. It should have been reported as a net loss of $1,198,000 rather than a net loss of $1,816,000 as previously reported. This difference in the net loss was primarily the result of recognizing in the previously reported financial statements an expense of $1,207,000 in other expenses rather than an expense of $207,000 and not recognizing in the previously reported financials an expense of $952,000 for interest expense-accetion of debt discount, which was partially offset by a $570,000 gain on derivative valuation. In the Balance Sheet as of December 31, 2006, total long-term liabilities were overstated by $1,122,000. They should have been reported as $1,533,000 rather than $2,655,000 as previously reported. This difference in total long-term liabilities was primarily the result of recognizing in the previously reported financial statements a $1,288,000 decrease in convertible notes payable, net of discount.
Certain amounts in the financial statements for the fiscal year ended December 31, 2005 were also incorrect as a result of valuing the convertible notes using the Monte Carlo simulation model. In the Statement of Operations for the twelve months ended December 31, 2005, the net loss was overstated by $4,004,000. It should have been reported as a net loss of $1,385,000 rather than a net loss of $5,389,000 as previously reported. The difference in the net loss was primarily the result of recognizing in the previously reported financial statements an expense of $2,870,000 in other expenses rather than an expense of $370,000 and not recognizing in the previously reported financials a $3,974,000 gain in derivative valuation, which was partially offset by a $1,669,000 expense in initial fair value of derivative and warrant. In the Balance Sheet as of December 31, 2005, total long-term liabilities were overstated by $1,504,000. They should have been reported as $534,000 rather than $2,038,000 as previously reported. This difference in total long-term liabilities was primarily the result of recognizing in the previously reported financial statements a $1,669,000 decrease in convertible notes payable, net of discount.
The Company expects to file a Form 10-KSB for the fiscal year ended December 31, 2007, which will include revised financial information and disclosures for fiscal 2006 as a result of valuing the convertible notes using the Monte Carlo simulation model. The revised financial information for fiscal 2006 will include a restated Balance Sheet as of December 31, 2006 and a restated Statement of Operations for 2006.
na, da bin ich aber mal auf den Start in die neue Woche gespannt.
Bin immer noch davon überzeugt, dass dieser Wert in Kürze einen Rebound hinlegt.
Sweeper
Bin immer noch davon überzeugt, dass dieser Wert in Kürze einen Rebound hinlegt.
Sweeper
Antwort auf Beitrag Nr.: 34.117.934 von STARSWEEPER am 17.05.08 22:14:21QStarsweeper
Bei mir ist auch noch Hoffnung vorhanden, finde es nur komisch, dass die Deadline zur Veröffentlichung der Geschäftszahlen am Freitag ausgelaufen ist und ich noch immer nichts finde.
Aber vielleicht legt diese Aktie einen Rebound hin wie es die welt noch nicht erlebt hat...
Bei mir ist auch noch Hoffnung vorhanden, finde es nur komisch, dass die Deadline zur Veröffentlichung der Geschäftszahlen am Freitag ausgelaufen ist und ich noch immer nichts finde.
Aber vielleicht legt diese Aktie einen Rebound hin wie es die welt noch nicht erlebt hat...
Antwort auf Beitrag Nr.: 34.118.363 von stern16 am 18.05.08 08:32:47Hi stern16,
hier u. da konnte man schon nachlesen was da veröffentlicht wurde.
Einen Auszug stellte ein User ja auch hier in's Board.
In einem Ami-Board fand ich gerade dieses Posting, welches denjenigen, die in dieses Invest vielleicht ihr Vertrauen verloren haben wieder Mut machen sollte.
Posted by: LDB29
In reply to: armin666 who wrote msg# 3269 Date:5/18/2008 1:35:13 PM
Post #of 3271
Now That They Released The 10KSB And The 8K Showing That They Are In A Better Position Financialy The E Being Removed Monday Or Tuesday The 10QSB On The Way The FDA Aproval On The Photon Laser System Would Be Huge This Company Has Big Things That Will Happen In 2008.
Gross profit for the twelve months ended December 31, 2007 increased to
46% of total revenues, compared to 42% of total revenues for the same period in 2006.
Sales of the Blood Flow Analyzer(TM) increased due in part from the
reorganization of the Company's sales force. The Company anticipates continuing
the upward trend in Blood Flow Analyzer(TM) sales through additional efforts by
the Company to gain more wide spread support from the Blood Flow Analyzer(TM)
through increased clinical awareness, product development and improved marketing
plans.
Grüsse Sweeper
hier u. da konnte man schon nachlesen was da veröffentlicht wurde.
Einen Auszug stellte ein User ja auch hier in's Board.
In einem Ami-Board fand ich gerade dieses Posting, welches denjenigen, die in dieses Invest vielleicht ihr Vertrauen verloren haben wieder Mut machen sollte.
Posted by: LDB29
In reply to: armin666 who wrote msg# 3269 Date:5/18/2008 1:35:13 PM
Post #of 3271
Now That They Released The 10KSB And The 8K Showing That They Are In A Better Position Financialy The E Being Removed Monday Or Tuesday The 10QSB On The Way The FDA Aproval On The Photon Laser System Would Be Huge This Company Has Big Things That Will Happen In 2008.
Gross profit for the twelve months ended December 31, 2007 increased to
46% of total revenues, compared to 42% of total revenues for the same period in 2006.
Sales of the Blood Flow Analyzer(TM) increased due in part from the
reorganization of the Company's sales force. The Company anticipates continuing
the upward trend in Blood Flow Analyzer(TM) sales through additional efforts by
the Company to gain more wide spread support from the Blood Flow Analyzer(TM)
through increased clinical awareness, product development and improved marketing
plans.
Grüsse Sweeper
nur zur Info.
Stelle hier mal meine kurze Korrespondenz mit Mr. Cannefax rein.
Habe diese auch in's Ami-Board gestellt.
@all
Yesterday evening I wrot following e-mail to Mr. Cannefax:
To: r_cannefax@msn.com
Subject: The big E in the name of Pmed
Date: Thu, 22 May 2008 21:06:43 +0200
Dear Mr. Cannefax,
would you be so kind to tell me, why the big E hasn't gone yet?
We know, PMED has done there homework now. Some of our shareholders asked this question-and I read this question in some boards in your country.
I told our group that I 'm very confident in you-Mr. Cannefax and that Pmed belongs to the leader in this medical products. After that, the most of them were calm with there trouble.
Thanks for your respons.
With best regards from old Germany
Here the quick, short answer from Pmed:
After finally getting our 10K filed, we are still working on filing the 10Q which we expect to have filed by the end of this week.
Paradigm Medical Industries, Inc.
801-977-8970
With kind regards
Sweeper
So, nun warte ich zunächst mal die Reaktion der amerikanischen User ab. Danach melde ich mich dann wieder.
Sweeper
Stelle hier mal meine kurze Korrespondenz mit Mr. Cannefax rein.
Habe diese auch in's Ami-Board gestellt.
@all
Yesterday evening I wrot following e-mail to Mr. Cannefax:
To: r_cannefax@msn.com
Subject: The big E in the name of Pmed
Date: Thu, 22 May 2008 21:06:43 +0200
Dear Mr. Cannefax,
would you be so kind to tell me, why the big E hasn't gone yet?
We know, PMED has done there homework now. Some of our shareholders asked this question-and I read this question in some boards in your country.
I told our group that I 'm very confident in you-Mr. Cannefax and that Pmed belongs to the leader in this medical products. After that, the most of them were calm with there trouble.
Thanks for your respons.
With best regards from old Germany
Here the quick, short answer from Pmed:
After finally getting our 10K filed, we are still working on filing the 10Q which we expect to have filed by the end of this week.
Paradigm Medical Industries, Inc.
801-977-8970
With kind regards
Sweeper
So, nun warte ich zunächst mal die Reaktion der amerikanischen User ab. Danach melde ich mich dann wieder.
Sweeper
Antwort auf Beitrag Nr.: 34.161.089 von STARSWEEPER am 23.05.08 17:32:02Hallo Starsweeper,
vielen Dank für's reinstellen. Jetzt bin ich echt neugierig wie's weitergeht. Bin gespannt wie der Quartalsbericht ausfällt.
Alles Gute!
vielen Dank für's reinstellen. Jetzt bin ich echt neugierig wie's weitergeht. Bin gespannt wie der Quartalsbericht ausfällt.
Alles Gute!
!
Dieser Beitrag wurde moderiert. Grund: Spammposting
Tach zusammen, und was macht unser Wert? Gibts was Neues? Oder nähern wir uns dem "Tod"???
Max
Max
das "E" ist ja noch da....!?!?!
max
max
Antwort auf Beitrag Nr.: 34.243.600 von Max82 am 05.06.08 11:45:33Hi max,
wie heisst doch ein altes Sprichwort? Es sagt:Totgesagte leben länger! Genau so sehe ich es auch bei PMED. Das E wird früher o. später wieder verschwinden.
Übrigens: Die Postingdichte im Amiboard stieg seit gestern enorm an. Alleine heut mehr als 100. Bin auch gespannt wie's hier weitergeht.
Gruss Sweeper
wie heisst doch ein altes Sprichwort? Es sagt:Totgesagte leben länger! Genau so sehe ich es auch bei PMED. Das E wird früher o. später wieder verschwinden.
Übrigens: Die Postingdichte im Amiboard stieg seit gestern enorm an. Alleine heut mehr als 100. Bin auch gespannt wie's hier weitergeht.
Gruss Sweeper
Finde auch, daß in dieser Aktie noch Hoffnung steckt.
PERIOD ENDING 31-Dec-07 30-Sep-07 30-Jun-07 31-Mar-07
Total Revenue 682 534 259 397
Cost of Revenue 375 270 150 225
Gross Profit 307 264 109 172
Operating Expenses
Research Development 83 71 126 64
Selling General and Administrative 544 361 465 304
Non Recurring (91) - - -
Others - - - -
Total Operating Expenses - - - -
Operating Income or Loss (229) (168) (482) (196)
Income from Continuing Operations
Total Other Income/Expenses Net 1,565 (67) (1,069) -
Earnings Before Interest And Taxes 1,336 (235) (1,551) (196)
Interest Expense 1,083 1 (51) 52
Income Before Tax 253 (236) (1,500) (248)
Income Tax Expense - - - -
Minority Interest - - - -
Net Income From Continuing Ops 253 (236) (1,500) (248)
Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -
Net Income 253 (236) (1,500) (248)
Preferred Stock And Other Adjustments - - - -
Net Income Applicable To Common Shares $253 ($236) ($1,500) ($248)
Total Revenue 682 534 259 397
Cost of Revenue 375 270 150 225
Gross Profit 307 264 109 172
Operating Expenses
Research Development 83 71 126 64
Selling General and Administrative 544 361 465 304
Non Recurring (91) - - -
Others - - - -
Total Operating Expenses - - - -
Operating Income or Loss (229) (168) (482) (196)
Income from Continuing Operations
Total Other Income/Expenses Net 1,565 (67) (1,069) -
Earnings Before Interest And Taxes 1,336 (235) (1,551) (196)
Interest Expense 1,083 1 (51) 52
Income Before Tax 253 (236) (1,500) (248)
Income Tax Expense - - - -
Minority Interest - - - -
Net Income From Continuing Ops 253 (236) (1,500) (248)
Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -
Net Income 253 (236) (1,500) (248)
Preferred Stock And Other Adjustments - - - -
Net Income Applicable To Common Shares $253 ($236) ($1,500) ($248)
Wenn ich das recht sehe. Steigender Umsatz und erster kleiner Gewinn.
Antwort auf Beitrag Nr.: 34.290.635 von Bombenleger am 12.06.08 15:50:13Machen wir es mal kurz mit diesen Karnickelstall!
Es gibt in der Zwischenzeit 3,7 Mrd. Aktien und in der Bilanz haben die mal ganz kurz über 1 Mio. Dollar als Zinsaufwand aus dem Hut gesaubert!
The following table identifies our outstanding commitments to issue shares, including the shares underlying the convertible notes and warrants issuable upon conversion of the notes and exercise of the warrants:
Underlying Shares
Security of Common Stock
Notes (1) 3,637,280,000
Warrants (2) 54,034,392
Preferred Stock (3) 862,404
Stock Options (4) 11,500,000
-------------------
Total 3,703,676,796
Fazit: Es gibt eindeutig mehr Paradigm Medical Aktie wie Dumme in dieser Welt!
Es gibt in der Zwischenzeit 3,7 Mrd. Aktien und in der Bilanz haben die mal ganz kurz über 1 Mio. Dollar als Zinsaufwand aus dem Hut gesaubert!
The following table identifies our outstanding commitments to issue shares, including the shares underlying the convertible notes and warrants issuable upon conversion of the notes and exercise of the warrants:
Underlying Shares
Security of Common Stock
Notes (1) 3,637,280,000
Warrants (2) 54,034,392
Preferred Stock (3) 862,404
Stock Options (4) 11,500,000
-------------------
Total 3,703,676,796
Fazit: Es gibt eindeutig mehr Paradigm Medical Aktie wie Dumme in dieser Welt!
Antwort auf Beitrag Nr.: 34.290.635 von Bombenleger am 12.06.08 15:50:13http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?F…
Einfach mal lesen und es wird einem so richtig kotzübel dabei!
Einfach mal lesen und es wird einem so richtig kotzübel dabei!
20-Jun-2008
Quarterly Report
Item 2: Management's Discussion and Analysis or Plan of Operation
This report contains forward-looking statements and information relating to the Company that is based on beliefs of management as well as assumptions made by, and information currently available to management. These statements reflect its current view respecting future events and are subject to risks, uncertainties and assumptions, including the risks and uncertainties noted throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward-looking statements not to come true as anticipated, believed, projected, expected or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.
Critical Accounting Policies
Revenue Recognition. The Company recognizes revenue in compliance with Staff Accounting Bulletin 101, Revenue Recognition in Financial Statements (SAB 101), as revised by Staff Accounting Bulletin No. 104, Revenue Recognition (SAB 104). SAB 101 and SAB 104 detail four criteria that must exist before revenue is recognized:
1. Persuasive evidence of an arrangement exits. Prior to shipment of product, the Company required a signed purchase order and, depending upon the customer, a down payment toward the final invoiced price or full payment in advance with certain international product distributors.
2. Delivery and performance have occurred. Unless the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when the product ships. If the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when such installation or acceptance has occurred. Title to the product passes to its customer upon shipment. This revenue recognition policy does not differ among its various different product lines. The Company guarantees the functionality of its product. If its product does not function as marketed when received by the customer, the Company either makes the necessary repairs on site or has the product shipped to the Company for the repair work. Once the product has been repaired and retested for functionality, it is re-shipped to the customer. The Company provides warranties that generally extend for one year from the date of sale. Such warranties cover the necessary parts and labor to repair the product as well as any shipping costs that may be required. The Company maintains a reserve for estimated warranty costs based on its historical experience and management's current expectations.
3. The sales price is fixed or determinable. The purchase order received from the customer includes the agreed-upon sales price. The Company does not accept customer orders, and therefore does not recognize revenue, until the sales price is fixed.
--------------------------------------------------------------------------------
4. Collectibility is reasonably assured. With limited exceptions, the Company requires down payments on product prior to shipment. In some cases the Company requires payment in full prior to shipment. The Company also performs credit checks on new customers and ongoing credit checks on existing customers. The Company maintains an allowance for doubtful accounts receivable based on historical experience and management's current expectations.
5. Revenues for sales of products that require specific installation and acceptance by the customer are recognized upon such installation and acceptance by the customer. Revenues for sales of other surgical systems, ultrasound diagnostic devices, and disposable products are recognized when the product is shipped. A signed purchase agreement and a depositor payment in full from customers are required before a product leaves the premises. Title passes at time of shipment (F.O.B. shipping point). The products of the Company contain both hardware and software components. The Company does not recognize revenue for the software components of the products separate from the product as a whole because the software is incidental to the product, as defined in paragraph 2 of SOP 97-2.
Recoverability of Inventory. Since its inception, the Company has purchased several complete lines of inventory. In some circumstances the Company has been able to utilize certain items acquired and others remain unused. On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
Recoverability of Goodwill and Other Intangible Assets. The Company's intangible assets consist of goodwill, product and technology rights, engineering and design costs, and patent costs. Intangibles with a determined life are amortized on a straight-line basis over their determined useful life and are also evaluated for potential impairment if events or circumstances indicate that the carrying amount may not be recoverable. Intangibles with an indefinite life, such as goodwill, are not amortized but are tested for impairment on an annual basis or when events and circumstances indicate that the asset may be impaired. Impairment tests include comparing the fair value of a reporting unit with its carrying net book value, including goodwill. To date, the Company's determination of the fair value of the reporting unit has been based on the estimated future cash flows of that reporting unit. Intangible assets other than goodwill have been fully amortized.
Allowance for Doubtful Accounts. The Company records an allowance for doubtful accounts to offset estimated uncollectible accounts receivable. Bad debt expense associated with the increases in the allowance for doubtful accounts is recorded as part of general and administrative expense. The Company's accounting policy generally is to record an allowance for receivables over 90 days past due unless there is significant evidence to support that the receivable is collectible.
General
The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31.
The Company is engaged in the design, development, manufacture and sale of high technology diagnostic and surgical eye care products. Given the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow. As seen in the results for the three months ended March 31, 2008, diagnostic products have been the major focus and the Photon� and other extensive research and development projects have been put on hold pending future evaluation when the Company's financial position improves. The Company does not focus on a specific diagnostic product or products but, instead, on the entire diagnostic group.
--------------------------------------------------------------------------------
Results of Operations
Three Months Ended March 31, 2008, Compared to Three Months Ended March 31, 2007
Net sales for the three months ended March 31, 2008 decreased by $168,000, or 42%, to $229,000 as compared to $397,000 for the same period of 2007. This reduction in sales was primarily due to decreased sales of the P40, P45 and P60 Ultrasound Biomicroscopes, the P37, P37II and P2700 Ocular Ultrasound A/B Scan Diagnostics, the P2000 A-Scan Biometric Ultrasound Analyzer, the P2200 and P2500 Pachymetric Analyzers, and the Blood Flow Analyzer�.
For the three months ended March 31, 2008, sales from the Company's diagnostic products totaled $185,000, or 80% of total revenues, compared to $370,000, or 93% of total revenues for the same period of 2007. The remaining 20% of sales, or $44,000 during the three months ended March 31, 2008, was from parts, disposables, and service revenue.
Sales of the P60 UBM Ultrasound Biomicroscope decreased by $149,000 to $5,000, or 2% of total revenues, for the three months ended March 31, 2008, compared to $154,000, or 39% of total revenues, for the same period last year. Sales of the Blood Flow Analyzer� decreased by $27,000 to $3,000, or 1% of total revenues, for the three months ended March 31, 2008, compared to net sales of $30,000, or 8% of total revenues, during the same period in 2007. Sales from the P37 and P37-II A/B Scan Ocular Ultrasound Diagnostic devices decreased by $50,000 to $41,000, or 18% of total revenues for the three months ended March 31, 2008, compared to $91,000, or 23% of total revenues, during the same period in 2007. Sales of the P2200,and P2500 Pachymetric Analyzers, and the P2000 A-Scan Biometric Ultrasound Analyzer decreased by $19,000 to $7,000, or 3% of total revenues, for the three month period ended March 31, 2008, compared to $26,000, or 6% of total revenues, for the same period of 2007. Combined sales of the LD 400 and TKS 5000 Autoperimetry Systems increased by $61,000 to $130,000, or 57% of the total revenues, for the three months ended March 31, 2008, compared to $69,000, or 17% of total revenues, for the same period of 2007.
Sales have been lower during the three months ended March 31, 2008 for the Company due to a variety of reasons. Sales of the P60 UBM Ultrasound Biomicroscope were reduced primarily due to the introduction of new software for the P60, which received FDA 510(k) premarket approval on May 26, 2005 that allowed the device to be sold in the United States. The hardware problems have since been resolved and the Company continues to work on improving the software package for the P60.
The Company anticipates reversing the downward trend in sales through additional efforts by the Company to gain more widespread support for the P60 UBM Ultrasound Biomicroscope, the Blood Flow Analyzer�, the LD400 Antoperimetry System, the P37-II Ocular Ultrasound A/B Scan Diagnostics, the 2200 and 2500 Pachymetric Analyzers, the P2000 A-Scan Biometric Ultrasound Analyzer, and the Lace Glaid through increased clinical awareness, increased product development, improved marketing plans and strategic product replacement, and ongoing development of the LD400 perimeter and the Lace Glaid. The Blood Flow Analyzer� is expected to have a new CPT reimbursement code for Medicare insurance providers issued during the latter part of 2008 or early 2009, reversing the downward sales trend experienced by the Blood Flow Analyzer�.
Gross profit for the three months ended March 31, 2008 decreased by 5% to 38% of total revenues, compared to 43% of total revenues for the same period in 2007. This decrease in gross profit was mainly due to increased costs of parts and labor. There was no increase to cost of sales as a result of a charge to the reserve for obsolete inventory in 2007.
Marketing and selling expenses increased by $68,000, or 59%, to $183,000, for the three months ended March 31, 2008, from $115,000 for the comparable period in 2007. This increase was due primarily to an increase in domestic and international marketing expenses, training expenses, related travel expenses and additional staff associated with the introduction of the Lace Glaid.
General and administrative expenses increased by $31,000, or 16%, to $220,000 for the three months ended March 31, 2008, from $189,000 for the comparable period in 2007. This increase was primarily due to an increase in salaries, primarily to merit increases of existing employees, as well as the addition of staff necessary for the introduction of the Lace Glaid.
--------------------------------------------------------------------------------
Also, during the three months ended March 31, 2008, the Company has not been able to collect receivables that were previously allowed in the allowance for doubtful accounts. During the three months ended March 31, 2008, the Company has not increased the allowance for doubtful accounts.
Research, development and service expenses increased by $24,000, or 38%, to $88,000 for the three months ended March 31, 2008, compared to $64,000 in the same period of 2007. This increase was mainly due to increased costs relating to the development of the revised P60 UBM software version, the increased level of marketing new products, and the addition of staff for product marketing.
Due to the Company's ongoing cash flow difficulties, most of the Company's vendors and suppliers were contacted during 2007 and 2006 with attempts to negotiate reduced payments and settlement of outstanding accounts payable. Although some vendors refused to negotiate and demanded payment in full, some vendors were willing to settle for a reduced amount. The accounts payable forgiven by vendors and suppliers resulted in a gain of $-0- during both of the periods ended March 31, 2008 and 2007. In 2008 the Company is continuing its negotiations with certain vendors and suppliers.
Liquidity and Capital Resources
The Company used $291,000 in cash in operating activities for the three months ended March 31, 2008, compared to $140,000 for the three months ended March 31, 2007. The increase in cash used for operating activities for the three months ended March 31, 2008 was primarily attributable to the Company's net loss and increases in inventory, and a significant decrease of the change of the fair value of derivative liabilities. There was no cash used for investment activities for the three months ended March 31, 2008, compared to no cash used for investment activities for the same period in 2007. Net cash used in financing activities was $0 for the three months ended March 31, 2008, compare to $-0- in the same period in 2007. The Company had working capital of $283,000 as of March 31, 2008. In the past, the Company has relied heavily upon sales of the Company's common and preferred stock to fund operations. There can be no assurance that such equity funding will be available on terms acceptable to the Company in the future.
As of March 31, 2008, the Company had net operating loss carryforwards (NOLs) of approximately $56 million. These loss carryforwards are available to offset future taxable income, if any, and have begun to expire in 2001and extend for twenty years. The Company's ability to use net operating loss carryforwards (NOLs) to offset future income is dependent upon certain limitations as a result of the pooling transaction with Vismed and the tax laws in effect at the time of the NOLs being utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carryforwards as a result of change of ownership.
As of March 31, 2008, the Company had accounts payable of $416,000, a significant portion of which was over 90 days past due, compared to accounts payable of $411,000 as of March 31, 2007. The Company has contacted many of the vendors or companies that have significant amounts of payables past due in an effort to delay payment, renegotiate a reduced settlement payment, or establish a longer term payment plan. While some companies have been willing to renegotiate the outstanding amounts, others have demanded payment in full. Under certain conditions, including but not limited to judgments rendered against the Company in a court of law, a group of creditors could force the Company into bankruptcy due to its inability to pay the liabilities arising out of such judgments at that time. In addition to the accounts payable noted above, the Company also has operating lease obligations that require the payment of approximately $110,000 in 2008, and $108,000 in 2007.
The Company has taken measures to reduce the amount of uncollectible accounts receivable such as more thorough and stringent credit approval, improved training and instruction by sales personnel, and frequent direct communication with the customer subsequent to delivery of the system. The allowance for doubtful accounts was 20% of total outstanding receivables as of March 31, 2008, compared to 12% of total outstanding receivables as of March 31, 2007.
The Company intends to continue its efforts to reduce the allowance for doubtful accounts as a percentage of accounts receivable. The Company has ongoing efforts to collect a significant portion of the sales price in advance of the sale or in a timely manner after delivery. The Company believes that by requiring a large portion of payment prior to shipment, it has greatly improved the collectibility of its receivables.
--------------------------------------------------------------------------------
The Company carried an allowance for obsolete or estimated non-recoverable inventory of $244,000 at March 31, 2008 and $1,320,000 at March 31, 2007, or 21% and 61% of total inventory, respectively. The Company's means of expansion and development of product has been largely from acquisition of businesses, product lines, existing inventory, and the rights to specific products. Through such acquisitions, the Company has acquired substantial inventory, some of which the eventual use and recoverability was uncertain. In addition, the Company has a significant amount of inventory relating to the Photon� laser system, which does not yet have FDA approval in order to sell the product domestically. Therefore, the allowance for inventory was established to reserve for these potential eventualities.
On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
At this time, the Company's Photon� Laser Ocular Surgery Workstation requires regulatory FDA approval in order to be sold in the United States. Any possible future efforts to complete the clinical trials on the Photon� in order to file for FDA approval would depend on the Company obtaining adequate funding. The Company estimates that the funds needed to complete the clinical trials in order to obtain the necessary regulatory approval on the Photon� to be approximately $225,000.
Effect of Inflation and Foreign Currency Exchange
The Company has not realized a reduction in the selling price of its products as a result of domestic inflation. Nor has it experienced unfavorable profit reductions due to currency exchange fluctuations or inflation with its foreign customers. All sales transactions to date have been denominated in U.S. dollars. The Company has experienced an increase in products being manufactured in England and Italy, and in parts being acquired from the European Community due to the fluctuations of the dollar compared to the Euro and the Pound Sterling. This has increased the cost of several products. There may be an impact on profits as a result of this decrease in the value of the dollar because the profit margins will decrease if higher product pricing has a negative impact on sales.
New Accounting Pronouncements
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities, including an amendment of FASB Statement No. 115 ("SFAS 159"). SFAS 159 permits companies to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value, and establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 is effective on January 1, 2008, and is not expected to have a material effect on the Company's consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations ("SFAS 141R"). SFAS 141R establishes the principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interest in the acquiree, and the goodwill acquired. SFAS 141R also establishes disclosure requirements to enable the evaluation of the nature and financial effects of the business combination. SFAS 141R is effective on January 1, 2009, and is not expected to have a material effect on the Company's consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51 ("SFAS 160"). SFAS 160 will change the accounting and reporting for minority interests, which will be recharacterized as noncontrolling interests and classified as a component of equity. This new consolidation method will significantly change the accounting for transactions with minority interest holders. SFAS 160 is effective on January 1, 2009, and is not expected to have a material effect on the Company's consolidated financial statements.
--------------------------------------------------------------------------------
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities ("SFAS 161"). SFAS 161 amends SFAS 133, Accounting for Derivative Instruments and Hendging Activities to require enhanced disclosures concerning the manner in which an entity uses derivatives (and the reasons it uses them), the manner in which derivatives and related hedged items are accounted for under SFAS 133 and interpretations thereof, and the effects that derivatives and related hedged items have on an entity's financial position, financial performance, and cash flows. SFAS 161 is effective for financial statements of fiscal years and interim periods beginning after November 15, 2008. The Company has not yet determined the effects on its consolidated financial statements, if any, that may result upon the adoption of SFAS 161.
Quarterly Report
Item 2: Management's Discussion and Analysis or Plan of Operation
This report contains forward-looking statements and information relating to the Company that is based on beliefs of management as well as assumptions made by, and information currently available to management. These statements reflect its current view respecting future events and are subject to risks, uncertainties and assumptions, including the risks and uncertainties noted throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward-looking statements not to come true as anticipated, believed, projected, expected or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.
Critical Accounting Policies
Revenue Recognition. The Company recognizes revenue in compliance with Staff Accounting Bulletin 101, Revenue Recognition in Financial Statements (SAB 101), as revised by Staff Accounting Bulletin No. 104, Revenue Recognition (SAB 104). SAB 101 and SAB 104 detail four criteria that must exist before revenue is recognized:
1. Persuasive evidence of an arrangement exits. Prior to shipment of product, the Company required a signed purchase order and, depending upon the customer, a down payment toward the final invoiced price or full payment in advance with certain international product distributors.
2. Delivery and performance have occurred. Unless the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when the product ships. If the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when such installation or acceptance has occurred. Title to the product passes to its customer upon shipment. This revenue recognition policy does not differ among its various different product lines. The Company guarantees the functionality of its product. If its product does not function as marketed when received by the customer, the Company either makes the necessary repairs on site or has the product shipped to the Company for the repair work. Once the product has been repaired and retested for functionality, it is re-shipped to the customer. The Company provides warranties that generally extend for one year from the date of sale. Such warranties cover the necessary parts and labor to repair the product as well as any shipping costs that may be required. The Company maintains a reserve for estimated warranty costs based on its historical experience and management's current expectations.
3. The sales price is fixed or determinable. The purchase order received from the customer includes the agreed-upon sales price. The Company does not accept customer orders, and therefore does not recognize revenue, until the sales price is fixed.
--------------------------------------------------------------------------------
4. Collectibility is reasonably assured. With limited exceptions, the Company requires down payments on product prior to shipment. In some cases the Company requires payment in full prior to shipment. The Company also performs credit checks on new customers and ongoing credit checks on existing customers. The Company maintains an allowance for doubtful accounts receivable based on historical experience and management's current expectations.
5. Revenues for sales of products that require specific installation and acceptance by the customer are recognized upon such installation and acceptance by the customer. Revenues for sales of other surgical systems, ultrasound diagnostic devices, and disposable products are recognized when the product is shipped. A signed purchase agreement and a depositor payment in full from customers are required before a product leaves the premises. Title passes at time of shipment (F.O.B. shipping point). The products of the Company contain both hardware and software components. The Company does not recognize revenue for the software components of the products separate from the product as a whole because the software is incidental to the product, as defined in paragraph 2 of SOP 97-2.
Recoverability of Inventory. Since its inception, the Company has purchased several complete lines of inventory. In some circumstances the Company has been able to utilize certain items acquired and others remain unused. On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
Recoverability of Goodwill and Other Intangible Assets. The Company's intangible assets consist of goodwill, product and technology rights, engineering and design costs, and patent costs. Intangibles with a determined life are amortized on a straight-line basis over their determined useful life and are also evaluated for potential impairment if events or circumstances indicate that the carrying amount may not be recoverable. Intangibles with an indefinite life, such as goodwill, are not amortized but are tested for impairment on an annual basis or when events and circumstances indicate that the asset may be impaired. Impairment tests include comparing the fair value of a reporting unit with its carrying net book value, including goodwill. To date, the Company's determination of the fair value of the reporting unit has been based on the estimated future cash flows of that reporting unit. Intangible assets other than goodwill have been fully amortized.
Allowance for Doubtful Accounts. The Company records an allowance for doubtful accounts to offset estimated uncollectible accounts receivable. Bad debt expense associated with the increases in the allowance for doubtful accounts is recorded as part of general and administrative expense. The Company's accounting policy generally is to record an allowance for receivables over 90 days past due unless there is significant evidence to support that the receivable is collectible.
General
The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31.
The Company is engaged in the design, development, manufacture and sale of high technology diagnostic and surgical eye care products. Given the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow. As seen in the results for the three months ended March 31, 2008, diagnostic products have been the major focus and the Photon� and other extensive research and development projects have been put on hold pending future evaluation when the Company's financial position improves. The Company does not focus on a specific diagnostic product or products but, instead, on the entire diagnostic group.
--------------------------------------------------------------------------------
Results of Operations
Three Months Ended March 31, 2008, Compared to Three Months Ended March 31, 2007
Net sales for the three months ended March 31, 2008 decreased by $168,000, or 42%, to $229,000 as compared to $397,000 for the same period of 2007. This reduction in sales was primarily due to decreased sales of the P40, P45 and P60 Ultrasound Biomicroscopes, the P37, P37II and P2700 Ocular Ultrasound A/B Scan Diagnostics, the P2000 A-Scan Biometric Ultrasound Analyzer, the P2200 and P2500 Pachymetric Analyzers, and the Blood Flow Analyzer�.
For the three months ended March 31, 2008, sales from the Company's diagnostic products totaled $185,000, or 80% of total revenues, compared to $370,000, or 93% of total revenues for the same period of 2007. The remaining 20% of sales, or $44,000 during the three months ended March 31, 2008, was from parts, disposables, and service revenue.
Sales of the P60 UBM Ultrasound Biomicroscope decreased by $149,000 to $5,000, or 2% of total revenues, for the three months ended March 31, 2008, compared to $154,000, or 39% of total revenues, for the same period last year. Sales of the Blood Flow Analyzer� decreased by $27,000 to $3,000, or 1% of total revenues, for the three months ended March 31, 2008, compared to net sales of $30,000, or 8% of total revenues, during the same period in 2007. Sales from the P37 and P37-II A/B Scan Ocular Ultrasound Diagnostic devices decreased by $50,000 to $41,000, or 18% of total revenues for the three months ended March 31, 2008, compared to $91,000, or 23% of total revenues, during the same period in 2007. Sales of the P2200,and P2500 Pachymetric Analyzers, and the P2000 A-Scan Biometric Ultrasound Analyzer decreased by $19,000 to $7,000, or 3% of total revenues, for the three month period ended March 31, 2008, compared to $26,000, or 6% of total revenues, for the same period of 2007. Combined sales of the LD 400 and TKS 5000 Autoperimetry Systems increased by $61,000 to $130,000, or 57% of the total revenues, for the three months ended March 31, 2008, compared to $69,000, or 17% of total revenues, for the same period of 2007.
Sales have been lower during the three months ended March 31, 2008 for the Company due to a variety of reasons. Sales of the P60 UBM Ultrasound Biomicroscope were reduced primarily due to the introduction of new software for the P60, which received FDA 510(k) premarket approval on May 26, 2005 that allowed the device to be sold in the United States. The hardware problems have since been resolved and the Company continues to work on improving the software package for the P60.
The Company anticipates reversing the downward trend in sales through additional efforts by the Company to gain more widespread support for the P60 UBM Ultrasound Biomicroscope, the Blood Flow Analyzer�, the LD400 Antoperimetry System, the P37-II Ocular Ultrasound A/B Scan Diagnostics, the 2200 and 2500 Pachymetric Analyzers, the P2000 A-Scan Biometric Ultrasound Analyzer, and the Lace Glaid through increased clinical awareness, increased product development, improved marketing plans and strategic product replacement, and ongoing development of the LD400 perimeter and the Lace Glaid. The Blood Flow Analyzer� is expected to have a new CPT reimbursement code for Medicare insurance providers issued during the latter part of 2008 or early 2009, reversing the downward sales trend experienced by the Blood Flow Analyzer�.
Gross profit for the three months ended March 31, 2008 decreased by 5% to 38% of total revenues, compared to 43% of total revenues for the same period in 2007. This decrease in gross profit was mainly due to increased costs of parts and labor. There was no increase to cost of sales as a result of a charge to the reserve for obsolete inventory in 2007.
Marketing and selling expenses increased by $68,000, or 59%, to $183,000, for the three months ended March 31, 2008, from $115,000 for the comparable period in 2007. This increase was due primarily to an increase in domestic and international marketing expenses, training expenses, related travel expenses and additional staff associated with the introduction of the Lace Glaid.
General and administrative expenses increased by $31,000, or 16%, to $220,000 for the three months ended March 31, 2008, from $189,000 for the comparable period in 2007. This increase was primarily due to an increase in salaries, primarily to merit increases of existing employees, as well as the addition of staff necessary for the introduction of the Lace Glaid.
--------------------------------------------------------------------------------
Also, during the three months ended March 31, 2008, the Company has not been able to collect receivables that were previously allowed in the allowance for doubtful accounts. During the three months ended March 31, 2008, the Company has not increased the allowance for doubtful accounts.
Research, development and service expenses increased by $24,000, or 38%, to $88,000 for the three months ended March 31, 2008, compared to $64,000 in the same period of 2007. This increase was mainly due to increased costs relating to the development of the revised P60 UBM software version, the increased level of marketing new products, and the addition of staff for product marketing.
Due to the Company's ongoing cash flow difficulties, most of the Company's vendors and suppliers were contacted during 2007 and 2006 with attempts to negotiate reduced payments and settlement of outstanding accounts payable. Although some vendors refused to negotiate and demanded payment in full, some vendors were willing to settle for a reduced amount. The accounts payable forgiven by vendors and suppliers resulted in a gain of $-0- during both of the periods ended March 31, 2008 and 2007. In 2008 the Company is continuing its negotiations with certain vendors and suppliers.
Liquidity and Capital Resources
The Company used $291,000 in cash in operating activities for the three months ended March 31, 2008, compared to $140,000 for the three months ended March 31, 2007. The increase in cash used for operating activities for the three months ended March 31, 2008 was primarily attributable to the Company's net loss and increases in inventory, and a significant decrease of the change of the fair value of derivative liabilities. There was no cash used for investment activities for the three months ended March 31, 2008, compared to no cash used for investment activities for the same period in 2007. Net cash used in financing activities was $0 for the three months ended March 31, 2008, compare to $-0- in the same period in 2007. The Company had working capital of $283,000 as of March 31, 2008. In the past, the Company has relied heavily upon sales of the Company's common and preferred stock to fund operations. There can be no assurance that such equity funding will be available on terms acceptable to the Company in the future.
As of March 31, 2008, the Company had net operating loss carryforwards (NOLs) of approximately $56 million. These loss carryforwards are available to offset future taxable income, if any, and have begun to expire in 2001and extend for twenty years. The Company's ability to use net operating loss carryforwards (NOLs) to offset future income is dependent upon certain limitations as a result of the pooling transaction with Vismed and the tax laws in effect at the time of the NOLs being utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carryforwards as a result of change of ownership.
As of March 31, 2008, the Company had accounts payable of $416,000, a significant portion of which was over 90 days past due, compared to accounts payable of $411,000 as of March 31, 2007. The Company has contacted many of the vendors or companies that have significant amounts of payables past due in an effort to delay payment, renegotiate a reduced settlement payment, or establish a longer term payment plan. While some companies have been willing to renegotiate the outstanding amounts, others have demanded payment in full. Under certain conditions, including but not limited to judgments rendered against the Company in a court of law, a group of creditors could force the Company into bankruptcy due to its inability to pay the liabilities arising out of such judgments at that time. In addition to the accounts payable noted above, the Company also has operating lease obligations that require the payment of approximately $110,000 in 2008, and $108,000 in 2007.
The Company has taken measures to reduce the amount of uncollectible accounts receivable such as more thorough and stringent credit approval, improved training and instruction by sales personnel, and frequent direct communication with the customer subsequent to delivery of the system. The allowance for doubtful accounts was 20% of total outstanding receivables as of March 31, 2008, compared to 12% of total outstanding receivables as of March 31, 2007.
The Company intends to continue its efforts to reduce the allowance for doubtful accounts as a percentage of accounts receivable. The Company has ongoing efforts to collect a significant portion of the sales price in advance of the sale or in a timely manner after delivery. The Company believes that by requiring a large portion of payment prior to shipment, it has greatly improved the collectibility of its receivables.
--------------------------------------------------------------------------------
The Company carried an allowance for obsolete or estimated non-recoverable inventory of $244,000 at March 31, 2008 and $1,320,000 at March 31, 2007, or 21% and 61% of total inventory, respectively. The Company's means of expansion and development of product has been largely from acquisition of businesses, product lines, existing inventory, and the rights to specific products. Through such acquisitions, the Company has acquired substantial inventory, some of which the eventual use and recoverability was uncertain. In addition, the Company has a significant amount of inventory relating to the Photon� laser system, which does not yet have FDA approval in order to sell the product domestically. Therefore, the allowance for inventory was established to reserve for these potential eventualities.
On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
At this time, the Company's Photon� Laser Ocular Surgery Workstation requires regulatory FDA approval in order to be sold in the United States. Any possible future efforts to complete the clinical trials on the Photon� in order to file for FDA approval would depend on the Company obtaining adequate funding. The Company estimates that the funds needed to complete the clinical trials in order to obtain the necessary regulatory approval on the Photon� to be approximately $225,000.
Effect of Inflation and Foreign Currency Exchange
The Company has not realized a reduction in the selling price of its products as a result of domestic inflation. Nor has it experienced unfavorable profit reductions due to currency exchange fluctuations or inflation with its foreign customers. All sales transactions to date have been denominated in U.S. dollars. The Company has experienced an increase in products being manufactured in England and Italy, and in parts being acquired from the European Community due to the fluctuations of the dollar compared to the Euro and the Pound Sterling. This has increased the cost of several products. There may be an impact on profits as a result of this decrease in the value of the dollar because the profit margins will decrease if higher product pricing has a negative impact on sales.
New Accounting Pronouncements
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities, including an amendment of FASB Statement No. 115 ("SFAS 159"). SFAS 159 permits companies to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value, and establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 is effective on January 1, 2008, and is not expected to have a material effect on the Company's consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations ("SFAS 141R"). SFAS 141R establishes the principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interest in the acquiree, and the goodwill acquired. SFAS 141R also establishes disclosure requirements to enable the evaluation of the nature and financial effects of the business combination. SFAS 141R is effective on January 1, 2009, and is not expected to have a material effect on the Company's consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51 ("SFAS 160"). SFAS 160 will change the accounting and reporting for minority interests, which will be recharacterized as noncontrolling interests and classified as a component of equity. This new consolidation method will significantly change the accounting for transactions with minority interest holders. SFAS 160 is effective on January 1, 2009, and is not expected to have a material effect on the Company's consolidated financial statements.
--------------------------------------------------------------------------------
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities ("SFAS 161"). SFAS 161 amends SFAS 133, Accounting for Derivative Instruments and Hendging Activities to require enhanced disclosures concerning the manner in which an entity uses derivatives (and the reasons it uses them), the manner in which derivatives and related hedged items are accounted for under SFAS 133 and interpretations thereof, and the effects that derivatives and related hedged items have on an entity's financial position, financial performance, and cash flows. SFAS 161 is effective for financial statements of fiscal years and interim periods beginning after November 15, 2008. The Company has not yet determined the effects on its consolidated financial statements, if any, that may result upon the adoption of SFAS 161.
und Leute, wie siehts aus hier aus?? Ich bitte um Meinungen...
Starsweeper??
Max
Starsweeper??
Max
Na immerhin wurde dem PMEDE das "E" entfernt, so dass Paradigm Medical wieder unter PMED zu finden ist!
Sehr substantieller Wert.
Unsere Betrugs-OTC-Klitsche zerbröselt heute um über 50%
Unsere Betrugs-OTC-Klitsche zerbröselt heute um über 50%
Hi Gemeinde
seit heute morgen sind meine wieder handelbar im Amiland!!!!!!!!
Das PMEDE ist weg,
aber jetzt das komische
es ist 11.12 Uhr und ich habe +125%.
Gibts was neues hier,dann bitte mal schreiben!!!
Habe jetzt leider keine zeit da ich zur Arbeit muss
und erst pünktlich zum Fussball wieder da bin.
Gruss
seit heute morgen sind meine wieder handelbar im Amiland!!!!!!!!
Das PMEDE ist weg,
aber jetzt das komische
es ist 11.12 Uhr und ich habe +125%.
Gibts was neues hier,dann bitte mal schreiben!!!
Habe jetzt leider keine zeit da ich zur Arbeit muss
und erst pünktlich
zum Fussball wieder da bin.Gruss
Antwort auf Beitrag Nr.: 34.370.053 von Trucker-Jens am 25.06.08 11:17:07komme gerade aus dem Urlaub zurück-u. was sehe ich? Ja, das E ist weg. das gibt doch Hoffnung. Habe mir dann gleich die letzten 100 Postings im Ami-Board durchgelesen u. auch dort eine durchweg positive Einstellung zu unserem Wert feststellen können seit disese zusätzliche E entfernt wurde. Na also-das ist doch mal was!
Grüsse Sweeper
Grüsse Sweeper
10-Jul-2008
Annual Report
Item 6. Management's Discussion and Analysis or Plan of Operation
This report contains forward-looking statements and information relating to the Company that is based on beliefs of management as well as assumptions made by, and information currently available to management. These statements reflect its current view respecting future events and are subject to risks, uncertainties and assumptions, including the risks and uncertainties noted throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward-looking statements not to come true as anticipated, believed, projected, expected or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.
Critical Accounting Policies
Revenue Recognition. The Company recognizes revenue in compliance with Staff Accounting Bulletin 101, Revenue Recognition in Financial Statements (SAB 101), as revised by Staff Accounting Bulletin No. 104, Revenue Recognition (SAB 104). SAB 101 and SAB 104 detail four criteria that must exist before revenue is recognized:
1. Persuasive evidence of an arrangement exists. Prior to shipment of product, the Company required a signed purchase order and, depending upon the customer, a down payment toward the final invoiced price or full payment in advance with certain international product distributors.
2. Delivery and performance have occurred. Unless the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when the product ships. If the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when such installation or acceptance has occurred. Title to the product passes to its customer upon shipment. This revenue recognition policy does not differ among its various different product lines. The Company guarantees the functionality of its product. If its product does not function as marketed when received by the customer, the Company either makes the necessary repairs on site or has the product shipped to the Company for the repair work. Once the product has been repaired and retested for functionality, it is reshipped to the customer. The Company provides warranties that generally extend for one year from the date of sale. Such warranties cover the necessary parts and labor to repair the product as well as any shipping costs that may be required. The Company maintains a reserve for estimated warranty costs based on its historical experience and management's current expectations.
3. The sales price is fixed or determinable. The purchase order received from the customer includes the agreed upon sales price. The Company does not accept customer orders, and therefore does not recognize revenue, until the sales price is fixed.
4. Collectibility is reasonably assured. With limited exceptions, the Company requires down payments on product prior to shipment. In some cases the Company requires payment in full prior to shipment. The Company also performs credit checks on new customers and ongoing credit checks on existing customers. The Company maintains an allowance for doubtful accounts receivable based on historical experience and management's current expectations.
5. Revenues for sales of products that require specific installation and acceptance by the customer are recognized upon such installation and acceptance by the customer. Revenues for sales of other surgical systems, ultrasound diagnostic devices, and disposable products are recognized when the product is shipped. A signed purchase agreement and a deposit or payment in full from customers is required before a product leaves the premises. Title passes at time of shipment (F.O.B. shipping point). The Company's products contain both hardware and software components. The Company does not recognize revenue for the software components of the products separate from the product as a whole because the software is incidental to the product, as defined in paragraph 2 of SOP 97-2.
Recoverability of Inventory. Since its inception, the Company has purchased several complete lines of inventory. In some circumstances the Company has been able to utilize certain items acquired and others remain unused. On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
Recoverability of Goodwill and Other Intangible Assets. The Company's intangible assets consist of goodwill, product and technology rights, engineering and design costs, and patent costs. Intangibles with a determined life are amortized on a straight-line basis over their determined useful life and are also evaluated for potential impairment if events or circumstances indicate that the carrying amount may not be recoverable. Intangibles with an indefinite life, such as goodwill, are not amortized but are tested for impairment on an annual basis or when events and circumstances indicate that the asset may be impaired. Impairment tests include comparing the fair value of a reporting unit with its carrying net book value, including goodwill. To date, the Company's determination of the fair value of the reporting unit has been based on the estimated future cash flows of that reporting unit.
Allowance for Doubtful Accounts. The Company records an allowance for doubtful accounts to offset estimated uncollectible accounts receivable. Bad debt expense associated with the increases in the allowance for doubtful accounts is recorded as part of general and administrative expense. The Company's accounting policy generally is to record an allowance for receivables over 90 days past due unless there is significant evidence to support that the receivable is collectible.
General
The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31.
The Company is engaged in the design, development, manufacture and sale of high technology diagnostic and surgical eye care products. Given the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow. As seen in the results for the twelve months ended December 31, 2007, diagnostic products have been the major focus and the Photon(TM) and other extensive research and development projects have been put on hold pending future evaluation when the Company's financial position improves. The Company does not focus on a specific diagnostic product or products but, instead, on this entire diagnostic product group.
During the year ended December 31, 2007, the Company recorded an increase in the warranty accrual of $72,000. This increase was a result of a comprehensive analysis by management regarding historical warranty costs. Historically, the Company has recorded a monthly warranty expense and related increase to the warranty accrual. However, in recent periods the usage of the warranty accrual has continued to increase. After reviewing the recent historical data, management determined that the warranty accrual should be increased by $72,000 to $227,000. Management will continue to closely monitor the warranty accrual usage to ensure that the proper amount has been accrued.
During the twelve months ended December 31, 2007, management made certain adjustments to the financial statements, including a decrease in the reserve for obsolete or estimated non-recoverable inventory of $1,076,000. The Company also recorded a net increase in the allowance for doubtful accounts receivable of $37,000, impairment of intangibles of $-0-, and decreases in accruals to settle outstanding disputes in the amount of $91,000.
The Company's ultrasound diagnostic products include a P55 pachymetric analyzer, a P2200 pachymetric analyzer, a P2000 Ultrasound A-Scan biometric analyzer, a P2500 combination A/Scan and Pachymeter, a P37 Ultrasound A/B Scan, a P37-II Ultrasound A/B Scan, a P2700 Ultrasound A/B Scan, a P3700 Ultrasound A/B Scan, a P40 Ultrasound Biomicroscope, a P45 Plus Ultrasound Biomicroscope, and a P60 Ultrasound Biomicroscope, the technology for which was acquired from Humphrey Systems in 1998. The Company introduced the P45 Plus in the fall of 2000, which combines the A/B Scan, and the biomicroscope into one instrument. The Company introduced the P60 in March 2005, which represents the fourth generation of UBM devices and has better visual clarity and image flexibility than earlier versions. In addition, the Company markets its Blood Flow Analyzer(TM) acquired in the purchase of Ocular Blood Flow Ltd. in June 2000. Other diagnostic products are the Dicon(TM) LD400 Auto Perimeter and the Dicon (TM) CT 200e Corneal Topographer, which were acquired in the acquisition of Vismed d/b/a Dicon in June 2000.
Because of the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow to the Company. As reflected in the results for the fiscal year ended December 31, 2007, diagnostic products are currently the Company's major focus and the Photon(TM) and other extensive research and development projects have been put on hold pending future evaluation when the financial position of the Company improves. Due to the lack of current evidence to support recoverability, the Company has recorded an inventory reserve to offset the inventory associated with the Precisionist Thirty Thousand(TM) and the Photon(TM) as well as certain other inventory items that are estimated to be non-recoverable due to the lack of significant turnover of such items in recent periods.
Activities for the twelve months ended December 31, 2007 and 2006 included sales of the Company's products and related accessories and disposable products. Raymond P.L. Cannefax was named President and Chief Executive Officer on January 5, 2006. On March 20, 2006, the Company named Luis A. Mostacero as Vice President of Finance. Mr. Mostacero previously served as the Company's Controller from June 2000 to August 2005. On January 8, 2008, Mr. Mostacero was also appointed as Chief Financial Officer. On October 11, 2006, Christina O'Connor was appointed as Vice President of International Sales and Julio C. Maximo as Vice President of Operations. On April 10, 2006, the Company named Michael S. Austin as Vice President of Sales and Marketing. On November 28, 2006, Mr. Austin resigned from the Company. On January 4, 2007, Alfred B. Franklin was appointed as Vice President of Domestic Sales. Mr. Franklin resigned on May 10, 2007, to pursue other opportunities. On May 10, 2007, Stephen L. Davis was appointed as Vice President of Domestic Sales and Marketing. Mr. Davis resigned on February 14, 2008, to pursue other opportunities.
On May 7, 2002, the Company received a letter from the FDA requesting further clinical information regarding the Photon(TM). The Company is in the process of generating the additional clinical information in response to the letter. The Company cannot market or sell the Photon(TM) in the United States until FDA approval is granted. On November 4, 2002, the Company received FDA approval for expanded indications of use of the Blood Flow Analyzer(TM) for pulsatile ocular blood flow, volume and pulsatility equivalence index. Also, the Company is continuing its efforts to educate the payors of Medicare claims throughout the country about the Blood Flow Analyzer(TM), its purposes and the significance of its performance in patient care in order to achieve reimbursements to the providers. These efforts should lead to a more positive effect on sales.
In April 2001, the Company received written authorization from the CPT Editorial Research and Development Department of the American Medical Association to use a common procedure terminology or CPT code number 92120 for its Blood Flow Analyzer(TM), for reimbursement purposes for doctors using the device. However, certain insurance payors have elected not to reimburse doctors using the Blood Flow Analyzer(TM). The Company believes the reasons why insurance payors initially elected not to reimburse doctors using the CPT code were the relatively high volume of claims that began to be submitted under CPT code number 92120 compared to the limited volume of claims previously submitted under this code, and the time consumed by the Blood Flow Analyzer(TM) test, which some payors may have believed was less than what is allowed under CPT code number 92120. This trend began shortly after insurance payors were presented with reimbursement requests under this code, and the Company believes these reasons were the basis for the initiation of nonpayment.
The impact of this nonpayment by certain payors on the Company's future operations is a lower volume of sales, particularly in those states where reimbursement is not yet approved or is delayed. Currently, there is reimbursement by insurance payors in 20 states and partial reimbursement in six other states. As insurance payors have the prerogative whether to provide reimbursement to doctors using the Blood Flow Analyzer(TM), the Company is continuing to work with insurance payors in states where there is no reimbursement to doctors using the CPT code to demonstrate the value of the instrument. However, some insurance payors are currently not providing reimbursement to doctors where a regional or state administrator of Medicare has elected not to provide Medicare coverage for the Blood Flow Analyzer(TM). The Company is continuing to work with the regional and state administrators of Medicare who have denied Medicare coverage for the Blood Flow Analyzer(TM) to demonstrate the value of the instrument.
There were a number of factors that contributed to the decrease in sales of the Company's diagnostic products. The U.S. recessionary economic trend has impacted the Company's domestic sales. Additionally, the Company restructured its sales organization and sales channels by decreasing its direct sales force who are full-time employees to five direct sales employees and one independent sales organization as of December 31, 2007. The dependent sales force has been reduced because the Company does not have sufficient revenues to justify a larger direct sales force. One of the challenges for fiscal 2008 will be the judicious reestablishment of the sales force in anticipation of increased sales.
The Company intends to increase its efforts to sell its diagnostic products through independent sales representatives and ophthalmic equipment distributors, which are paid commissions only for their sales. As of December 31, 2007, the Company had 24 ophthalmic and medical product distributors outside the United States. The Company hopes to benefit from these recently hired sales representatives and distributors in the United States as they gain familiarity, through training, of the Company's diagnostic products.
Outstanding Commitments to Issue Shares
The following table identifies our outstanding commitments to issue
shares, including the shares underlying the convertible notes and warrants
issuable upon conversion of the notes and exercise of the warrants:
Underlying Shares
Security of Common Stock
Notes (1) 3,637,280,000
Warrants (2) 54,034,392
Preferred Stock (3) 862,404
Stock Options (4) 11,500,000
-------------------
Total 3,703,676,796
(1) Assumes full conversion of $3,928,262 of notes issued to AJW Partners, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC, and New Millennium Capital Partners II, LLC at a conversion price of $.00108 per share (based upon a market price of $.0018 as of January 14, 2008 with a 40% discount).
(2) Consisting of warrants exerciseable at prices ranging from $.001 per share to $6.75 per share, including warrants issued to AJW Partners, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC, and New Millennium Capital Partners II, LLC to purchase 16,534,392 shares of common stock at an exercise price of $.20 per share, exerciseable through the period from April 27, 2010 to June 30, 2010, and warrants to purchase 12,000,000 shares of common stock at an exerciseable price of $.10 per share, exerciseable through the period from February 28, 2011 to April 20, 2012, warrants to purchase 10,000,000 shares of common stock at an exercise price of $.005 per share, exerciseable through June 11, 2012, and warrants to purchase 15,000,000 shares of common stock at an exercise price of $.001 per share, exerciseable through December 24, 2012.
(3) Consisting of 6,753 shares of common stock issuable upon conversion of 5,627 shares of Series A preferred stock, 10,783 shares of common stock issuable upon conversion of 8,986 shares of Series B preferred stock, 8,750 shares of common stock issuable upon conversion of 5,000 shares of Series D preferred stock, 13,333 shares of common stock issuable upon conversion of 250 shares of Series E preferred stock, 234,550 shares of common stock issuable upon conversion of 4,398.75 shares of Series F preferred stock, and 588,235 shares of common stock issuable upon conversion of 588,235 shares of Series G preferred stock.
(4) Consisting of stock options granted to executive officers and employees to purchase 9,250,000 shares of common stock at exercise prices ranging from $.01 per share to $2.75 per share, and stock options granted to directors to purchase 2,250,000 shares of common stock at exercise prices ranging from $.01 per share to $2.75 per share.
There are a total of 3,703,701,796 shares underlying our convertible notes, warrants, preferred stock and stock options, assuming full conversion of the outstanding notes and preferred stock and the exercise of all the outstanding warrants and stock options. The number of our authorized shares of common stock is 1,400,000,000 shares. The large number of our shares of common stock underlying our notes, warrants, preferred stock and stock options will require us to increase the number of authorized shares. Failure to obtain stockholder approval to increase the number of authorized shares could result in the noteholders commencing legal action against us and foreclosing on all of our assets to recover damages. Any such action would require us to curtail or cease our operations.
Convertible Notes
April 27, 2005 Sale of $2,500,000 in Convertible Notes. To obtain funding for the Company's ongoing operations, the Company entered into a securities purchase agreement with four accredited investors on April 27, 2005 for the sale of (i) $2,500,000 in convertible notes and (ii) warrants to purchase 16,534,392 shares of its common stock. The sale of the convertible notes and warrants is to occur in three traunches and the investors provided the Company with an aggregate of $2,500,000 as follows:
o $850,000 was disbursed on April 27, 2005;
o $800,000 was disbursed on June 23, 2005 after the Company filed a registration statement on June 22, 2005 to register the shares of common stock issuable upon conversion of the convertible notes and exercise of warrants; and
o $850,000 was disbursed on June 30, 2005, the effective date of the registration statement.
Under the terms of the securities purchase agreement, the Company agreed it would not, without the prior written consent of a majority-in-interest of the investors, negotiate or contract with any party to obtain additional equity financing (including debt financing with an equity component) that involves (i) the issuance of common stock at a discount to the market price of the common stock on the date of issuance (taking into account the value of any warrants or options to acquire common stock in connection therewith), (ii) the issuance of convertible securities that are convertible into an indeterminate number of shares of common stock, or (iii) the issuance of warrants during the lock-up period beginning April 27, 2005 and ending on the later of (a) 270 days from April 27, 2005, or (b) 180 days from the date the registration statement is declared effective.
In addition, the Company agreed not to conduct any equity financing (including debt financing with an equity component) during the period beginning April 27, 2005 and ending two years after the end of the above lock-up period unless it first provided each investor an option to purchase its pro rata share (based on the ratio of each investor's purchase under the securities purchase agreement) of the securities being offered in any proposed equity financing. Each investor must be provided written notice describing any proposed equity financing at least 20 business days prior to the closing of such proposed equity financing and the option must be extended to each investor during the 15-day period following delivery of such notice.
The $2,500,000 in convertible notes bear interest at 8% per annum from the date of issuance. Interest is computed on the basis of a 365-day year and is payable quarterly in cash, with six months of interest payable up front. The interest rate resets to zero percent for any month in which the stock price is greater than 125% of the initial market price, or $.0945, for each trading day during that month. Any amount of principal or interest on the convertible notes that is not paid when due will bear interest at the rate of 15% per annum from the date due thereof until such amount is paid. The notes mature in three years from the date of issuance, and are convertible into the Company's common stock at the noteholders' option, at the lower of (i) $.09 or (ii) 60% of the average of the three lowest intraday trading prices for the common stock on the OTC Bulletin Board for the 20 trading days before but not including the conversion date. Accordingly, there is no limit on the number of shares into which the notes may be converted.
The convertible notes are secured by the Company's assets, including the Company's inventory, accounts receivable and intellectual property. Moreover, the Company has a call option under the terms of the notes. The call option provides the Company with the right to prepay all of the outstanding convertible notes at any time, provided there is no event of default by the Company and the Company's stock is trading at or below $.09 per share. An event of default includes the failure by the Company to pay the principal or interest on the notes when due or to timely file a registration statement as required by the Company or obtain effectiveness with the Securities and Exchange Commission of the registration statement. Prepayment of the notes is to be made in cash equal to either (a) 125% of the outstanding principal and accrued interest for prepayments occurring within 30 days following the issue date of the notes; (b) 130% of the outstanding principal and accrued interest for prepayments occurring between 31 and 60 days following the issue date of the notes; or (c) 145% of the outstanding principal and accrued interest for prepayments occurring after the 60th day following the issue date of the notes.
The warrants are exercisable until five years from the date of issuance at a purchase price of $.20 per share. The investors may exercise the warrants on a cashless basis if the shares of common stock underlying the warrants are not registered pursuant to an effective registration statement. In the event the investors exercise the warrants on a cashless basis, the Company will not receive any proceeds therefrom. In addition, the exercise price of the warrants will be adjusted in the event the Company issues common stock at a price below market, with the exception of any securities issued as of the date of the warrants or issued in connection with the callable secured convertible notes issued pursuant to the securities purchase agreement.
The noteholders have agreed to restrict their ability to convert their convertible notes or exercise their warrants and receive shares of the Company's common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock. However, the noteholders may repeatedly sell shares of common stock in order to reduce their ownership percentage, and subsequently convert additional convertible notes.
February 28, 2006 Sale of $1,500,000 in Convertible Notes. To obtain additional funding for the Company's ongoing operations, the Company entered into a second securities purchase agreement on February 28, 2006 with the same four accredited investors for the sale of (i) $1,500,000 in convertible notes and (ii) warrants to purchase 12,000,000 shares of its common stock. The sale of the convertible notes and warrants is to occur in three traunches and the investors are obligated to provide the Company with an aggregate of $1,500,000 as follows:
o $500,000 was disbursed on February 28, 2006;
o $500,000 was disbursed on June 28, 2006 after the Company filed a registration statement on June 15, 2006 to register the shares of common stock underlying the convertible notes. The registration statement was subsequently withdrawn on July 25, 2006 and a new registration statement was filed on September 15, 2006 to register 60,000,000 shares of common stock issuable upon conversion of the notes.
o $500,000 was disbursed on April 30, 2007, the day prior to the effective date of the registration statement on May 1, 2007.
Under the terms of the securities purchase agreement, the Company also agreed it would not, without the prior written consent of a majority-in-interest of the investors, negotiate or contract with any party to obtain additional equity financing (including debt financing with an equity component) that involves (i) the issuance of common stock at a discount to the market price of the common stock on the date of issuance (taking into account the value of any warrants or options to acquire common stock in connection therewith), (ii) the issuance of convertible securities that are convertible into an indeterminate number of shares of common stock, or (iii) the issuance of warrants during the lock-up period beginning February 28, 2006 and ending on the later of (a) 270 . . .
Annual Report
Item 6. Management's Discussion and Analysis or Plan of Operation
This report contains forward-looking statements and information relating to the Company that is based on beliefs of management as well as assumptions made by, and information currently available to management. These statements reflect its current view respecting future events and are subject to risks, uncertainties and assumptions, including the risks and uncertainties noted throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward-looking statements not to come true as anticipated, believed, projected, expected or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.
Critical Accounting Policies
Revenue Recognition. The Company recognizes revenue in compliance with Staff Accounting Bulletin 101, Revenue Recognition in Financial Statements (SAB 101), as revised by Staff Accounting Bulletin No. 104, Revenue Recognition (SAB 104). SAB 101 and SAB 104 detail four criteria that must exist before revenue is recognized:
1. Persuasive evidence of an arrangement exists. Prior to shipment of product, the Company required a signed purchase order and, depending upon the customer, a down payment toward the final invoiced price or full payment in advance with certain international product distributors.
2. Delivery and performance have occurred. Unless the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when the product ships. If the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when such installation or acceptance has occurred. Title to the product passes to its customer upon shipment. This revenue recognition policy does not differ among its various different product lines. The Company guarantees the functionality of its product. If its product does not function as marketed when received by the customer, the Company either makes the necessary repairs on site or has the product shipped to the Company for the repair work. Once the product has been repaired and retested for functionality, it is reshipped to the customer. The Company provides warranties that generally extend for one year from the date of sale. Such warranties cover the necessary parts and labor to repair the product as well as any shipping costs that may be required. The Company maintains a reserve for estimated warranty costs based on its historical experience and management's current expectations.
3. The sales price is fixed or determinable. The purchase order received from the customer includes the agreed upon sales price. The Company does not accept customer orders, and therefore does not recognize revenue, until the sales price is fixed.
4. Collectibility is reasonably assured. With limited exceptions, the Company requires down payments on product prior to shipment. In some cases the Company requires payment in full prior to shipment. The Company also performs credit checks on new customers and ongoing credit checks on existing customers. The Company maintains an allowance for doubtful accounts receivable based on historical experience and management's current expectations.
5. Revenues for sales of products that require specific installation and acceptance by the customer are recognized upon such installation and acceptance by the customer. Revenues for sales of other surgical systems, ultrasound diagnostic devices, and disposable products are recognized when the product is shipped. A signed purchase agreement and a deposit or payment in full from customers is required before a product leaves the premises. Title passes at time of shipment (F.O.B. shipping point). The Company's products contain both hardware and software components. The Company does not recognize revenue for the software components of the products separate from the product as a whole because the software is incidental to the product, as defined in paragraph 2 of SOP 97-2.
Recoverability of Inventory. Since its inception, the Company has purchased several complete lines of inventory. In some circumstances the Company has been able to utilize certain items acquired and others remain unused. On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
Recoverability of Goodwill and Other Intangible Assets. The Company's intangible assets consist of goodwill, product and technology rights, engineering and design costs, and patent costs. Intangibles with a determined life are amortized on a straight-line basis over their determined useful life and are also evaluated for potential impairment if events or circumstances indicate that the carrying amount may not be recoverable. Intangibles with an indefinite life, such as goodwill, are not amortized but are tested for impairment on an annual basis or when events and circumstances indicate that the asset may be impaired. Impairment tests include comparing the fair value of a reporting unit with its carrying net book value, including goodwill. To date, the Company's determination of the fair value of the reporting unit has been based on the estimated future cash flows of that reporting unit.
Allowance for Doubtful Accounts. The Company records an allowance for doubtful accounts to offset estimated uncollectible accounts receivable. Bad debt expense associated with the increases in the allowance for doubtful accounts is recorded as part of general and administrative expense. The Company's accounting policy generally is to record an allowance for receivables over 90 days past due unless there is significant evidence to support that the receivable is collectible.
General
The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31.
The Company is engaged in the design, development, manufacture and sale of high technology diagnostic and surgical eye care products. Given the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow. As seen in the results for the twelve months ended December 31, 2007, diagnostic products have been the major focus and the Photon(TM) and other extensive research and development projects have been put on hold pending future evaluation when the Company's financial position improves. The Company does not focus on a specific diagnostic product or products but, instead, on this entire diagnostic product group.
During the year ended December 31, 2007, the Company recorded an increase in the warranty accrual of $72,000. This increase was a result of a comprehensive analysis by management regarding historical warranty costs. Historically, the Company has recorded a monthly warranty expense and related increase to the warranty accrual. However, in recent periods the usage of the warranty accrual has continued to increase. After reviewing the recent historical data, management determined that the warranty accrual should be increased by $72,000 to $227,000. Management will continue to closely monitor the warranty accrual usage to ensure that the proper amount has been accrued.
During the twelve months ended December 31, 2007, management made certain adjustments to the financial statements, including a decrease in the reserve for obsolete or estimated non-recoverable inventory of $1,076,000. The Company also recorded a net increase in the allowance for doubtful accounts receivable of $37,000, impairment of intangibles of $-0-, and decreases in accruals to settle outstanding disputes in the amount of $91,000.
The Company's ultrasound diagnostic products include a P55 pachymetric analyzer, a P2200 pachymetric analyzer, a P2000 Ultrasound A-Scan biometric analyzer, a P2500 combination A/Scan and Pachymeter, a P37 Ultrasound A/B Scan, a P37-II Ultrasound A/B Scan, a P2700 Ultrasound A/B Scan, a P3700 Ultrasound A/B Scan, a P40 Ultrasound Biomicroscope, a P45 Plus Ultrasound Biomicroscope, and a P60 Ultrasound Biomicroscope, the technology for which was acquired from Humphrey Systems in 1998. The Company introduced the P45 Plus in the fall of 2000, which combines the A/B Scan, and the biomicroscope into one instrument. The Company introduced the P60 in March 2005, which represents the fourth generation of UBM devices and has better visual clarity and image flexibility than earlier versions. In addition, the Company markets its Blood Flow Analyzer(TM) acquired in the purchase of Ocular Blood Flow Ltd. in June 2000. Other diagnostic products are the Dicon(TM) LD400 Auto Perimeter and the Dicon (TM) CT 200e Corneal Topographer, which were acquired in the acquisition of Vismed d/b/a Dicon in June 2000.
Because of the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow to the Company. As reflected in the results for the fiscal year ended December 31, 2007, diagnostic products are currently the Company's major focus and the Photon(TM) and other extensive research and development projects have been put on hold pending future evaluation when the financial position of the Company improves. Due to the lack of current evidence to support recoverability, the Company has recorded an inventory reserve to offset the inventory associated with the Precisionist Thirty Thousand(TM) and the Photon(TM) as well as certain other inventory items that are estimated to be non-recoverable due to the lack of significant turnover of such items in recent periods.
Activities for the twelve months ended December 31, 2007 and 2006 included sales of the Company's products and related accessories and disposable products. Raymond P.L. Cannefax was named President and Chief Executive Officer on January 5, 2006. On March 20, 2006, the Company named Luis A. Mostacero as Vice President of Finance. Mr. Mostacero previously served as the Company's Controller from June 2000 to August 2005. On January 8, 2008, Mr. Mostacero was also appointed as Chief Financial Officer. On October 11, 2006, Christina O'Connor was appointed as Vice President of International Sales and Julio C. Maximo as Vice President of Operations. On April 10, 2006, the Company named Michael S. Austin as Vice President of Sales and Marketing. On November 28, 2006, Mr. Austin resigned from the Company. On January 4, 2007, Alfred B. Franklin was appointed as Vice President of Domestic Sales. Mr. Franklin resigned on May 10, 2007, to pursue other opportunities. On May 10, 2007, Stephen L. Davis was appointed as Vice President of Domestic Sales and Marketing. Mr. Davis resigned on February 14, 2008, to pursue other opportunities.
On May 7, 2002, the Company received a letter from the FDA requesting further clinical information regarding the Photon(TM). The Company is in the process of generating the additional clinical information in response to the letter. The Company cannot market or sell the Photon(TM) in the United States until FDA approval is granted. On November 4, 2002, the Company received FDA approval for expanded indications of use of the Blood Flow Analyzer(TM) for pulsatile ocular blood flow, volume and pulsatility equivalence index. Also, the Company is continuing its efforts to educate the payors of Medicare claims throughout the country about the Blood Flow Analyzer(TM), its purposes and the significance of its performance in patient care in order to achieve reimbursements to the providers. These efforts should lead to a more positive effect on sales.
In April 2001, the Company received written authorization from the CPT Editorial Research and Development Department of the American Medical Association to use a common procedure terminology or CPT code number 92120 for its Blood Flow Analyzer(TM), for reimbursement purposes for doctors using the device. However, certain insurance payors have elected not to reimburse doctors using the Blood Flow Analyzer(TM). The Company believes the reasons why insurance payors initially elected not to reimburse doctors using the CPT code were the relatively high volume of claims that began to be submitted under CPT code number 92120 compared to the limited volume of claims previously submitted under this code, and the time consumed by the Blood Flow Analyzer(TM) test, which some payors may have believed was less than what is allowed under CPT code number 92120. This trend began shortly after insurance payors were presented with reimbursement requests under this code, and the Company believes these reasons were the basis for the initiation of nonpayment.
The impact of this nonpayment by certain payors on the Company's future operations is a lower volume of sales, particularly in those states where reimbursement is not yet approved or is delayed. Currently, there is reimbursement by insurance payors in 20 states and partial reimbursement in six other states. As insurance payors have the prerogative whether to provide reimbursement to doctors using the Blood Flow Analyzer(TM), the Company is continuing to work with insurance payors in states where there is no reimbursement to doctors using the CPT code to demonstrate the value of the instrument. However, some insurance payors are currently not providing reimbursement to doctors where a regional or state administrator of Medicare has elected not to provide Medicare coverage for the Blood Flow Analyzer(TM). The Company is continuing to work with the regional and state administrators of Medicare who have denied Medicare coverage for the Blood Flow Analyzer(TM) to demonstrate the value of the instrument.
There were a number of factors that contributed to the decrease in sales of the Company's diagnostic products. The U.S. recessionary economic trend has impacted the Company's domestic sales. Additionally, the Company restructured its sales organization and sales channels by decreasing its direct sales force who are full-time employees to five direct sales employees and one independent sales organization as of December 31, 2007. The dependent sales force has been reduced because the Company does not have sufficient revenues to justify a larger direct sales force. One of the challenges for fiscal 2008 will be the judicious reestablishment of the sales force in anticipation of increased sales.
The Company intends to increase its efforts to sell its diagnostic products through independent sales representatives and ophthalmic equipment distributors, which are paid commissions only for their sales. As of December 31, 2007, the Company had 24 ophthalmic and medical product distributors outside the United States. The Company hopes to benefit from these recently hired sales representatives and distributors in the United States as they gain familiarity, through training, of the Company's diagnostic products.
Outstanding Commitments to Issue Shares
The following table identifies our outstanding commitments to issue
shares, including the shares underlying the convertible notes and warrants
issuable upon conversion of the notes and exercise of the warrants:
Underlying Shares
Security of Common Stock
Notes (1) 3,637,280,000
Warrants (2) 54,034,392
Preferred Stock (3) 862,404
Stock Options (4) 11,500,000
-------------------
Total 3,703,676,796
(1) Assumes full conversion of $3,928,262 of notes issued to AJW Partners, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC, and New Millennium Capital Partners II, LLC at a conversion price of $.00108 per share (based upon a market price of $.0018 as of January 14, 2008 with a 40% discount).
(2) Consisting of warrants exerciseable at prices ranging from $.001 per share to $6.75 per share, including warrants issued to AJW Partners, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC, and New Millennium Capital Partners II, LLC to purchase 16,534,392 shares of common stock at an exercise price of $.20 per share, exerciseable through the period from April 27, 2010 to June 30, 2010, and warrants to purchase 12,000,000 shares of common stock at an exerciseable price of $.10 per share, exerciseable through the period from February 28, 2011 to April 20, 2012, warrants to purchase 10,000,000 shares of common stock at an exercise price of $.005 per share, exerciseable through June 11, 2012, and warrants to purchase 15,000,000 shares of common stock at an exercise price of $.001 per share, exerciseable through December 24, 2012.
(3) Consisting of 6,753 shares of common stock issuable upon conversion of 5,627 shares of Series A preferred stock, 10,783 shares of common stock issuable upon conversion of 8,986 shares of Series B preferred stock, 8,750 shares of common stock issuable upon conversion of 5,000 shares of Series D preferred stock, 13,333 shares of common stock issuable upon conversion of 250 shares of Series E preferred stock, 234,550 shares of common stock issuable upon conversion of 4,398.75 shares of Series F preferred stock, and 588,235 shares of common stock issuable upon conversion of 588,235 shares of Series G preferred stock.
(4) Consisting of stock options granted to executive officers and employees to purchase 9,250,000 shares of common stock at exercise prices ranging from $.01 per share to $2.75 per share, and stock options granted to directors to purchase 2,250,000 shares of common stock at exercise prices ranging from $.01 per share to $2.75 per share.
There are a total of 3,703,701,796 shares underlying our convertible notes, warrants, preferred stock and stock options, assuming full conversion of the outstanding notes and preferred stock and the exercise of all the outstanding warrants and stock options. The number of our authorized shares of common stock is 1,400,000,000 shares. The large number of our shares of common stock underlying our notes, warrants, preferred stock and stock options will require us to increase the number of authorized shares. Failure to obtain stockholder approval to increase the number of authorized shares could result in the noteholders commencing legal action against us and foreclosing on all of our assets to recover damages. Any such action would require us to curtail or cease our operations.
Convertible Notes
April 27, 2005 Sale of $2,500,000 in Convertible Notes. To obtain funding for the Company's ongoing operations, the Company entered into a securities purchase agreement with four accredited investors on April 27, 2005 for the sale of (i) $2,500,000 in convertible notes and (ii) warrants to purchase 16,534,392 shares of its common stock. The sale of the convertible notes and warrants is to occur in three traunches and the investors provided the Company with an aggregate of $2,500,000 as follows:
o $850,000 was disbursed on April 27, 2005;
o $800,000 was disbursed on June 23, 2005 after the Company filed a registration statement on June 22, 2005 to register the shares of common stock issuable upon conversion of the convertible notes and exercise of warrants; and
o $850,000 was disbursed on June 30, 2005, the effective date of the registration statement.
Under the terms of the securities purchase agreement, the Company agreed it would not, without the prior written consent of a majority-in-interest of the investors, negotiate or contract with any party to obtain additional equity financing (including debt financing with an equity component) that involves (i) the issuance of common stock at a discount to the market price of the common stock on the date of issuance (taking into account the value of any warrants or options to acquire common stock in connection therewith), (ii) the issuance of convertible securities that are convertible into an indeterminate number of shares of common stock, or (iii) the issuance of warrants during the lock-up period beginning April 27, 2005 and ending on the later of (a) 270 days from April 27, 2005, or (b) 180 days from the date the registration statement is declared effective.
In addition, the Company agreed not to conduct any equity financing (including debt financing with an equity component) during the period beginning April 27, 2005 and ending two years after the end of the above lock-up period unless it first provided each investor an option to purchase its pro rata share (based on the ratio of each investor's purchase under the securities purchase agreement) of the securities being offered in any proposed equity financing. Each investor must be provided written notice describing any proposed equity financing at least 20 business days prior to the closing of such proposed equity financing and the option must be extended to each investor during the 15-day period following delivery of such notice.
The $2,500,000 in convertible notes bear interest at 8% per annum from the date of issuance. Interest is computed on the basis of a 365-day year and is payable quarterly in cash, with six months of interest payable up front. The interest rate resets to zero percent for any month in which the stock price is greater than 125% of the initial market price, or $.0945, for each trading day during that month. Any amount of principal or interest on the convertible notes that is not paid when due will bear interest at the rate of 15% per annum from the date due thereof until such amount is paid. The notes mature in three years from the date of issuance, and are convertible into the Company's common stock at the noteholders' option, at the lower of (i) $.09 or (ii) 60% of the average of the three lowest intraday trading prices for the common stock on the OTC Bulletin Board for the 20 trading days before but not including the conversion date. Accordingly, there is no limit on the number of shares into which the notes may be converted.
The convertible notes are secured by the Company's assets, including the Company's inventory, accounts receivable and intellectual property. Moreover, the Company has a call option under the terms of the notes. The call option provides the Company with the right to prepay all of the outstanding convertible notes at any time, provided there is no event of default by the Company and the Company's stock is trading at or below $.09 per share. An event of default includes the failure by the Company to pay the principal or interest on the notes when due or to timely file a registration statement as required by the Company or obtain effectiveness with the Securities and Exchange Commission of the registration statement. Prepayment of the notes is to be made in cash equal to either (a) 125% of the outstanding principal and accrued interest for prepayments occurring within 30 days following the issue date of the notes; (b) 130% of the outstanding principal and accrued interest for prepayments occurring between 31 and 60 days following the issue date of the notes; or (c) 145% of the outstanding principal and accrued interest for prepayments occurring after the 60th day following the issue date of the notes.
The warrants are exercisable until five years from the date of issuance at a purchase price of $.20 per share. The investors may exercise the warrants on a cashless basis if the shares of common stock underlying the warrants are not registered pursuant to an effective registration statement. In the event the investors exercise the warrants on a cashless basis, the Company will not receive any proceeds therefrom. In addition, the exercise price of the warrants will be adjusted in the event the Company issues common stock at a price below market, with the exception of any securities issued as of the date of the warrants or issued in connection with the callable secured convertible notes issued pursuant to the securities purchase agreement.
The noteholders have agreed to restrict their ability to convert their convertible notes or exercise their warrants and receive shares of the Company's common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock. However, the noteholders may repeatedly sell shares of common stock in order to reduce their ownership percentage, and subsequently convert additional convertible notes.
February 28, 2006 Sale of $1,500,000 in Convertible Notes. To obtain additional funding for the Company's ongoing operations, the Company entered into a second securities purchase agreement on February 28, 2006 with the same four accredited investors for the sale of (i) $1,500,000 in convertible notes and (ii) warrants to purchase 12,000,000 shares of its common stock. The sale of the convertible notes and warrants is to occur in three traunches and the investors are obligated to provide the Company with an aggregate of $1,500,000 as follows:
o $500,000 was disbursed on February 28, 2006;
o $500,000 was disbursed on June 28, 2006 after the Company filed a registration statement on June 15, 2006 to register the shares of common stock underlying the convertible notes. The registration statement was subsequently withdrawn on July 25, 2006 and a new registration statement was filed on September 15, 2006 to register 60,000,000 shares of common stock issuable upon conversion of the notes.
o $500,000 was disbursed on April 30, 2007, the day prior to the effective date of the registration statement on May 1, 2007.
Under the terms of the securities purchase agreement, the Company also agreed it would not, without the prior written consent of a majority-in-interest of the investors, negotiate or contract with any party to obtain additional equity financing (including debt financing with an equity component) that involves (i) the issuance of common stock at a discount to the market price of the common stock on the date of issuance (taking into account the value of any warrants or options to acquire common stock in connection therewith), (ii) the issuance of convertible securities that are convertible into an indeterminate number of shares of common stock, or (iii) the issuance of warrants during the lock-up period beginning February 28, 2006 and ending on the later of (a) 270 . . .
Na, wenn sich das nicht gut liest!
Also-immer schön auf der hut sein bei diesem Wert!!!
Grüsse
14.07.2008 19:50
Paradigm Medical Industries Records Initial Sales of Early Glaucoma Detection Device
Paradigm Medical Industries, (News) Inc. (OTCBB: PMED) has begun selling the Glaid-PERG electrophysiology instrument for the early detection of glaucoma. Pricing and volumes were not disclosed.
”We've recorded sales in select U.S. cities of this revolutionary FDA-approved device, following its introduction at the American Society for Cataract Refractive Surgeons (ASCRS) in April,“ said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. ”And we will have an aggressive launch for the remainder of the year.
”The PERG (pattern Electroretinogram) should be a standard of care since it provides the earliest detection of glaucoma suspects with the intent to arrest the progression of the disease and preventing or minimizing it without further damage to the retina,“ Mr. Cannefax added. ”In addition to early detection, the PERG is very valuable in the management of glaucoma.“
Glaucoma, caused by deterioration of the optic nerve and related ganglion cells, is the second leading cause of permanent vision loss. It affects one of five people over age 50. There are more than 64 million cases of glaucoma worldwide, including more than three million in the U.S. The cost to the U.S. government related to glaucoma is estimated to be more than $1.5 billion annually.
”The PERG has gone through extensive development at Bascom Palmer Eye Institute (Miami and Palm Beach, FL) and other major ophthalmic centers in North America. Paradigm Medical is now taking this diagnostic tool from the research segment to the commercial marketplace,“ Mr. Cannefax noted. ”We believe the PERG should be a mandatory test given to every individual who has a family history of glaucoma or is otherwise disposed to being a glaucoma suspect. And we believe it should be given as part of eye examinations to everyone over age 45 on a regular basis.“
Paradigm Medical has an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the latter's Glaid-PERG device. The PERG was approved by the U.S. Food and Drug Administration (FDA) in 2004 and is approved for Medicare coverage.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Also-immer schön auf der hut sein bei diesem Wert!!!
Grüsse
14.07.2008 19:50
Paradigm Medical Industries Records Initial Sales of Early Glaucoma Detection Device
Paradigm Medical Industries, (News) Inc. (OTCBB: PMED) has begun selling the Glaid-PERG electrophysiology instrument for the early detection of glaucoma. Pricing and volumes were not disclosed.
”We've recorded sales in select U.S. cities of this revolutionary FDA-approved device, following its introduction at the American Society for Cataract Refractive Surgeons (ASCRS) in April,“ said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. ”And we will have an aggressive launch for the remainder of the year.
”The PERG (pattern Electroretinogram) should be a standard of care since it provides the earliest detection of glaucoma suspects with the intent to arrest the progression of the disease and preventing or minimizing it without further damage to the retina,“ Mr. Cannefax added. ”In addition to early detection, the PERG is very valuable in the management of glaucoma.“
Glaucoma, caused by deterioration of the optic nerve and related ganglion cells, is the second leading cause of permanent vision loss. It affects one of five people over age 50. There are more than 64 million cases of glaucoma worldwide, including more than three million in the U.S. The cost to the U.S. government related to glaucoma is estimated to be more than $1.5 billion annually.
”The PERG has gone through extensive development at Bascom Palmer Eye Institute (Miami and Palm Beach, FL) and other major ophthalmic centers in North America. Paradigm Medical is now taking this diagnostic tool from the research segment to the commercial marketplace,“ Mr. Cannefax noted. ”We believe the PERG should be a mandatory test given to every individual who has a family history of glaucoma or is otherwise disposed to being a glaucoma suspect. And we believe it should be given as part of eye examinations to everyone over age 45 on a regular basis.“
Paradigm Medical has an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the latter's Glaid-PERG device. The PERG was approved by the U.S. Food and Drug Administration (FDA) in 2004 and is approved for Medicare coverage.
Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Antwort auf Beitrag Nr.: 34.505.778 von STARSWEEPER am 14.07.08 21:15:34Hi sweeper,gibts dich noch , gibts pmed noch?.......
scheinen dead zu sein....
scheinen dead zu sein....
Antwort auf Beitrag Nr.: 35.473.711 von hessenkoenig am 08.10.08 11:55:31Grüß Dich Hessenkönig.
Klaro gibt es mich, wie auch PMED noch. Hatte kürzlich PMEDs CEO Cannefax angemailt. Seine Antwort erreichte mich noch keine 5 min. später. Vergaß es total sie hier zu veröffentlichen-stellte sie stattdessen bei Investorhub rein. Verkauft wird von mir im Moment absolut nichts. Der Markt wird auch wieder drehen. Normal müsste man noch ein wenig warten u. dann einsammeln was das Zeug hält.
Freut mich jedenfalls, daß hier doch nochmal jemand gepostet hat. Ich jedenfalls schaue jeden Abend um diese Zeit mal hier vorbei.
Wünsche allen Nochinvestierten starke Nerven für die kommenden Wochen.Bald werden die Zittrigen raus sein! Danach werden auch wieder bessere Zeiten so wie bisher nach jedem Crash kommen.
Gruß Sweeper
Klaro gibt es mich, wie auch PMED noch. Hatte kürzlich PMEDs CEO Cannefax angemailt. Seine Antwort erreichte mich noch keine 5 min. später. Vergaß es total sie hier zu veröffentlichen-stellte sie stattdessen bei Investorhub rein. Verkauft wird von mir im Moment absolut nichts. Der Markt wird auch wieder drehen. Normal müsste man noch ein wenig warten u. dann einsammeln was das Zeug hält.
Freut mich jedenfalls, daß hier doch nochmal jemand gepostet hat. Ich jedenfalls schaue jeden Abend um diese Zeit mal hier vorbei.
Wünsche allen Nochinvestierten starke Nerven für die kommenden Wochen.Bald werden die Zittrigen raus sein! Danach werden auch wieder bessere Zeiten so wie bisher nach jedem Crash kommen.
Gruß Sweeper
Hallo Leute!
Habe heute von meiner Bank die Mitteilung erhalten, dass Paradigm einen Reversesplit macht. Per 15.11.08 bekommt man für 10 Aktien eine neue Aktie. Demzufolge müsste dann ja auch der Kurs um das 10-fache steigen, damit das Verhältnis wieder stimmt.
Leider tut sich aber am Kurs nicht gerade viel. Und somit haben wir wieder mal den kürzeren gezogen. Oder wie seht ihr das ?
VG
Habe heute von meiner Bank die Mitteilung erhalten, dass Paradigm einen Reversesplit macht. Per 15.11.08 bekommt man für 10 Aktien eine neue Aktie. Demzufolge müsste dann ja auch der Kurs um das 10-fache steigen, damit das Verhältnis wieder stimmt.
Leider tut sich aber am Kurs nicht gerade viel. Und somit haben wir wieder mal den kürzeren gezogen. Oder wie seht ihr das ?
VG
Antwort auf Beitrag Nr.: 36.022.214 von oxxy am 20.11.08 20:29:22Das ist das ENDE !!!
Reverse-Splits gehen NIE gut aus.
Optisch verteuern, um noch mehr Drecksaktien auf den Markt schmeissen zu können.
Reverse-Splits gehen NIE gut aus.
Optisch verteuern, um noch mehr Drecksaktien auf den Markt schmeissen zu können.
Hi Leute,
möchte mich nach langer Zeit mal wieder melden.
Viele denken bestimmt, Sweeper habe das Boot längst verlassen. Dieses jedoch stimmt nicht. Sweeper beobachtet diesen Wert täglich u. ist auch noch investiert. In den zurückliegenden Monaten gab es für mich keine Veranlassung mich hier zu melden. Sicher kamen , man kann es deutlich sagen keine positiven Meldungen vom Unternehmen-bis heute. Manche von Euch haben es bestimmt schon vernommen, was ich hier im Anhang mal reinstellen will.
Schaun wir mal, wie's weitergeht. Ich jedenfalls halte es da mit voitsi der kürzlich einem wohl in Untergangsstimmung geratenen User auf interhub antwortete, er halte PMED bis zur bitteren Neige gegen 0.
Grüsse Sweeper
Hier der Bericht von heute:
21.11.2008 15:40
Paradigm Medical Names Stephen Davis as President
The Board of Directors of Paradigm Medical Industries, (News) Inc. (OTCBB: PMED) named Stephen L. Davis as President, effective November 18, 2008. He replaces Raymond Cannefax, who was terminated.
Mr. Davis, who previously served as the Company's Vice-President Sales and Marketing from May 2007 to February 2008, has more than 20 years experience in the ophthalmic industry.
”We believe Stephen Davis will be able to help expand the Company's proprietary products and devices domestically and internationally,“ said Paradigm Medical's Board Chairman Randall Mackey. ”He is an exceptional manager and strategist.“
Mr. Davis noted, ”Short-term, my efforts will be to reinvigorate Paradigm Medical's global sales and marketing efforts and ensure product availability to our customers. And we will continue to exercise strong financial management. Our product mix is unsurpassed in the ophthalmic industry and we will continue to meet the current and future needs of the market.
”Longer-term, my goal is to capitalize on our strengths, which will result in solid and sustainable growth for the Company and maximizing our returns,“ Mr. Davis added.
From 2001-2007, Mr. Davis served as President of SL Davis Group, Inc., which provides business development, distribution management and sales training services. From 1991-1999, Mr. Davis was President and Chief Executive Officer for Zinetics Medical, Inc., which manufactured and distributed medical devices for the gastroenterology and critical care markets. He has held other senior management positions at Co-Care Medical Services, Inc., and Ioptex Intraocular Lenses, Inc.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.
This press release contains statement that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
möchte mich nach langer Zeit mal wieder melden.
Viele denken bestimmt, Sweeper habe das Boot längst verlassen. Dieses jedoch stimmt nicht. Sweeper beobachtet diesen Wert täglich u. ist auch noch investiert. In den zurückliegenden Monaten gab es für mich keine Veranlassung mich hier zu melden. Sicher kamen , man kann es deutlich sagen keine positiven Meldungen vom Unternehmen-bis heute. Manche von Euch haben es bestimmt schon vernommen, was ich hier im Anhang mal reinstellen will.
Schaun wir mal, wie's weitergeht. Ich jedenfalls halte es da mit voitsi der kürzlich einem wohl in Untergangsstimmung geratenen User auf interhub antwortete, er halte PMED bis zur bitteren Neige gegen 0.
Grüsse Sweeper
Hier der Bericht von heute:
21.11.2008 15:40
Paradigm Medical Names Stephen Davis as President
The Board of Directors of Paradigm Medical Industries, (News) Inc. (OTCBB: PMED) named Stephen L. Davis as President, effective November 18, 2008. He replaces Raymond Cannefax, who was terminated.
Mr. Davis, who previously served as the Company's Vice-President Sales and Marketing from May 2007 to February 2008, has more than 20 years experience in the ophthalmic industry.
”We believe Stephen Davis will be able to help expand the Company's proprietary products and devices domestically and internationally,“ said Paradigm Medical's Board Chairman Randall Mackey. ”He is an exceptional manager and strategist.“
Mr. Davis noted, ”Short-term, my efforts will be to reinvigorate Paradigm Medical's global sales and marketing efforts and ensure product availability to our customers. And we will continue to exercise strong financial management. Our product mix is unsurpassed in the ophthalmic industry and we will continue to meet the current and future needs of the market.
”Longer-term, my goal is to capitalize on our strengths, which will result in solid and sustainable growth for the Company and maximizing our returns,“ Mr. Davis added.
From 2001-2007, Mr. Davis served as President of SL Davis Group, Inc., which provides business development, distribution management and sales training services. From 1991-1999, Mr. Davis was President and Chief Executive Officer for Zinetics Medical, Inc., which manufactured and distributed medical devices for the gastroenterology and critical care markets. He has held other senior management positions at Co-Care Medical Services, Inc., and Ioptex Intraocular Lenses, Inc.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.
This press release contains statement that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Meine Bank hat mir heute mitgeteilt, dass der Splitt sogar mit einem Verhältnis von 100 : 1 durchgeführt werden soll.
Einen unseriösen Touch hat das ganze schon. Erst werden die Aktien nach und nach auf eine Stückzahl von 1,4 Milliarden vermehrt, ohne das die bereits Investierten am Splitt beteiligt werden, jetzt wird die Aktienzahl im Verhältnis 1:100 reduziert, da werden plötzlich alle Investierten mit ins Boot genommen! Pfui, dass ist für mich eindeutig Betrug.
Einen unseriösen Touch hat das ganze schon. Erst werden die Aktien nach und nach auf eine Stückzahl von 1,4 Milliarden vermehrt, ohne das die bereits Investierten am Splitt beteiligt werden, jetzt wird die Aktienzahl im Verhältnis 1:100 reduziert, da werden plötzlich alle Investierten mit ins Boot genommen! Pfui, dass ist für mich eindeutig Betrug.
Immer wenn der Kurs in den USA so niedrig ist, dass es nicht weiter runter gehen kann,
kommen 100:1 oder 1000:1 Splits, danch dauert es ein paar Tage und der Kurs ist wieder bei 0,0001.
Wiederholt sich ständig, das Geld ist futsch, habe ich schon zig Mal erlebt.
Nie wieder Pennystocks, war mir ne Lehre !!!
Dafür sind diese Betrugsklitschen erfunden worden, alles ganz legal...
kommen 100:1 oder 1000:1 Splits, danch dauert es ein paar Tage und der Kurs ist wieder bei 0,0001.
Wiederholt sich ständig, das Geld ist futsch, habe ich schon zig Mal erlebt.
Nie wieder Pennystocks, war mir ne Lehre !!!
Dafür sind diese Betrugsklitschen erfunden worden, alles ganz legal...
Werde kein Stück vom PMED verkaufen, da eh nichts mehr wert ist, doch zukaufen werde ich von dieser Penneraktie sicherlich nichts mehr. Eigentlich müsste man sich zusamentun und Sammelklage einreichen.
Antwort auf Beitrag Nr.: 36.045.864 von stern16 am 22.11.08 21:57:06Von solchen Sammelklagen gibt es sicher tausende...gebracht haben die alle nichts.
Verkaufen werde ich auch nicht, weil:
GEHT NICHT, NIX MEHR WERT.
Es sollte allen eine Lehre sein:
In solchen Mist steckt nie mahr euere Geld.
Der Hype ist kurz, wer das Glück hat, ihn mit zu machen...SUPER.
Alle anderen zahlen drauf und bleiben auf der Strecke !!!!!
Verkaufen werde ich auch nicht, weil:
GEHT NICHT, NIX MEHR WERT.
Es sollte allen eine Lehre sein:
In solchen Mist steckt nie mahr euere Geld.
Der Hype ist kurz, wer das Glück hat, ihn mit zu machen...SUPER.
Alle anderen zahlen drauf und bleiben auf der Strecke !!!!!
Laut dem von Starsweeper eingestellten Bericht ist Cannefax als Chef abgesägt worden. Der neue, Stephen Davis, läßt auf bessere Zeiten hoffen.
Abwarten!
Abwarten!
Paradigm Medical Names Stephen Davis as President
Paradigm Medical Names Stephen Davis as PresidentSALT LAKE CITYUT-PARADIGM/DAVIS
SALT LAKE CITY--(BUSINESS WIRE)--
The Board of Directors of Paradigm Medical Industries, Inc. (OTCBB: PMED) named Stephen L. Davis as President, effective November 18, 2008. He replaces Raymond Cannefax, who was terminated.
Mr. Davis, who previously served as the Company?s Vice-President Sales and Marketing from May 2007 to February 2008, has more than 20 years experience in the ophthalmic industry.
?We believe Stephen Davis will be able to help expand the Company?s proprietary products and devices domestically and internationally,? said Paradigm Medical?s Board Chairman Randall Mackey. ?He is an exceptional manager and strategist.?
Mr. Davis noted, ?Short-term, my efforts will be to reinvigorate Paradigm Medical?s global sales and marketing efforts and ensure product availability to our customers. And we will continue to exercise strong financial management. Our product mix is unsurpassed in the ophthalmic industry and we will continue to meet the current and future needs of the market.
?Longer-term, my goal is to capitalize on our strengths, which will result in solid and sustainable growth for the Company and maximizing our returns,? Mr. Davis added.
From 2001-2007, Mr. Davis served as President of SL Davis Group, Inc., which provides business development, distribution management and sales training services. From 1991-1999, Mr. Davis was President and Chief Executive Officer for Zinetics Medical, Inc., which manufactured and distributed medical devices for the gastroenterology and critical care markets. He has held other senior management positions at Co-Care Medical Services, Inc., and Ioptex Intraocular Lenses, Inc.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.
This press release contains statement that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Paradigm Medical Names Stephen Davis as PresidentSALT LAKE CITYUT-PARADIGM/DAVIS
SALT LAKE CITY--(BUSINESS WIRE)--
The Board of Directors of Paradigm Medical Industries, Inc. (OTCBB: PMED) named Stephen L. Davis as President, effective November 18, 2008. He replaces Raymond Cannefax, who was terminated.
Mr. Davis, who previously served as the Company?s Vice-President Sales and Marketing from May 2007 to February 2008, has more than 20 years experience in the ophthalmic industry.
?We believe Stephen Davis will be able to help expand the Company?s proprietary products and devices domestically and internationally,? said Paradigm Medical?s Board Chairman Randall Mackey. ?He is an exceptional manager and strategist.?
Mr. Davis noted, ?Short-term, my efforts will be to reinvigorate Paradigm Medical?s global sales and marketing efforts and ensure product availability to our customers. And we will continue to exercise strong financial management. Our product mix is unsurpassed in the ophthalmic industry and we will continue to meet the current and future needs of the market.
?Longer-term, my goal is to capitalize on our strengths, which will result in solid and sustainable growth for the Company and maximizing our returns,? Mr. Davis added.
From 2001-2007, Mr. Davis served as President of SL Davis Group, Inc., which provides business development, distribution management and sales training services. From 1991-1999, Mr. Davis was President and Chief Executive Officer for Zinetics Medical, Inc., which manufactured and distributed medical devices for the gastroenterology and critical care markets. He has held other senior management positions at Co-Care Medical Services, Inc., and Ioptex Intraocular Lenses, Inc.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.
This press release contains statement that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Antwort auf Beitrag Nr.: 19.967.988 von calibra21 am 31.01.06 06:36:17@all Investors of PMED
Lange nichts mehr gehört voneinander. Wer da nun denkt unser Invest sei tot, der wird eines Tages ganz gewiss eines Besseren belehrt werden. Habe gestern eine Mail an den neuen CEO von PMED abgesetzt und dieser antwortete in der Tat sofort. Ich war selbst erstaunt, daß das so fix ging. Das, was er schreibt klingt für mich absolut gut. PMED hat,so meine Meinung ganz gewiss eine gute Zukunft vor sich-hier allerdings brauchts halt noch Geduld-u. die sollte man bei'm Einstieg in solch ein Invest auch mitbringen. So, hier nun Mr. Davis' Antwort:
Dear Mr. ...
I understand your interest and at the same time your concerns.
PMED has recently begun to reposition its efforts to begin to take a more defined approach to implementing the growth of our current mix of products and also begin to introduce more effectively our new products. As we improve products, distribution, customer service and at the same time, effectively control our resources, we will begin to improve our organization and also our market value.
Since accepting the responsibility of President/CEO just a little over two weeks ago, I have begun to selectively build the team I will need to get PMED back into the active arena we belong in. Secondly, I have spent the past two weeks reviewing our financials and customer issues. I have also begun the task of re-building vendor relations. At the same time, I have begun discussions towards completing plans for updating and improving our current products and similar discussions about new products we would like to add/develop.
As I am sure you and our other investors are aware, it will take additional capital to accomplish these tasks and get us moving back into a positive growth direction. We will be doing everything possible to assure we have the necessary funds to finally position Paradigm back on track as a leader in the world wide Ultrasound and Glaucoma markets.
..., you have my personal commitment and also the same commitment from the team I am assembling, that we will not fail as a result of our collective effort!
Thank you for your trust and support!
Sincerely,
Steve L. Davis
President/CEO
Paradigm Medical Industries, Inc.
Office: 801 977-8970
Cellular: 801 618-7954
E-mail: sdavis@paradigm-medical.com
Lange nichts mehr gehört voneinander. Wer da nun denkt unser Invest sei tot, der wird eines Tages ganz gewiss eines Besseren belehrt werden. Habe gestern eine Mail an den neuen CEO von PMED abgesetzt und dieser antwortete in der Tat sofort. Ich war selbst erstaunt, daß das so fix ging. Das, was er schreibt klingt für mich absolut gut. PMED hat,so meine Meinung ganz gewiss eine gute Zukunft vor sich-hier allerdings brauchts halt noch Geduld-u. die sollte man bei'm Einstieg in solch ein Invest auch mitbringen. So, hier nun Mr. Davis' Antwort:
Dear Mr. ...
I understand your interest and at the same time your concerns.
PMED has recently begun to reposition its efforts to begin to take a more defined approach to implementing the growth of our current mix of products and also begin to introduce more effectively our new products. As we improve products, distribution, customer service and at the same time, effectively control our resources, we will begin to improve our organization and also our market value.
Since accepting the responsibility of President/CEO just a little over two weeks ago, I have begun to selectively build the team I will need to get PMED back into the active arena we belong in. Secondly, I have spent the past two weeks reviewing our financials and customer issues. I have also begun the task of re-building vendor relations. At the same time, I have begun discussions towards completing plans for updating and improving our current products and similar discussions about new products we would like to add/develop.
As I am sure you and our other investors are aware, it will take additional capital to accomplish these tasks and get us moving back into a positive growth direction. We will be doing everything possible to assure we have the necessary funds to finally position Paradigm back on track as a leader in the world wide Ultrasound and Glaucoma markets.
..., you have my personal commitment and also the same commitment from the team I am assembling, that we will not fail as a result of our collective effort!
Thank you for your trust and support!
Sincerely,
Steve L. Davis
President/CEO
Paradigm Medical Industries, Inc.
Office: 801 977-8970
Cellular: 801 618-7954
E-mail: sdavis@paradigm-medical.com
hm in usa 9900 % im plus?!?!?
Paradigm Medical Poised to Expand Stake in $250-Million U.S. Ophthalmic Diagnostic Device Market
Tuesday December 16, 1:25 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PDMI.OB - News) has launched several internal programs aimed at expanding its position in the U.S. and global diagnostic ultrasound and early glaucoma detection markets. The Company’s initial efforts are aimed directly at the $25-million opportunity for its P60 Ultrasound BioMicroscope (UBM) and the growing glaucoma detection markets.
ADVERTISEMENT
“We are redirecting our efforts to reposition our leading products in the ultrasound market, where the Company has been the premier developer of new, high-technology devices,” said Paradigm Medical’s new President, Stephen Davis. “Our short-term goal is focused on new design enhancements for our three proprietary products: the P60 UBM, the Blood Flow Analyzer™ (BFA), and the LD400 autoperimeter, and increasing sales of the Glaid-PERG throughout North America.”
The Glaid-PERG electrophysiology instrument is used for the early detection of glaucoma. Paradigm Medical has an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the latter’s Glaid-PERG device. “We are also reinforcing other global collaborations in the U.S., Europe and Asia,” Mr. Davis noted.
“The U.S. market for ophthalmic diagnostic ultrasound devices is over $250 million and growing at more than 5% per year. The global opportunity is probably double that,” Mr. Davis added. “Paradigm Medical is also readying several new products that could be commercialized by mid-2009. We are known in the industry as ‘The UBM Company,’ based on our innovation and array of ultrasound devices for the ophthalmic and medical industries. And we remain dedicated to not only growing our share of the market but also to expanding the size of the market through new proprietary products and technology.”
The Company’s P60 UBM is used for viewing structures in the eye involved with glaucoma pathologies and surgical procedures. The Blood Flow Analyzer™ is used for early detection and treatment management of glaucoma and other retina related diseases. The LD400 Autoperimeter is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Stephen Davis, President
801-977-8970
www.paradigm-medical.com
Tuesday December 16, 1:25 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PDMI.OB - News) has launched several internal programs aimed at expanding its position in the U.S. and global diagnostic ultrasound and early glaucoma detection markets. The Company’s initial efforts are aimed directly at the $25-million opportunity for its P60 Ultrasound BioMicroscope (UBM) and the growing glaucoma detection markets.
ADVERTISEMENT
“We are redirecting our efforts to reposition our leading products in the ultrasound market, where the Company has been the premier developer of new, high-technology devices,” said Paradigm Medical’s new President, Stephen Davis. “Our short-term goal is focused on new design enhancements for our three proprietary products: the P60 UBM, the Blood Flow Analyzer™ (BFA), and the LD400 autoperimeter, and increasing sales of the Glaid-PERG throughout North America.”
The Glaid-PERG electrophysiology instrument is used for the early detection of glaucoma. Paradigm Medical has an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the latter’s Glaid-PERG device. “We are also reinforcing other global collaborations in the U.S., Europe and Asia,” Mr. Davis noted.
“The U.S. market for ophthalmic diagnostic ultrasound devices is over $250 million and growing at more than 5% per year. The global opportunity is probably double that,” Mr. Davis added. “Paradigm Medical is also readying several new products that could be commercialized by mid-2009. We are known in the industry as ‘The UBM Company,’ based on our innovation and array of ultrasound devices for the ophthalmic and medical industries. And we remain dedicated to not only growing our share of the market but also to expanding the size of the market through new proprietary products and technology.”
The Company’s P60 UBM is used for viewing structures in the eye involved with glaucoma pathologies and surgical procedures. The Blood Flow Analyzer™ is used for early detection and treatment management of glaucoma and other retina related diseases. The LD400 Autoperimeter is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Stephen Davis, President
801-977-8970
www.paradigm-medical.com
Antwort auf Beitrag Nr.: 36.217.309 von Baembi am 16.12.08 20:19:57Denke mal das ist die Antwort auf Deine Frage:
Gruß Sweeper
Posted by: flaflyersfan Date: Monday, December 15, 2008 3:38:55 PM
In reply to: starsweeper who wrote msg# 3889 Post # of 3891
starsweeper, your PMED shares are becoming PDMI shares;
http://www.otcbb.com/asp/dailylist_detail.asp?d=12/12/2008&m…
For every 100 shares of PMED you had, you get 1 share of PDMI.
Bid is .002, Ask is .90. It may be a few days or several weeks for the new shares to be in your account.
Hope this helps. Good luck.
Gruß Sweeper
Posted by: flaflyersfan Date: Monday, December 15, 2008 3:38:55 PM
In reply to: starsweeper who wrote msg# 3889 Post # of 3891
starsweeper, your PMED shares are becoming PDMI shares;
http://www.otcbb.com/asp/dailylist_detail.asp?d=12/12/2008&m…
For every 100 shares of PMED you had, you get 1 share of PDMI.
Bid is .002, Ask is .90. It may be a few days or several weeks for the new shares to be in your account.
Hope this helps. Good luck.
Antwort auf Beitrag Nr.: 19.967.988 von calibra21 am 31.01.06 06:36:17nur noch mal den heutigen Schlußstand überm großen Teich.
Sweeper
PARADIGM MED IND NEW(OTC BB: PDMI.OB)
Last Trade: 0.05
Trade Time: 3:56PM ET
Change: 0.05 (49899.16%)
Prev Close: 0.00
Open: 0.01
Bid: 0.01 x 9000
Ask: 0.51 x 2500
1y Target Est: N/A
Day's Range: 0.01 - 0.05
52wk Range: N/A
Volume: 64,000
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)
Quotes delayed, except where indicated otherwise. For consolidated real-time quotes (incl. pre/post market data), sign up for a free trial of Real-time Quotes.
Sweeper
PARADIGM MED IND NEW(OTC BB: PDMI.OB)
Last Trade: 0.05
Trade Time: 3:56PM ET
Change: 0.05 (49899.16%)
Prev Close: 0.00
Open: 0.01
Bid: 0.01 x 9000
Ask: 0.51 x 2500
1y Target Est: N/A
Day's Range: 0.01 - 0.05
52wk Range: N/A
Volume: 64,000
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)
Quotes delayed, except where indicated otherwise. For consolidated real-time quotes (incl. pre/post market data), sign up for a free trial of Real-time Quotes.
Antwort auf Beitrag Nr.: 36.218.655 von STARSWEEPER am 16.12.08 22:29:47In meinem Depot sind meine PM - Aktien nach dem Splitt noch immer gesperrt, weiß jemand wenn die Sperre aufgehoben wird und die Anteile wieder frei handelbar sind??
Gruß Stren16
Gruß Stren16
Antwort auf Beitrag Nr.: 36.798.183 von stern16 am 19.03.09 07:25:50Hi Stern 16,
da solltest Du aber mal schnellstens mit Deiner Bank sprechen. Die Sperre müßte schon längst aufgehoben sein.
Jedenfalls bleiben wir in diesem Wert investiert-eR wird auch wieder steigen.
Stay long-stay cool!
Gruß Sweeper
da solltest Du aber mal schnellstens mit Deiner Bank sprechen. Die Sperre müßte schon längst aufgehoben sein.
Jedenfalls bleiben wir in diesem Wert investiert-eR wird auch wieder steigen.
Stay long-stay cool!
Gruß Sweeper
@all
habe gestern mit Mr. Davis kommuniziert.
Hier seine Antwort per Mail. Schau'n wir mal wie's weitergeht.
Ich denke mal, das liest sich nicht schlecht.
Grüße
Sweeper
Dear ....,
Since we last communicated, much has taken place at Paradigm Medical. I will attempt to catch you and the other shareholders up.
As you know, there was a reverse stock split approved by shareholders in December. That was necessary as painful as it was for the shareholders, it was necessary to move Paradigm back into the market. The organization had been left in a serious state and required some radical attention. We quickly began to develop a new relationship with some other investors other than the NIR Group. One's that would be as interested in the growth as in keeping the "patient" alive! We are in the final stages of receiving funding to sustain and grow the business.
I have been busy creating an extensive business plan that includes new re-organization, new management members and new corporate partners. The last effort will result in some new products that our distributive sales force in the International market and our new sales force in the US will be selling. We will return to the core of developing and finding the best instruments for early diagnosis of Glaucoma and other related associated diseases. We have set high expectations and our forecasts will reflect growth that has been sorely lacking for the past three years.
Finally, I apologize for our current Web Site. It will be totally overhauled.
Things are on the verge of improving......keep in touch and watch for the press releases beginning April 7th.
Stephen
Stephen L. Davis
2278 Oak Leaf Way
Sandy, UT 84092
(801) 571-5764 Residence
(801) 618-7954 Mobile
habe gestern mit Mr. Davis kommuniziert.
Hier seine Antwort per Mail. Schau'n wir mal wie's weitergeht.
Ich denke mal, das liest sich nicht schlecht.
Grüße
Sweeper
Dear ....,
Since we last communicated, much has taken place at Paradigm Medical. I will attempt to catch you and the other shareholders up.
As you know, there was a reverse stock split approved by shareholders in December. That was necessary as painful as it was for the shareholders, it was necessary to move Paradigm back into the market. The organization had been left in a serious state and required some radical attention. We quickly began to develop a new relationship with some other investors other than the NIR Group. One's that would be as interested in the growth as in keeping the "patient" alive! We are in the final stages of receiving funding to sustain and grow the business.
I have been busy creating an extensive business plan that includes new re-organization, new management members and new corporate partners. The last effort will result in some new products that our distributive sales force in the International market and our new sales force in the US will be selling. We will return to the core of developing and finding the best instruments for early diagnosis of Glaucoma and other related associated diseases. We have set high expectations and our forecasts will reflect growth that has been sorely lacking for the past three years.
Finally, I apologize for our current Web Site. It will be totally overhauled.
Things are on the verge of improving......keep in touch and watch for the press releases beginning April 7th.
Stephen
Stephen L. Davis
2278 Oak Leaf Way
Sandy, UT 84092
(801) 571-5764 Residence
(801) 618-7954 Mobile
wie man unschwer feststellen kann kommt wieder Bewegung in diesen Wert.
Bitte auf die Presseveröffentlichungen ab dem 7.4.09 achten.
Grüße Sweeper
Bitte auf die Presseveröffentlichungen ab dem 7.4.09 achten.
Grüße Sweeper
Antwort auf Beitrag Nr.: 36.918.385 von STARSWEEPER am 03.04.09 21:31:49was ist hier los ?? Habe damals in Frankfurt gekauft, jetzt kein Kurs ist das Geld weg
Was ist mit der Aktie los ??
Oje Fragen über Fragen, wer kann mir kurzes Update geben ?
Habe damals in Frankfurt gekauft, jetzt kein Kurs ist das Geld weg Was ist mit der Aktie los ??
Oje Fragen über Fragen, wer kann mir kurzes Update geben ?
Antwort auf Beitrag Nr.: 36.921.124 von NewWorldOrder am 04.04.09 22:13:12Hi NWO,
gib ganz einfach bei Yahoo Finanzen PDMI ein dann wirst Du dort alles erfahren. Ab dem 7.4. gibt es wohl Presseveröffentlichungen zu diesem Wert-so jedenfalls schrieb mir kürzlich Mr. Davis. Bin auch gespannt wie es hier demnächst weitergeht.
Gruß Sweeper.
gib ganz einfach bei Yahoo Finanzen PDMI ein dann wirst Du dort alles erfahren. Ab dem 7.4. gibt es wohl Presseveröffentlichungen zu diesem Wert-so jedenfalls schrieb mir kürzlich Mr. Davis. Bin auch gespannt wie es hier demnächst weitergeht.
Gruß Sweeper.
Ein Unfall...
Postingfrequenz auf IHUB enorm. Heute schon mehr als 100.
Sweeper
Sweeper
keiner mehr investiert?
heute mehr als 300 postings. Vol. ca. 26.000.000
Schaun wir mal wie's morgen weiter geht.
Sweeper
heute mehr als 300 postings. Vol. ca. 26.000.000
Schaun wir mal wie's morgen weiter geht.
Sweeper
Was für ein Dreckswert, nun sind es wieder 517 Mill. Aktien. Selten so einen Schwachsinn erlebt!!!!!!!!!!!!!!!!!!!!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 97 | ||
| 92 | ||
| 43 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 15 | ||
| 15 | ||
| 15 | ||
| 14 |
| Wertpapier | Beiträge | |
|---|---|---|
| 14 | ||
| 11 | ||
| 9 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 5 |
